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Introduction
General introduction
Hearing is one of man’s most important senses. Not only can we interact with our surroundings 
by sound, but most of human communication is based on the production and recognition 
of sound and speech. An intact function of the hearing organ is one of the key elements 
in the development of speech and language. Loss of hearing can cause an important 
disability in the development of language in children or in the communicational skills in 
adults and therefore it strongly influences learning capabilities and school development. 
Furthermore, hearing is of great importance for our physical safety, since it can protect us 
from harm by other persons, animals or objects. Multiple causes are known for both 
congenital as acquired and inherited hearing loss. 
Anatomy and physiology of the hearing organ
The human ear is divided into three main parts (figure 1). Firstly, the outer ear, which 
contains the auricle or pinna and the outer ear canal. The ear canal is made up of skin, 
cartilage and bone, from the pinna up to the eardrum. The function of the outer ear is to 
collect sound and guide it towards the middle ear. It slightly enhances the sounds 
Figure 1  Anatomy of the ear.
Courtesy unknown.
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between 2000 to 3000 Hertz (Hz). Furthermore the pinna has a function in directional 
hearing by picking up various cues in sound that can be interpreted by the brain (e.g. 
frequency, time and pitch differences) (1).
The second part is the middle ear which consists of the ear drum, the auditory ossicles 
(malleus, incus and stapes), their connecting ligaments, tendons and muscles and the 
Eustachian tube. The function of the ear drum and the ossicles is to transfer and enhance 
the vibrations of sound in air effectively to the fluid of the inner ear (called transformation). 
It has an amplification function, due to the surface proportion between de ear drum and 
the oval window, which connects the ossicular chain to the inner ear fluid. Thereby it 
compensates for the loss of amplitude (or sound loudness) by the transfer of air vibration 
to the fluid vibration in the inner ear. The muscles connected to the ossicles (tensor 
tympani and stapedial muscle) are able to stiffen the ossicular chain during loud sounds 
and large pressure shifts. The function of this stiffening remains uncertain (2). They can 
contract, thereby stiffening the connection between the ear drum and the inner ear and 
decreasing the amplitude of the vibration. The Eustachian tube functions as an access to 
the middle ear to equalize the air pressure with the surrounding environment. Moreover, 
it has a function in the clearance and protection of the middle ear. It is the connection 
between middle ear and nasopharynx and is made up by cartilage and partly by bone (1, 3).
The inner ear contains the labyrinth, which consists of the vestibule and semicircular 
canals (balance organ) and the cochlea, which is the actual hearing organ itself. It is made 
up by three canals, separated by membranes (see figure 2). The most important of the 
membranes, the basilar membrane, contains the organ of Corti (figure 3). This organ is 
made up of specific hair cells, containing stereocilia, which are capable of creating an 
Figure 2  Anatomy of the cochlea.
Courtesy of Wikimedia user OpenStax.
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action potential when they are displaced. This action potential initiates a signal through 
the cochlear nerve to the brain. Displacement of the hair cells occurs when the vibrations 
of sound, transferred by the ossicles to the inner ear fluid through the oval window, 
induces fluid vibrations in the cochlea. These vibrations are transferred over the basilar 
membrane. High pitched frequencies only reach the base of the membrane and low 
pitched frequencies are conducted up to the apical part of the membrane. The round 
window membrane ensures that the amplitude of the pressure fluctuations in the cochlea 
is kept as small as possible. Since complex sound is made up of multiple combined 
frequencies, the transfer of the vibration into fluid waves along the basilar membrane 
causes multiple hair cells to be displaced at the same time. This enables the cochlea to 
send multiple combined action potentials to the brain, thereby sensing the complete 
complexity of sound, e.g. music or speech in noise. The human spectrum of sound 
perception reaches from 20 to 20.000 Hz between 0 and 110 decibels (dBHL) (1, 3).
Hearing loss
Sensorineural hearing loss
A decrease in hearing is defined as hearing loss and it can be divided into three groups. 
Sensorineural hearing loss (SNHL) in general is caused by a deficit in the sensory hearing 
organ in the cochlea or in the neural pathway to the brain. It can be congenital or acquired 
or a combination of both. Hearing loss can either present as high frequency hearing loss, 
e.g. presbyacusis or due to ototoxicity, or a flat hearing loss on all frequencies. Middle and 
low frequency hearing loss are mostly associated with inherited sensorineural cochlear 
damage or due to advanced meniere’s disease and mostly progressive. According to the 
world health organization, the severity of hearing loss is expressed in mild hearing loss 
(25-40 dBHL), moderate (40-60 dBHL), severe (60-80 dBHL) and profound (>80 dBHL)(4). 
See figure 4 for an example of various sound levels.
Figure 3   Organ of Corti.
Courtesy of Wikimedia user Madhero88.
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Conductive hearing loss
Another form of decrease in hearing is conductive hearing loss (CHL). In this form, regular 
hearing is present in a normal functioning cochlea, but the sounds do not pass the 
external ear and/or the middle ear correctly or the sound transfer is ineffective. Therefore, 
a so called air-bone gap is present in pure tone audiometry, which is the difference 
between the air conduction hearing loss thresholds and the function of the inner ear 
measured by bone conduction thresholds. The hearing loss may be temporary, e.g. due to 
secretory fluids in the middle ear, or permanent and even progressive. The severity of CHL 
is determined by the type of pathology. In absence of the external ear canal a maximum 
CHL of 60 dBHL may be present. 
Mixed hearing loss
At last, mixed hearing loss (MHL) may be present with a combination of pathologies. For 
example, a tympanic membrane perforation may be present in a patient with an age 
related sensorineural hearing loss, or otosclerosis may have affected the oval window as 
well as the cochlear function. Revalidation of hearing may be challenging in MHL, since 
Figure 4   Audiogram of familiar sounds.
Courtesy of Phonak.
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the sounds need to be enhanced loud enough to overcome the CHL at first and secondly 
to compensate for the remaining SNHL component. In certain situations, this may add up 
to severe hearing loss.
Pathology of the ear
Apart from aging of the cochlea, many diseases of the ear can affect the hearing function, 
both temporarily and permanent and varying from slight hearing loss to total deafness. 
The causes can be divided per location and consist of infections, inflammation, malformation 
or destruction of vital structures by (benign or malignant) tumors or by trauma. 
Outer ear pathology
At birth, some illness that influences hearing can be present. Congenital malformations of 
the pinna (called microtia), the ear canal or even middle ear structures can lead to various 
forms of uni- or bilateral conductive hearing loss. Microtia occurs mostly isolated, but it 
may occur in conjunction with other anomalies, such as hemifacial microsomia or as a 
syndrome like Goldenhar, DiGeorge or Treacher-Collins syndrome (5).
When a defect to the outer ear canal is present, a partial or complete obstruction may 
occur. In congenital cases the complete outer ear canal may be absent. In acquired cases, 
mostly due to recurrent infections, narrowing of the ear canal or an acquired atresia causes a 
inadequate transfer of the sound vibrations through the ear canal, leading to hearing loss. 
External otitis is an infection of the skin in the outer ear canal. In most cases this is of short 
duration due to pathologic causes such as bacteria or fungi. For other patients, the skin in 
the outer ear canal may suffer from seborrheic eczema. Another cause may be due to 
poor ventilation because of a narrow entrance to the ear canal. Therefore, the condition in 
the ear canal changes and chronic recurrent infections may occur. Another cause of poor 
ventilation may occur due to wearing blocking ear molds of hearing aids in the ear canal.
When the tympanic membrane is (partly) absent, an open connection to the middle ear 
is present. This may cause recurrent infections, especially when the middle ear is exposed 
to water. Furthermore, a perforation of the tympanic membrane will cause conductive 
hearing loss, as the sound transfer function of the membrane is diminished. 
Middle ear pathology 
Various causes of middle ear pathology can cause hearing loss. In most cases the ossicular 
chain is involved, either when a congenital absence or malformation is present or due to 
acquired interruptions. In children, the most common cause of hearing loss is chronic 
serous otitis media. This causes an accumulation of mucus in the middle ear that alters the 
transfer function of sound and causes a conductive hearing loss. The etiology of this 
disease is caused by a malfunction of the ventilation of the middle ear by the eustachian 
tube. It can lead to chronic recurring middle ear infections or a permanent decrease 
in middle ear pressure that may alter the tympanic membrane. When the tympanic 
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membrane gets retracted into the middle ear, it may cause arrosion of the ossicular chain, 
in most cases located at the long process of the incus. The membrane may even 
completely retract against the medial wall of the middle ear cavity, creating a so called 
atelectasis. When the tympanic membrane gets retracted even further in the superior and 
posterior quadrant, it may cause retraction pockets that may lead to cholesteatoma. In 
limited disease this may only damage the tympanic membrane or the ossicles. In extensive 
disease, the mastoid may be involved.
Another well known cause of conductive and mixed hearing loss is otosclerosis. Due to a 
disturbed balance between bone resorption and formation, the stapes may form 
otospongiosis that will fixate the stapes footplate in the oval window. Because of this 
fixation, the vibrations of the tympanic membrane and ossicular chain will not reach the 
cochlear fluid properly. Typically, during audiometry a so-called ‘Carhart’s notch’ is visible 
and a conductive hearing loss in the lower and higher frequencies with a pseudo 
sensorineural hearing loss around 2-4 kHz (6). In advanced cases of otosclerosis, the bone 
surrounding the cochlea may also be involved in the spongiotic process. It may even 
distort the cochlear lumen (7). Then sensorineural hearing loss is found in these patients. 
It has been argued that some of the released enzymes and toxins may damage the inner 
ear hair cells (8).
Besides the more frequent causes mentioned, some disease of the middle ear are less 
common but can also be responsible for hearing loss. This concerns benign lesions like 
paraganglioma or schwannoma. These causes are outside the scope of this thesis.
Middle ear surgery
For several middle ear diseases, ear surgery to restore hearing is an option for treatment, 
i.e. in otosclerosis, tympanosclerosis, ossicular chain disruptions, tympanic membrane 
perforations or chronic otitis media. On the other hand, for cholesteatoma, surgery is 
imminent as the disease will progress when untreated and further damage to the middle 
ear structures can thereby be prevented. So for some indications the hearing loss itself 
may be the indication for surgical treatment, whereas the result in hearing will be secondary 
in cholesteatoma surgery. 
In cases of otosclerosis or osteogenesis imperfecta, a stapedotomy can be performed, 
replacing the fixed stapes by a small prosthesis, also called a piston, connected to the 
intact incus. For serous otitis media, grommet insertion through the tympanic membrane 
is an easy solution to temporarily resolve the accumulation of mucus in the middle ear and 
provide improvement of aeration of the middle ear. In situations where the ossicular chain 
is damaged, either due to retraction of the tympanic membrane or due to cholesteatoma, 
the incus and/or the stapes may be replaced by a so called partial or total ossicular 
replacement prosthesis or by using autogeneous material like remnants of the incus. In 
small defects cement or hydroxyapatite can be applied. In all these procedures the goal is 
to (partially) resolve the conductive hearing loss. In some cases, this cannot be completely 
19
1
Introduction
achieved and a remaining conductive or mixed hearing loss may still be present after the 
intervention.
Inner ear pathology 
For inner ear hearing loss, numerous causes are known. Congenital causes are either 
genetic abnormalities in the anatomy of the inner ear or congenital infections, e.g. Rubella 
or Cytomegalovirus. Genetic defects may occur in various forms or in combination with 
other deformations or diseases in syndromic hearing loss. The severity and age of onset can 
vary widely from mild hearing loss at later age to severe hearing loss or deafness at birth.
Acquired causes can be very various. It ranges from trauma, prematurity and infections 
(either of the middle ear, the cochlea or the cochleovestibular nerve) to ototoxicity by 
drugs such as aminoglycosides, loop diuretics and chemotherapeutics. For example, 
cisplatin and carboplatin cause damage to the cochlear hair cells. In most cases it starts with 
a high frequency hearing loss, but with severe cases all frequencies can be affected (9). 
Presbycusis is also known as the aging process of the inner ear. It mostly starts of as a 
measurable increase of hearing thresholds in the high frequencies in the sixth decade of 
age. The general idea is that the organ of Corti and the stria vascularis in the cochlea 
increasingly degenerate. During the years the thresholds increases even further, leading to 
a hearing loss in the mid- and lower frequencies and rehabilitation will be required.
Another form of inner ear pathology is noise induced hearing loss (NIHL). It can be divided 
in two basic types: acoustic trauma or gradually developing NIHL. The first can be the 
result of an acute exposure to an excessive sound pressure, i.e. from explosions, firecrackers 
or gunfire. It is mostly accompanied by tinnitus. Sound over 120 dBSPL may cause inner ear 
damage to the outer and/or inner hair cells. For gradually developing NIHL, long term 
exposure to sound over 85 dBSPL for longer than 8 hours per day is harmful. In many cases 
the exposure is due to occupational noise, such as loud music or due to operating 
machines. In some cases a predisposition is found for patient with certain genetic 
variations (10). The chronic repeated long term activation of the outer hair cells causes a 
continuous metabolic activity that may alter some of the proteins in the ear. Furthermore, 
it may cause the formation of free radicals of oxygen molecules, which may damage the 
organ of Corti (11). The frequency range of NIHL starts around 4 kHz and may gradually 
increase to the higher frequencies at first and the lower frequencies later on.
Retrocochlear pathology
Besides the inner ear, pathology of the vestibulocochlear nerve, the brainstem and 
cerebrum might also be causative for sensorineural hearing loss. Especially vestibular 
schwannoma is more common as a cause for damage to the cochlear part of the eighth 
cranial nerve due to pressure. Even though the cochlea functions properly and the hair 
cells within it are not damaged, when the nerve itself cannot properly conduct the hearing 
information through the pathway to the central parts of the brain, the sounds will not be 
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properly perceived. Other causes are of cerebrovascular or neurological origin. These diseases 
are outside the scope of this thesis as no revalidation can be achieved by hearing aids.
Functional hearing tests
Pure tone audiometry
As hearing is a function of sound perception, the levels in hearing can be tested by 
determining the exact sound level per frequency that a person can perceive. These 
thresholds are expressed in frequency specific relative hearing decibels, called dBHL. The 
test is conducted in a standard soundproof environment. In a regular pure tone audiogram 
6 thresholds are determined in the frequency range of 250 to 8000 Hz in octave steps. In 
certain situations, the intermediate frequencies of 0.75, 1.5, 3 and 6 kHz will also be 
determined. This can be graphically presented as exemplified in figure 4. For speech 
understanding the frequency range from 0.5 to 4 kHz is specifically important. In the 
Netherlands, the averaged thresholds of 0.5, 1 and 2 kHz are referred to as the fletcher-
index, whereas the averaged thresholds of 1, 2 and 4 kHz are referred to as the fletch-
er-high-index. In English literature, the most common used value is the pure tone average 
(PTA) for the average of 0.5, 1 and 2 kHz (in common with the fletcher index) or the pure 
tone average of 0.5, 1, 2 and 4 kHz, referred to as PTA4. 
In the audiometry test, tones are presented with a headphone (air conduction thresholds), 
but these test tones can also be presented by a speaker in the soundproof audiometric 
booth. In this way, hearing can also be tested while using hearing aids (so called free field 
aided condition). Furthermore, by applying the sound directly as vibrations to the skull, 
these are directly transferred to the cochlea by bone conduction. By comparing the bone 
conduction thresholds with the air conduction thresholds (by using the headphone), 
different types of hearing loss can be determined.
Speech testing
To have an idea of the capacity of a person to understand speech, this can be tested by a 
word recognition test. During the test, words at varying sound level intensity are produced 
and the test-subject has to reproduce the words. Each word is scored for correctness of 
the phonemes, the various sounds in monosyllabic words. The outcome is noted as the 
percentage of correctness per sound level, although the speech reception threshold (SRT) 
is the most relevant parameter. This threshold is determined as the presentation level in 
dBHL for which the subject was able to reproduce 50% of the phonemes correctly. 
Speech testing in noise
An even more important function of hearing is to understand speech in noisy conditions 
and to distinguish the spoken words of one person from the other. On average, a normal 
hearing person is able to understand speech correctly in conditions where the noise will 
be 5 dB louder than the spoken words. For patients suffering from hearing loss, this ability 
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will be diminished and thereby speech understanding will be strongly compromised. This 
is especially due to hearing loss in the higher frequencies. An example of an adaptive 
sentence in noise test is a so-called Plomp test (12). During this test, a spoken sentence is 
played in varying conditions of noise loudness. Thereby the actual speech in noise (SIN), 
or signal to noise ratio can be determined in decibels.
Rehabilitation of hearing loss
Conventional hearing aids 
When a person suffers from hearing loss, rehabilitation can be achieved in various ways. In 
the Dutch healthcare system, funding is granted for conventional hearing aids (CHA) if the 
hearing loss exceeds 35 dBHL or more at 1, 2 and 4 kHz. The types of hearing aids may vary 
from devices in the ear canal to devices behind the auricle in varying sizes. 
If the level of hearing loss increases, more powerful hearing aids are required. CHA are 
capable to provide a maximum loudness up to the uncomfortable loudness level of a 
patient. To provide more powerful sound, the hearing aid will in general need to be larger 
in size. It also is more important that the ear canal is properly closed off by an ear mould in 
order to prevent the escape of energy of the sound. Unfortunately, this causes feedback 
and re-amplification of sounds produced by the hearing aid. 
Conventional hearing aids come with some disadvantages and limitations. Firstly, the ear 
mould may cause medical complaints of chronic external otitis due to blocking of the ear 
canal. Another complaint of this blocking is the distortion of the sound of the patient’s 
own voice, called the occlusion effect. In patients with a tympanic membrane perforation 
or radical cavity, the closing of the ear canal may cause or aggravate infections of the 
middle ear or cavity. Secondly, hearing aids are associated with social stigma. The problems 
described above may give rise to a contraindication for the use of conventional hearing 
aids.  A patient with hearing loss faced with these problems is dependable on alternative 
solutions.
Acoustic implants
For several decades various acoustic implants have been developed and applied as an 
alternative to conventional hearing aids. The drive of the development has been a result 
of the medical problems rising with conventional hearing aids. They are based on different 
kinds of sound amplification or stimulation of the cochlea. Each device has its own 
advantages and disadvantages that need to be considered. Acoustic devices require a 
surgical procedure and risks need to be taken into consideration. In general, the costs of 
acoustic implants are higher than the costs for conventional hearing aids.
Bone conduction implants
Since the 1950s and 1960s bone conduction devices have been available. These devices 
are based on a technique that applies vibrations to the skull, thereby directly stimulating 
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the inner ear. The mechanism is based on conduction of the sounds on the skull to the 
external ear canal, the ossicles and the cochlea itself. Firstly, these devices were bodily 
worn against the skull or built into spectacles. From 1977, a percutaneous solution was 
developed and the vibrations were directly applied by a vibrating sound processing 
device coupled to an implanted skin penetrating coupler into the skull. This technique 
increased the effectiveness of the transfer of the vibrations and reduced the issues 
involved with the pressure on the skin. The device was called a bone-anchored hearing 
aid or Baha. Because of the appearance of several types of bone conduction implants 
since the development of the BAHA, more general terms for the percutaneous titanium 
implant like bone anchored hearing implant (BAHI) or bone implant (BI) are more 
appropriate nowadays (13, 14). See figure 5 for the components of the Baha system. 
The indication for a BI was primarily conductive hearing loss, either uni- or bilateral. 
Following the percutaneous application and the availability of newer devices with a 
higher output, BI were also indicated for mixed hearing loss (15-17). The indication range 
is set for a maximum level of sensorineural hearing loss up to 55 dBHL. Another application 
is for single sided deafness, where the device can be implanted on the deaf side to use it 
for contralateral stimulation (18).
Currently two percutaneous bone conduction implants are commercially available, 
namely the Baha system (Cochlear BAS, Gothenburg, Sweden) and the Ponto system 
(Oticon Medical, Copenhagen, Denmark). More recently transcutaneous bone conduction 
Figure 5   The three components of the Baha system: the implant, the percutaneous 
abutment, and the vibrating sound processor.
Courtesy of Cochlear.
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implants have been introduced. These devices consist of an implanted magnet coupled 
to the skull underneath the skin. Onto the magnet, an external sound processor is coupled 
that transfers the vibrations through the skin. This technique has been applied in the 
Otomag system (Sophono, Boulder, CO, USA) (19) and the Baha Attract system (Cochlear 
BAS, Gothenburg, Sweden) (20). Another option is an implanted vibrating stimulator into 
the skull behind the ear and an externally worn audio processor that communicates by 
radio frequency signals through the skin, as applied in the Bonebridge system (Med-El, 
Innsbruck, Austria) (21-24).
Active middle ear implants
Active middle ear implants or AMEI have been around for almost two decades (25, 26). 
This type of implant consists of an active transducer and an implantable processor (figure 6). 
It can be either semi or fully implantable. If the microphone is also implanted, the fully 
implantable device will be invisibly hidden under the skin. In the semi implantable device, 
an externally worn sound processor magnetically couples to the implant and communicates 
with the internal part to send the audiometric information as well as the energy provision 
Figure 6   Detailed image of the Vibrant Soundbridge.
Courtesy of Med-el.
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for the implant. The active transducer is coupled to any part of the ossicular chain to 
mechanically drive the ossicles to vibrate, which consequently drives the inner ear fluids. 
In general the upper limit of hearing loss for the devices is set at 65 – 70 dBHL (27).
AMEI have initially been developed for sensorineural hearing loss as an alternative for 
conventional hearing aids. Especially in patients with therapy resistant external otitis, the 
implants are ideal since they avoid and prevent blocking of the external ear canal. 
Esthetical arguments have also been decisive for many patients. Since about a decade, 
surgical techniques for AMEI have been adapted to also suit patients with mixed hearing 
loss due to ossicular and middle ear pathology. Several couplers have been developed to 
couple the AMEI directly to the round window or stapes supra structure or footplate. 
(28-30)
Currently three AMEI are commercially available, viz. the Envoy Esteem (St. Croix Medical, 
Minneapolis, MN, USA) (31), the Middle Ear Transducer and Carina (Cochlear, Sydney, 
Australia) (figure 7) and the Vibrant Soundbridge or VSB (Med-El, Innsbruck, Austria). The 
latter two devices are the major topic of this thesis and will be additionally described 
further on.
Figure 7   Detailed image of Otologics / Cochlear middle ear transducer (MET).
Courtesy of Otologics / Cochlear.
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Direct acoustic cochlear implants
The technique of direct acoustic cochlear stimulation (DACS) was introducted by Häusler 
in 2008 (32). It is indicated for severe combined hearing loss in advanced otosclerosis. It 
comprises of an implantable hearing aid that combines the application of a regular 
stapedotomy piston with the surgical placement of an actuator with a so called artificial 
incus (figure 8). The magnet in the actuator drives the artificial incus and directly 
transduces the inner ear fluid through the coupled stapes piston. An experimental device 
based on this technique was constructed under the name of Codacs investigational 
device by Cochlear (Cochlear Benelux, Mechelen, Belgium). The clinical results of this 
implant will be discussed in this thesis.
Cochlear implants
For severe to profound sensorineural hearing loss and complete deafness, CHA are no 
longer effective. Cochlear implants have been available since the 1980’s. By introducing an 
electrode array into the scala tympani of the cochlea, electric stimuli can be delivered to 
the dendritic and ganglion cells of the cochlear nerve. This artificial method of delivering 
electrical pulses in the cochlea provided a new method of hearing. The results have been 
well established both in pre- and postlingually deaf subjects. For postlingual deaf adults, 
the majority is able to reach good levels of speech recognition in quiet and the ability to 
use the telephone (33, 34). In prelingual deafness in children, good results have been 
found for both the outcome in hearing as well as speech and language development (33, 35). 
Because of these impressive results and adequate cost-effectiveness on societal level, the 
eligibility criteria for cochlear implantation are still expanding.
Figure 8   Codacs direct acoustic cochlear stimulator.
Courtesy of Cochlear.
26
Chapter 1
General scope of this thesis
For almost 3 decades, research in the field of otology in Nijmegen has been focused on 
finding the best solutions for previously unresolved severe hearing problems. As such, the 
application of cochlear implants, bone-conduction implants and active middle ear 
implants has been addressed as ‘last-resort’ solutions. Defining the application criteria and 
evaluating these treatments is still ongoing. In the mid-nineties, based on this research, 
cochlear implants and bone conduction implants were accepted as regular treatment 
options in the Dutch healthcare system; cochlear implants for patients with profound 
hearing loss and bone-conduction implants (Baha) for patients with chronic running ears 
and for patients with aural atresia. In 2006, active middle ear implants were also accepted 
as regular healthcare, namely for patients with sensorineural hearing loss in combination 
with chronic external otitis due to intolerance of ear moulds of conventional hearing aids. 
Through the years, these implantable hearing devices have been improved by the 
introduction of better sound processing algorithms and improved coupling options, 
including direct stimulation of the cochlea.
The aim of this thesis is to present ongoing research regarding long-term stability, device 
usage and satisfaction of middle ear implantation, and to introduce a model that compares 
amplification options for patients with mixed hearing loss. In these patients, middle ear implants 
(including implants that directly stimulate the cochlea) can be applied as well as bone- 
conduction implants. A synopsis and scope of the thesis’ chapters are described below.
Scope per chapter
The indications for the various acoustic implants are overlapping, as has been described 
by Verhaegen in her doctorate thesis on active implants in 2012 (36). It is important to 
conduct more studies to provide evidence on long term stability of the implants and on 
patient satisfaction. Furthermore, the development of new acoustic implants will broaden 
the indication range and bring more competition to this field of hearing loss rehabilitation. 
This thesis provides the results of several studies on the surgical and functional outcome 
of some specific acoustic implants and on the comparison between the systems.  
Part 2 describes two studies on the long term use of active middle ear implants Vibrant 
Soundbridge (VSB) and Otologics MET (oMET). Chapter 2.1 presents a study on the long 
term evaluation of patient satisfaction in active middle ear implantation for patient with 
severe external otitis. Since the beginning of middle ear implantation surgery in Nijmegen 
in 1996 the patient satisfaction has been evaluated using different patient questionnaires. 
A short term study on the results of patient satisfaction had already been published (Snik 
2006 & 2007). The recent study reevaluates the outcome after an average postoperative 
period of 7.5 years and describes the patient satisfaction and quality of life compared to 
the preoperative measurements, with conventional hearing aids, and the short term 
results after 6 and 12 months with the AMEI.
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Chapter 2.2 focuses on the surgical complications in the implantation process of the VSB 
for patients with sensorineural hearing loss and external otitis by an experimental 
approach through the ear canal. This so called transcanal approach was developed to 
simplify the implantation procedure and avoid the need to drill the mastoid. The study 
compares the audiometric evaluations to the regular surgical approach and describes the 
encountered surgical complications. 
Chapter 2.3 focuses on the clinical long term outcome in active middle ear implantation. 
The complete cohort of patients with an AMEI was evaluated for technical and medical 
complications and the implant survival was studied. 
Part 3 focuses on a new technique in acoustic implants called direct acoustic cochlear 
stimulation. 
In chapter 3.1 the multicenter phase I study is described which evaluates the experimental 
Codacs investigational device (Codacs ID). This device is one of the first so-called direct 
acoustic cochlear implants or DACI and was applied in patients with severe sensorineural 
hearing loss due to otosclerosis. The chapter provides an extensive device description and 
pre- and post-operative hearing thresholds were evaluated in aided and unaided 
situations, as well as the surgical procedure, complications and patient satisfaction. 
In chapter 3.2 the results of a long term evaluation of the Codacs ID device are presented. 
This study has reevaluated the aided and unaided hearing thresholds, daily usage and 
patient satisfaction after an average postoperative period of 40 months to determine the 
stability of the outcome for the device.
Part 4 of this thesis serves a comparison between the various acoustic implants. We 
performed two studies to evaluate the audiological characteristics of the devices VSB, 
MET, various BCD and Codacs. 
Chapter 4.1 presents the results of a study in which patients with sensorineural hearing 
loss after implantation with a VSB, MET and Codacs were tested by so-called input-output 
measurements. In this way, we could analyze an averaged maximum output per implant 
and determine the available dynamic range for the amplification of sound. Furthermore, 
the average gain per device was determined. We developed a method to present the gain 
independent from any air-bone gap that would possibly remain after implantation. 
The study provides insights for the clinical considerations when determining which device 
will provide the best benefit for the patients’ current and future needs.
In chapter 4.2 a second study is presented which compares different acoustic devices 
for mixed hearing loss. New input-output measurements were conducted on the patients 
with a Codacs, as well as determining gain and maximum output. In another group of 
patients, the VSB middle ear implant had been directly coupled to the round and oval 
window of the cochlea. These patients were also evaluated. All results were compared to 
the available capabilities of three types of bone conduction implants to present an 
overview of the audiological aspects for the clinical options in the treatment of mixed 
hearing loss.
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Finally, in part 5 a general discussion and conclusion on this thesis is presented in 
chapter 5.1, followed by a summary of this thesis in English and Dutch. 
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Abstract
Objective: To evaluate the transcanal surgical implantation of the semi-implantable Vibrant 
Soundbridge device in patients with severe external otitis.
Patient and Methods:  Long-term postoperative complications and postoperative hearing 
thresholds were evaluated in 13 adults with bilateral sensorineural hearing loss (average of 
between 40 dB and 55 dB HL) and therapy-resistant external otitis after implantation of 
the Vibrant Soundbridge by a transcanal surgical method.
Results:  Postoperative audiometry findings were comparable with those reported after 
the transmastoidal posterior tympanotomy approach. In two patients the chorda tympani 
was intentionally sacrificed to maximize the size of the facial recess. Seven postoperative 
complications occurred in six patients (46%) during a mean follow-up period of 51 months: 
extrusion of the conducting wire into the ear canal (5), collapse of the cartilaginous part of 
the ear canal (1) and tympanic membrane perforation (1). In the revision surgeries that 
added additional layers of fascia for the patients with wire extrusions, repeated extrusion 
occurred in three of four cases.
Conclusions: The transcanal approach for implantation of the Vibrant Soundbridge has 
led to postoperative complications different from those reported after the transmastoidal 
posterior tympanotomy approach. External otitis should be considered as a contraindication 
for VSB surgery by the transcanal approach.
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Introduction
In September 1996, a European multicenter trial was started to evaluate the safety and 
effectiveness of the semi-implantable Vibrant Soundbridge hearing device (Symphonix 
Devices Inc., San Jose, California, USA and, later, Med-El, Innsbruck, Austria) (1, 2). Since 
then, both EU and FDA approval have been granted for the device. In 2003, the application 
of the Vibrant Soundbridge for use as a part of regular medical health care was approved 
in the Netherlands for hearing-impaired subjects with an extra medical indication, such as 
therapy-resistant external otitis that occurs spontaneous or that is due to an occluded ear 
canal.
The European study group that initially guided the phase III Vibrant Soundbridge clinical 
trial opted to introduce the transducer of the Vibrant Soundbridge (called the floating 
mass transducer or FMT) into the middle ear using a transmastoidal posterior tympanotomy 
approach (1). A transcanal approach that included widening of the external bony ear canal 
was considered to be an alternative approach. For reasons of uniformity, however, only 
one surgical technique was permitted.
The results of the initial Nijmegen Vibrant Soundbridge series that formed part of this 
European trial have been published (2-4). One of the six patients that had the implantation 
in the primary trial had insufficient aeration of the middle ear postoperatively as a result of 
chronic underpressure, which led to an air-bone gap of approximately 20 dB (3). In two 
other patients who were re-implanted, full mastoid cavity obliteration by connective 
tissue ensued, probably as a reaction to the silicon wire in the mastoid. It was assumed 
that obliteration of the mastoid cavity might lead to permanent aeration problems in ears 
that were poorly ventilated before implantation. In view of this presumed disadvantage of 
the transmastoidal posterior tympanotomy approach, we decided, after completion of 
the European trial, to perform an additional study to implant the FMT by a transcanal 
approach. In addition to providing a possible solution to mastoid aeration problems, our 
study offers an opportunity to examine the advantages and disadvantages of the 
transcanal approach in patients with therapy-resistant external otitis. The purpose of this 
study is to report the long-term outcome of patients whose FMT was implanted by means 
of the transcanal approach from 2003 to 2005.
Patients and methods
In the initial consecutive series from September 1996 to September 2003, 22 patients under - 
went Vibrant Soundbridge implantation using the transmastoidal posterior tympanotomy 
approach. From September 2003 to October 2005, 13 consecutive patients were implanted 
using the transcanal approach. An overview of these patients and their outcomes is 
presented in Table 1. 
38
Chapter 2
Ta
bl
e 
1 
 O
ve
rv
ie
w
 o
f p
at
ie
nt
s. 
N
o
Se
x
Si
de
A
ge
 
(y
ea
r)
Fo
llo
w
 u
p 
(m
on
th
)
PT
A
 (d
B)
 
op
er
at
ed
PT
A
 (d
B)
 
un
op
er
at
ed
Fo
llo
w
-u
p
A
ct
iv
e 
us
e 
 
of
 im
pl
an
t
1
F
A
D
78
49
37
33
U
nc
om
pl
ic
at
ed
, p
rim
ar
y 
co
ve
ra
ge
 o
f t
he
 g
ro
ov
e 
w
ith
 fa
sc
ia
D
ec
ea
se
d
2
M
A
S
62
57
45
48
St
ric
tu
re
 o
f t
he
 E
A
C
, m
ea
to
pl
as
ty
. R
ei
m
pl
an
ta
tio
n 
by
 
m
as
to
id
ec
to
m
y
Ye
s
3
M
A
D
56
50
40
43
Sa
cr
ifi
ce
 o
f c
ho
rd
a 
ty
m
pa
ni
, f
ur
th
er
 u
nc
om
pl
ic
at
ed
 F
U
N
on
-u
se
r
4
F
A
S
46
73
48
35
U
nc
om
pl
ic
at
ed
Ye
s
5
F
A
S
79
55
42
45
Pe
rf
or
at
io
n 
of
 th
e 
TM
 a
nd
 w
ire
 e
xt
ru
si
on
, r
ep
ea
te
d 
ex
tr
us
io
n 
af
te
r r
ev
is
io
n 
su
rg
er
y 
Ye
s
6
M
A
S
45
68
42
40
W
ire
 e
xt
ru
si
on
, r
ep
ea
te
d 
ex
tr
us
io
n 
af
te
r r
ev
is
io
n 
su
rg
er
y
Ye
s
7
F
A
D
44
50
35
45
U
nc
om
pl
ic
at
ed
 F
U
, e
xp
la
nt
at
io
n 
af
te
r o
to
sc
le
ro
si
s
Ex
pl
an
te
d
8
F
A
S
61
49
53
53
W
ire
 e
xt
ru
si
on
 in
 th
e 
EA
C
Ye
s
9
M
A
D
46
66
53
45
U
nc
om
pl
ic
at
ed
Ye
s
10
M
A
D
69
30
45
47
W
ire
 e
xt
ru
si
on
, r
ep
ea
te
d 
ex
tr
us
io
n 
af
te
r r
ev
is
io
n 
su
rg
er
y.
 
Se
bo
rr
ho
ei
c 
ec
ze
m
a 
of
 th
e 
EA
C
. E
xp
la
nt
at
io
n
Ex
pl
an
te
d
11
M
A
D
64
40
57
60
Sa
cr
ifi
ce
 o
f c
ho
rd
a 
ty
m
pa
ni
, f
ur
th
er
 u
nc
om
pl
ic
at
ed
 F
U
Ye
s
12
F
A
D
64
26
42
45
U
nc
om
pl
ic
at
ed
 F
U
, m
an
y 
co
m
pl
ai
nt
s 
of
 p
ai
n
Ye
s
13
M
A
S
57
51
47
37
W
ire
 e
xt
ru
si
on
 in
 th
e 
EA
C
Ye
s
M
ea
n
59
51
45
44
A
ge
 is
 a
t t
he
 d
at
e 
of
 im
pl
an
ta
tio
n.
 P
TA
 =
 p
ur
e 
to
ne
 a
ve
ra
ge
, 
EA
C
 =
 e
xt
er
na
l a
ud
ito
ry
 c
an
al
, F
U
 =
 fo
llo
w
 u
p,
 T
M
 =
 t
ym
p
an
ic
 m
em
br
an
e.
39
2
Active middle ear implants
A recent inquiry showed that nine of the thirteen patients implanted by the transcanal 
approach are currently using their VSB on a daily basis and are benefiting from it. Two of 
the four non-users were explanted as is stated in the results. One patient is a non-user as 
result of device-failure and one patient has deceased. The actual use of the implant is 
displayed in Table 1.
Preoperative sensorineural hearing loss of the patients (seven men and six women) at 0.5, 
1 and 2 kHz varied between 38 dB HL and 57 dB HL in the operated ear (with a mean of 45 
dB HL) and between 33 dB HL and 60 dB HL in the non-implanted ear (with a mean of 44 
dB HL). The age of the patients at implantation ranged from 44 to 79 years with a mean of 
59 years. All of the patients were suffering from therapy-resistant external otitis. 
Outcomes of this study include postoperative hearing thresholds and follow-up period 
complications. Changes in hearing thresholds were studied in both the implanted ear 
and, for reference purposes, the non-implanted ear. Pure-tone and bone conduction 
thresholds were measured using standard audiometric equipment.
Surgical technique
In the transcanal approach applied in our study, the retro-auricular skin and periosteum 
were incised, followed by the careful lateral to medial separation of the skin of the EAC 
(external auditory canal) from the posterior wall and by the widening of the posterior 
bony wall up to the level of the annulus. A groove with a width of approximately 1 mm 
was drilled postero-inferior laterally to postero-inferior medially to accommodate the 
silicon-coated conducting wire. The titanium clip of the FMT was manually bent 45 
degrees to enable placement over the lateral surface of the distal part of the long process 
of the incus, as described by Truy et al. in 2006 (5). The postero-inferior location of the 
groove combined with widening of the bony ear canal provided sufficient space to 
manipulate the FMT in the middle ear and attach it to the incus as prescribed, parallel to 
the stapes crura. The bony groove was covered and filled by bone-pâté and fibrin glue 
until the conducting wire could no longer be seen. However, the length of the 
silicon-coated wire was too long for direct placement. To solve this problem, an extra loop 
in the wire was placed over the lateral surface of the mastoid cortex. A bony well was 
drilled in the mastoid cortex postero-superior to the external bony ear canal to facilitate 
the receiver of the device. Fixation of the implant was obtained by suturing in the 
conventional manner.
In case of revision surgery, the transcanal operating technique was modified with either 
an emphasis on achieving a more complete seal with the fascia of the temporal muscle or 
on the drilling of an even deeper bony groove, or both.
40
Chapter 2
Results
Postoperative hearing thresholds
The mean preoperative and postoperative hearing thresholds of the patients’ implanted 
and non-implanted ears were evaluated. The threshold values were obtained relatively 
soon after implantation (mean 2.7 months, range 0.9 to 7.5 months). Figure 1 shows the 
mean normalised changes as a function of frequency. The different values were normalised 
using the measurements from the non-implanted ear. For reference purposes, we also 
present data from the initial European trial, which used the posterior tympanotomy 
approach (1), and from the results of Schmuziger et al. (6). The presented data were 
calculated from the original figures of pre- and postoperative thresholds in the implanted 
and non-implanted ears. Standard deviations of our data (not indicated) varied between 
8.5 and 17.8 dB. 
The postoperative normalised hearing thresholds were slightly deteriorated with a mean 
decrease at 0.5, 1 and 2 kHz of 5.5 dB (standard deviation ± 7.6 dB). Four of the thirteen 
patients had a clinical significant decrease of hearing thresholds at 0.5, 1 and 2 kHz with a 
range from 11.7 to 18.3 dB. 
Figure 1   Mean normalized change in hearing thresholds (pre-operative minus 
postoperative thresholds) as a function of frequency. To correct for any 
changes related to measurement conditions, the change in hearing threshold 
also was determined in the nonimplanted ear. Subtraction of that change  
was used to normalize the change in hearing threshold in the implanted ear. 
Present data are compared with those reported by Fisch et al. (1) and 
Schmuziger et al. (6). 
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Complications of surgery
The mean duration of the follow-up period ranged from 26 to 73 months with a mean of 
51 months. An overview of the complications is presented in Table 2. No injury of the 
facial nerve was observed, although in two patients (15%), the chorda tympani was 
intentionally sacrificed during surgery to maximize the size of the facial recess. In one 
patient, lacerations of the skin of the posterior bony canal occurred where the posterior 
bony canal obstructed the view of the tympanic ridge. The surgeon (C.C.) observed that 
the skin of the EAC was thin and much more vulnerable to damage in our group of 
patients, presumably as a result of skin changes caused by the persistent external otitis. 
Immediate postoperative healing of the skin of the external ear canal was nevertheless 
uneventful in all the patients. 
In one patient, the external cartilaginous meatus became narrowed 8 weeks postopera-
tively as a result of the retro-auricular skin and periosteal incisions. In this case, the 
pre-existent external otitis was therefore aggravated by the obstruction of the ear canal. 
The collapse of the ear canal occurred three months after surgery, and additional 
meatoplasty was performed with success (follow-up since meatoplasty: 36 months). 
In five patients (38%), the silicon-coated wire extruded through the skin of the EAC. The 
wire extrusion was noticed at a mean postoperative period of 25 months (range 4 to 41 
months). Revision surgery was performed on four of the patients. Although the revision 
surgery was uneventful, this procedure represented a risk of damage to the conducting 
wire because of its protrusion from the posterior edge of the external bony ear canal. 
Despite coverage of the silicon-coated wire with fascia, repeated extrusion through the 
skin of the EAC occurred in three of the four patients who underwent revision surgery. 
One of these three patients suffered from therapy-resistant seborrhoeic eczema of the 
external ear canal, and therefore explantation of the Vibrant Soundbridge became 
ultimately inevitable. Despite the extrusion of the wire in the EAC, the patients are still 
actively using their VSB. No clinical signs of infection of the conducting wire have been 
noticed during regular visits.
Table 2  Overview of reported complications.
Complication No. (%)
Tympanic membrane perforation 1 8
EAC collapse 1 8
Wire extrusion 5 38
Chorda tympani sacrificed 2 15
Percentage of the complete study group.  EAC = external auditory canal.
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Perforation of the tympanic membrane occurred in the eldest patient in the study group 
four months after implantation. Gradual widening of the perforation produced an air-bone 
gap that ultimately became 30 dB (average at 0.5, 1, 2 kHz) in contrast to the absence of 
decrease in hearing thresholds directly postoperative. Bone-conduction thresholds were 
not affected. As time progressed, deterioration occurred in the aided sound field 
thresholds and the aided speech score. The patient’s monosyllable phoneme score at 
65 dB SPL presentation level changed from 85% to 68% to 32% at present. Because of an 
increase of the perforation and extrusion of the wire in the EAC, a myringoplasty with 
cartilage tissue was performed in combination with reconstruction of the skin of the 
EAC four years after implantation. Unfortunately, extrusion of the wire reoccurred post-
operatively within five months. 
In another patient, an air-bone gap was detected 25 months after implantation, which 
gradually increased to 25 dB (average at 0.5, 1 and 2 kHz). The direct postoperative hearing 
thresholds had been unchanged. Repeated otoscopy showed a narrow ear canal that was 
repeatedly obstructed with earwax. However, removal of the wax did not lead to the 
expected improvement in air conduction thresholds. Therefore, the air-bone gap 
remained unexplained. In addition, there was slight deterioration (10 dB) in the bone 
conduction thresholds in the implanted ear. No cause was found for this hearing loss, but 
it has been noted in similar studies. These changes in hearing did not affect the aided 
hearing thresholds or the aided speech recognition score. Because of the lack of change 
in hearing capacity, revision surgery was not considered. 
Discussion
In the primary European clinical trial, placement of the FMT by means of the transmastoidal 
posterior tympanotomy approach led to chronic underpressure in the middle ear in 
certain patients who suffered preoperatively from inadequate middle ear aeration (3). To 
address this problem, a clinical study was initiated to evaluate implantation using a 
transcanal approach. In addition to the problems of aeration of the middle ear, the 
mastoidectomy and especially the posterior tympanotomy technique bring an additional 
risk of damage to the facial nerve and the chorda tympani. Although no facial palsies have 
been reported after VSB surgery in the literature, this phenomenon has been described in 
cochlear implantation, varying from 0.14% (7) to 0.7% (8) and, more recently, 2.3% (9). 
Damage to the chorda tympani has been described in VSB surgery varying from 2 to 15% 
(1, 6, 10).
To avoid the complications of the transmastoidal posterior tympanotomy approach, 
several transcanal methods have been proposed in Vibrant Soundbridge and cochlear 
implant surgery. Truy et al. (5) have described two different methods to allow the FMT to 
pass into the middle ear: the EAC-cutting approach and the EAC tunnel approach. Both 
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methods consist of a small mastoidectomy in combination with separation of the skin of 
the posterior wall of the EAC, a tympanomeatal flap and atticotomy. Next, a bony groove 
is drilled in the inferior part of the EAC. In the EAC tunnel approach, a tunnel is drilled from 
the mastoid cavity to the EAC above the emergence of the chorda tympani to facilitate 
the passing of the FMT. The article describes of two clinical cases in which the VSB was 
implanted by the EAC-cutting approach and the conducting wire covered by bone pâté 
and fibrin glue. Although the duration of follow-up was rather short, no postoperative 
complications were observed. Truy et al. concluded that their transcanal approach 
simplified the procedure and shortened the duration of surgery. 
A more recent publication by Bruschini et al. (11) presented the clinical results of a 
transcanal implantation method. The applied surgical technique consisted of a small 
cortical mastoidectomy, separation of the skin of the EAC from the posterior wall and a 
minimal superior atticotomy.
The small superficial mastoidectomy was drilled in order to facilitate the extra length of 
conducting wire of the VSB. The groove that was drilled measured 1.5 mm in diameter and 
extended from the annulus to the outer border of the EAC. The groove and wire were 
covered by bone pate and tissucol. During a mean follow-up period of 21 months, no 
postoperative complications were reported, and no decrease in postoperative hearing 
thresholds was observed. 
In cochlear implantation surgery a suprameatal approach (SMA) was developed in 2000 
by Kronenberg (12). In this method, a tunnel is drilled supraposteriorly to the suprameatal 
spine towards the EAC in combination with a subperiostal tunnel to facilitate the 
conducting wire. The SMA was recently compared with the classic approach by Postelmans 
et al. (13, 14). No facial nerve paralysis was reported in the SMA approach, whereas the 
classic approach led to two facial nerve injuries during the posterior tympanotomy. 
Another transcanal approach in cochlear implantation, called the transmeatal approach 
(TMA), has recently been described by Taibah (15). In this open-tunnel approach, the 
drilling of a groove that is comparable with that of our approach is combined with the 
drilling of a parallel tunnel towards the middle ear. In Taibah’s series of 131 patients, no 
extrusion of the wire was reported during a follow-up period of 2 to 46 months. In five of 
the cases (3.8%), a tympanic membrane perforation was reported. The method of drilling 
a bony groove with an overhanging roof in CI implantation has also been described by 
Slavutsky (16). After 3 to 18 months of follow-up, no wire extrusions were reported. 
In this article, we present the results of VSB surgery by a transcanal approach in 13 patients 
suffering from therapy-resistant external otitis. During the two years of this trial, the actual 
implantation of the VSB by the transcanal approach was successful in all operated patients. 
In two patients, the chorda tympani was sacrificed to maximize the size of the facial recess. 
No other perioperative complications were reported. The mean normalised postoperative 
air-conduction thresholds deteriorated slightly (5.5 dB). This deterioration was comparable 
with the presented outcome after implantation by transmastoidal posterior tympanotomy 
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approach (1, 6). Figure 1 suggests minor differences among the data of the three compared 
studies. In a recent publication by Bruschini et al. (11) in which a transcanal approach was 
evaluated, no differences in pre- and postoperative thresholds were reported. Nevertheless, 
in our study, 4 of the 13 patients had a larger decrease at 0.5, 1 and 2 kHz with a range from 
12 to 18 dB, namely patients 3, 7, 11 and 12 (see Table 1). No correlation between the 
deterioration in hearing thresholds and the presented complications was found. However, 
the mean hearing threshold deterioration of 5.5 dB at 0.5, 1 and 2 kHz in the entire group 
of patients suggests that the new approach does not involve significantly more risk to 
postoperative hearing thresholds than the traditional approach.
Apart from two per operative sacrificed chorda tympani, seven postoperative complications 
were observed in this study in six patients (46%) during a mean follow-up period of 
51 months. As shown in Table 2, these complications consisted of collapse of the EAC (1), 
the extrusion of the conducting wire (5) and perforation of the tympanic membrane (1). 
No further postoperative complications occurred during the follow-up period. No post -
operative complications were observed for seven patients (54%) in this study. 
In our opinion the high rate of postoperative complications in the transcanal approach 
can be traced to the presence of therapy-resistant external otitis. All of the patients in our 
study group were suffering from this condition because the combination of sensorineural 
hearing loss and therapy-resistant external otitis is the primary indication for VSB 
implantation in our clinic. Even though no results of studies of VSB surgery on a large 
group have been published, virtually no conducting wire extrusions have been recorded 
in large studies on the transcanal or transmeatal approaches in cochlear implant surgery 
(15, 16). In the publications concerning VSB implantation by Truy et al. (5) (n=2) and 
Bruschini (11) (n=12), no surgical complications were reported. No patients in either of 
these studies concerning VSB or cochlear implantation were suffering from external otitis. 
In treatment of patients with pre-existing external otitis, we considered the skin on the 
medial wall of the posterior bony ear canal to be fragile. Thus, modification of the surgical 
method to prevent the complication of conducting wire extrusion is required. The 
tunnelling technique proposed by Taibah (15) and Slavutsky (16) might be applied. The 
posterior and inferior bony ear canal provides sufficient space to do so without interfering 
with the diameter of the ear canal. However, in our series, a deepening of the bony groove 
and better coverage of the wire did not guarantee that repeated extrusion of the wire 
would be prevented. Because revision surgery was unsuccessful in four of five patients, we 
conclude that the transcanal approach for VSB implantation is unfavourable in patients 
suffering from therapy-resistant external otitis.
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Conclusion
We consider it of great importance to define the optimal clinical conditions and the 
indications for the application of this innovative device. In the interests of this definition, 
we have introduced the extra inclusion criterion of therapy-resistant external otitis in our 
clinic.  For treatment of this group of hearing-impaired patients, it is essential to have an 
alternative for the conventional hearing aid. Although the results of transcanal implantation 
of the Vibrant Soundbridge and cochlear implantation seem promising in general, the 
described approach in this article showed a high number of postoperative complications. 
This indicates that the condition of the skin of the external auditory canal in otitis externa 
is not suitable for covering of the conducting wire of the FMT. Despite the fact that the 
implanted patients do benefit from their VSB, we have not applied this method of 
implantation in our clinic since the end of the study period in 2005. The authors suggest 
that therapy-resistant external otitis should be considered as a contraindication for a 
transcanal approach in the implantation of the Vibrant Soundbridge.
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Abstract
Objective: To study long-term subjective benefit of patients with sensorineural hearing 
loss and chronic external otitis who use active middle ear implants.
Design: Single-subject repeated measures in a pre- and post-intervention design with 
multiple post intervention measurements (questionnaires).
Patients and methods: Moderate to severe sensorineural hearing loss (n=56) with severe 
chronic external otitis who use the Vibrant Soundbridge (VSB) or Otologics MET middle 
ear implant systems. The main outcome measures were: changes in hearing disability and 
handicap as evaluated using the Abbreviated Profile of Hearing Aid Benefit (APHAB), the 
Nijmegen Cochlear Implant Questionnaire (NCIQ) and the Glasgow Benefit Inventory 
(GBI). 
Results:  Data of 33 patients (mean post-operative duration of 7.5 years) were available. No 
difference in subjective results was found between the VSB and Otologics MET patient 
groups. Total percentage of non-use was 13%. Long-term APHAB results show a significant 
decrease in disability for 43% of the patients compared to 54% at 1-year postoperative. 
NCIQ results show a significant benefit for all sub domains with a negative trend over time. 
The GBI results show a significant long-term increase in quality of life with positive scores 
for 82% of the assessed patients. 
Conclusions: Long-term post-operative patient satisfaction and quality of life results 
show a significant difference compared to pre-operative measurements, with conventional 
hearing aids. A negative trend over time is found on all questionnaires, which might reflect 
patient aging (increase of hearing loss) or habituation to a situation with fewer concerns 
regarding a patient’s external otitis.
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Introduction
Some patients with hearing loss decline to use acoustic hearing aids because of cosmetic 
reasons or complaints about poor sound quality (1-3). For other patients, application of 
acoustic devices might be troublesome because of therapy-resistant chronic external 
otitis. Although ventilated or specially coated ear moulds might be beneficial for the latter 
patient group, many patients cease to use the hearing device due to pain or itching (4). For 
such patients, an active middle ear implant (AMEI) has been advocated.
An AMEI comprises an externally worn audio processor and an implanted signal processor 
and output transducer. The transducer is a specially developed implantable magnetic 
actuator that is in contact with the middle ear ossicles. The audio processor is magnetically 
connected to the implant and communicates with it through the skin by means of 
radiofrequency signals. AMEI are generally believed to be more attractive from a cosmetic 
point of view as the audioprocessor is easily hidden by hair. Furthermore, better sound 
quality has been claimed over conventional hearing aids (1-3) and, as the device bypasses 
the external ear canal, it might be the solution for patients with chronic external otitis (5). 
In 1996, we started implanting the semi-implantable Otologics MET (MET) device 
(Otologics LLC, Boulder, CO, USA) and the Vibrant Soundbridge (VSB) middle ear implant 
(Med-El, Innsbruck, Austria) in patients with sensorineural hearing loss who also had 
severe, therapy-resistant external otitis, thereby avoiding the use of ear moulds. 
To evaluate the subjective benefit of AMEI we sent questionnaires to all patients before 
implantation and at 6 and 12 months after middle ear implantation. The short-term results 
of this study have been published (5). In short, from a disability point of view, middle ear 
implants were not more positively appreciated than conventional devices. With regards to 
(disease-specific) quality of life, patients experienced a significant improvement in quality 
of life which the authors ascribed to the use of this ear mould-free hearing device that 
could be worn all day without pain or itching (6). 
To assess patient long-term subjective benefit, we recently performed an additional 
cross-sectional evaluation. All patients with at least two years of postoperative follow-up 
were selected. This group comprised 56 middle ear implant users. Since 2000, we used a 
standardized protocol to assess subjective benefit (5). In short, to assess the (remaining) 
disability, the Abbreviated Profile of Hearing Aid Benefit (APHAB) is administered (7). This 
questionnaire quantifies hearing difficulties in various everyday listening situations. In 
addition, we used the disease-specific quality of life questionnaires, namely the Nijmegen 
Cochlear Implant Questionnaire (NCIQ) and Glasgow Benefit Inventory (GBI). We evaluated 
daily use by a specific questionnaire, which is addressed as ‘daily use questionnaire’. To 
assess generic quality of life, we used the SF-36 questionnaire (6). However, as it became 
clear that this questionnaire is rather insensitive to problems with communication (6,8), we 
discontinued its use in 2006. 
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Long-term studies of subjective benefit in middle ear implant users are scarce; we identified 
only three studies in our review of the literature (9-11). These studies mainly comprised 
patients who were implanted with an active middle ear implant because they disliked 
their conventional hearing aid(s). 
Our present study might present a different outcome as our patients were not dissatisfied 
with their previous conventional devices, rather, the patients couldn’t wear these devices 
because of complaints of external otitis. In a recent systematic review on AMEI, Tysome et 
al. (12) conclude that the overall quality of the studies concerning AMEI is moderate to 
poor because of a lack of comparisons with conventional hearing aids. Unlike the included 
long-term implant studies in their systematic review, our research design is a prospective 
study with validated outcome measures. 
In summary, the aim of the study was to evaluate long-term gain in subjective benefit of 
AMEI implantation in a group of hearing impaired subjects with chronic external otitis.
Materials and methods
Study design 
To assess the patient’s subjective benefit over time, longitudinal data were collected. We 
used the same prospective, single-subject repeated-measures protocol as in the previous 
study (5). After being selected for middle ear implantation, patients filled in the APHAB 
and NCIQ questionnaires. The same questionnaires were also filled in 6 and 12 months 
after the middle ear implant audioprocessor had been fitted. These questionnaires were 
recently repeated by patients with a variable follow-up time of at least 24 months (referred 
to as the long term evaluation moment). The retrospective GBI questionnaire was 
completed at the 12-month follow-up and in the recent long term evaluation assessment. 
All the questionnaires were sent to the patients by mail. Concerning the recent survey, 
patients who had not returned the questionnaire were telephoned to enquire about their 
daily usage of the AMEI. With respect to audiology, follow-up comprised audiometric 
measurements and regular refitting during the first year of device use and at subsequent 
5-year intervals in cases of stable results. 
Study population 
The study population comprised 56 middle ear implant users who had been implanted 
between February 1997 and May 2010 at our department with a semi-implantable device. 
Because of the Dutch inclusion criteria for reimbursement of the AMEI, only patients with 
severe therapy resistant external otitis are eligible to be implanted. Fifteen patients were 
excluded from the long-term evaluation. Patients with known complications did not 
receive questionnaires and patients who did not meet the postoperative duration of two 
years. The exclusion criteria are presented in table 1.
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Altogether, 41 patients were included in the recent survey: the MET device was used by 8 
patients (19%) and the VSB was used unilateral by 29 patients (71%) and bilateral by 4 
patients (10%). All patients had symmetrical sensorineural hearing loss within 10 dB (at 0.5, 
1 and 2 kHz) with a mean hearing loss (at 0.5, 1 and 2 kHz) from 32 dB HL to 77 dB HL. All 
patients used conventional hearing aids before implantation; however, this was mostly on 
an irregular basis owing to external otitis. Baseline measurements were gathered pre- 
implantation and, as such, measurements reflect the aided condition with conventional 
hearing aids. The mean age of the study population was 60 years (range 28 to 76 years) 
and 24 patients (58.5%) were female. The number of questionnaires available for analysis 
at baseline, 6-month and 12-month evaluation moments were 42, 28 and 26, respectively. 
Questionnaires
APHAB questionnaire
To assess the (remaining) disability, the APHAB was used. This questionnaire quantifies 
hearing difficulties in various everyday listening situations (7) and contains four subscales: 
ease of communication (EC), listening in reverberate situations (RV), listening in background 
noise (BN) and aversiveness to sounds (AV). This fourth subscale measures negative reactions 
to environmental sounds. The results of each subscale are presented as percentages of 
difficulty with listening in that specific situation on a score from 0 to 100%. The APHAB 
questionnaire has been used in several studies on active middle ear implantation (1,2) as 
well as studies on conventional hearing devices (7).
Table 1  Overview of the total study population of the long term evaluation. 
Middle ear implant patients (n=56)
Excluded Included
1. Deceased 4 Assessment completed 33
2. Complications 4 Non use (3)
Incus necrosis (3)
TM perforation (1) Assessment not completed 8
3. Postoperative duration <2y 7 Non use (2)
Deceased (1)
Not interested (4)
No contact (1)
15 41
 
TM = tympanic membrane.
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Nijmegen Cochlear Implant Questionnaire 
The NCIQ assesses disease-related quality of life. It was initially developed to evaluate how 
cochlear implantation affects health status (13,14). The NCIQ comprises three sub domains: 
the general physical domain focuses on hearing and speech problems, the psychological 
domain assesses mainly self-esteem and the social domain addresses activity limitations 
and social interactions. Scores can range from 0 (extremely poor) to 100 (excellent). The 
NCIQ is reliable, robust and sensitive to clinical changes (13,15,16). Nowadays, the NCIQ is 
widely used within the field of cochlear implantation (17) and is also used to evaluate 
patients with conventional hearing devices (18) and patients with bone-anchored hearing 
aids (16). We have adapted the NCIQ to the use in the evaluation of middle ear implantation 
by excluding six of the questions that concern complete deafness or the use of sign 
language, namely, questions 8, 15, 33, 39, 56 and 57 (13).
GBI questionnaire
The GBI is a quality of life questionnaire developed to retrospectively assess the outcome of 
otorhinolaryngology interventions (19). Change in patient health status after the intervention is 
evaluated with respect to psychological and social functioning and physical well-being 
(19). The benefit score can range from –100 (extreme deterioration) to +100 (excellent 
improvement). Since the GBI is a retrospective questionnaire, recall bias might play a part in 
long-term evaluations. The GBI has been used to evaluate the benefit of cochlear implants, 
middle ear implants and bone-anchored hearing aids, as reviewed by Snik et al. (17). 
The ‘daily use’ questionnaire
This questionnaire is an adapted version of the questionnaire used by de Wolf et al (16) to 
evaluate use of the bone-anchored hearing aid. This questionnaire focuses on the per day 
duration of device use, the ease of controlling the device and the general appreciation of 
the device and the produced sounds. This questionnaire was only used in the recent 
long-term evaluation
Statistics
Differences between mean baseline and mean aided scores were analysed using ANOVAs 
and Student’s t-tests. For patients with a complete data set, paired t-tests were performed. 
All statistical tests were performed with SPSS (version 16). Significance level was set at 
p=0.05. Normal distribution was tested using the Shapiro-Wilk test of normality.
Individual differences in APHAB scores over time (baseline minus aided data; short-term 
compared to long-term data) were checked for significance using the guidelines formulated 
by Cox and Alexander (7). Alexander and Cox reported the 95% critical difference on the APHAB 
subscales EC, RV and BN to be 22%; any change exceeding 22% is therefore considered 
significant (20).  In the joint evaluation of the subscales EC, RV and BN, they considered a 
difference of 10% or more for each of the three subscales as significant (p < 0.02). 
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Results
Thirty-three patients (80%) returned the recent questionnaires. Table 1 lists the reasons 
why the remaining eight patients (20%) did not return the questionnaires. Three of the 
patients who returned the questionnaires had recently ceased using their devices but 
answered the questionnaire according to their situation before they stopped using their 
device. The mean postoperative duration of device use was 7.5 years (SD ± 3.4 years). 
Table 2 lists an overview of the patient characteristics and the results per sub domain of 
the APHAB and NCIQ questionnaire per evaluation. In Table 3 the results of the so-called 
“daily use questionnaire” are listed. A one-way ANOVA (data not presented) indicated no 
significant differences (p < 0.05) for the total scores of all outcome parameters between 
the Otologics MET and VSB devices (either unilateral or bilateral).
Table 2   Overview of available data, patient characteristics of the returned lists and 
questionnaire scores per evaluation moment. 
Evaluation moment Baseline 6-months 12-months Long term
Included 56 52 52 41
Excluded   0    4A    4A  15B
Returned list 42 (75%) 28 (54%) 26 (50%) 33 (80%)
Male : Female 15 : 27 11 : 17 11 : 15 11 : 22 
Mean age (range) 56 (18-80) 56 (19-79) 56 (19-79) 60 (28-76)
MET : VSB uni : VSB bil 8 : 30 : 4 7 : 17 : 4 5 : 17 : 4 5 : 25 : 3
NCIQ (mean, ± SD) n=17 n=22 n=23 n=31
Physical 49.9 ± 10.5 68.3 ± 13.9E 62.3 ± 15.6D 60.4 ± 14.2D
Physiological 52.5 ± 22.3 70.6 ± 15.6D 66.7 ± 19.3C 58.9 ± 17.3
Social 46.6 ± 23.5 66.9 ± 13.0D 62.0 ± 17.8C 64.1 ± 17.7D
Total 49.7 ± 16.4 68.6 ± 11.6E 63.7 ± 15.5D 61.1 ± 13.7C
APHAB (mean, ± SD) n=42 n=28 n=24 n=32
EC 53.2 ± 20.9 26.9 ± 18.9E 33.3 ± 22.8D 42.4 ± 21.3C
BN 70.7 ± 17.3 54.9 ± 17.2E 58.9 ± 17.2D 65.3 ± 19.6
RV 66.0 ± 15.9 49.0 ± 12.5E 47.7 ± 17.6E 59.4 ± 16.9
AV 36.7 ± 26.6 42.9 ± 26.2 47.0 ± 29.0 41.9 ± 27.7
Global 63.3 ± 14.8 43.6 ± 12.6E 46.6 ± 16.2E 55.6 ± 16.6C
MET: Otologics MET; VSB uni: Vibrant Soundbridge unilateral; VSB bil: Vibrant Soundbridge bilateral.
A Patients with known complications were excluded.  
B See table 1 for exclusion criteria. 
C Unpaired t-test versus baseline: C p < 0.05;  D p < 0.01;  E p < 0.001
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APHAB
Figure 1 displays the mean data of the APHAB sub-domains and total score (mean score 
for EC, BN and RV) as a function of follow-up. Statistical analysis of the post-intervention 
data compared to baseline data is presented in the figure and in table 2. Significant 
changes were found in the APHAB total domain (p< 0.05) for all evaluation moments 
Table 3  Results of The “daily use” questionnaire
Question Response  n (%)
Are you still using your MEI? Yes 30 (91)
No 3 (9)
How many hours per day have you been using  
the MEI on a regular basis?
Not worn 3 (9)
1-4 hours a day 2 (6)
4-8 hours a day   5 (16)
> 8 hours a day 22 (69)
In general, is your MEI worth the effort? No 1 (3)
A little   4 (13)
Moderately   4 (13)
Much   8 (26)
Very Much 14 (45)
Do you have difficulties placing your MEI? Yes 1 (3)
No 29 (97)
Can you handle the controls of your MEI well? Yes 27 (93)
No 2 (7)
How do you judge the sound of the MEI? Very Good 3 (9)
Good 18 (56)
Reasonable   7 (22)
Bad   4 (13)
Very bad 0 (-)
Would you recommend a MEI to a friend with  
the same hearing loss as yours?
Yes 27 (84)
No   5 (16)
How much would you be willing to pay for you  
MEI yourself?
Nothing   3 (11)
€   500   5 (19)
€ 1000 11 (41)
€ 2500   3 (11)
€ 5000   5 (18)
Would you, based on your experience with  
your MEI, choose your MEI again?
Yes 25 (83)
No   5 (17)
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although the difference with the baseline and the last evaluation moment is small. For the 
AV subscale, the increase in problems found at all evaluation moments was not significant. 
Over time, the benefit in APHAB scores seems to drops. The long-term evaluation shows a 
significant difference with the baseline data for the EC domain and the total score.
Next, an analysis was performed with a subgroup of the patients, viz. those with paired 
data. Table 4 lists the outcomes. Compared to baseline the number of patients with 
significant improvement was 19 (68%), 13 (54%) and 10 (43%) at the 6-month, 12-month 
and long-term evaluation moments, respectively.
NCIQ
Figure 2 displays the NCIQ questionnaire results per domain by evaluation moment. The 
6-month and 12-month evaluations show a significant difference with the baseline data 
for all sub domains, whereas the long-term evaluation is non-significant in the physiological 
subdomain. In table 2, the results are listed per sub domain. A significant difference in the 
long-term results is found for the physical (p < 0.01), social (p < 0.01) and total (p < 0.05) 
scores when analyzed with unpaired t-tests. When the results were analyzed with paired 
t-tests, the long-term benefit is significant for all general domains, including the total 
result (p < 0.01, n=9). At the 6-month evaluation moment, the difference with the baseline 
is significant for all subdomains (n=8). This is in contrast to the 12-month evaluation 
moment in which only the social subdomain difference is significant (n=8). Unfortunately, 
only few questionnaires were available for the paired analysis. The results are listed in 
Table 5.
Figure 1   Mean APHAB scores per evaluation moment. A lower value indicates a better 
result. AV indicates aversiveness; BN background noise; EC ease of 
communication; RV reverberation. Note: results of unpaired t-test versus 
baseline. *p < 0.05, ** p < 0.01, *** p < 0.001, NS = not statistically significant.
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Table 4   Outcome of the APHAB results per subscale displayed per  
evaluation moment.  
APHAB Subscale # (%) significant BENEFIT versus baseline
6 months 
(n=28)
12 months 
(n=24)
Long term 
(n=23)
Ease of Communication 16 (57%) 11 (46%) 7 (30%)
Reverberation 11 (39%) 9 (38%) 3 (13%)
Background Noise 9 (32%) 7 (29%) 5 (22%)
Aversiveness 0 (-) 0 (-) 2 (9%)
Global APHAB (EC, RV, BN) 16 (57%) 12 (50%) 9 (39%)
Significant improvement* 19 (68%) 13 (54%) 10 (43%)
APHAB Subscale # (%) significant DETERIORATION versus baseline
6 months 
(n=28)
12 months 
(n=24)
Long term 
(n=23)
Ease of Communication 0 (-) 1 (4%) 2 (9%)
Reverberation 1 (4%) 1 (4%) 0 (-)
Background Noise 0 (-) 0 (-) 2 (9%)
Aversiveness 0 (-) 0 (-) 6 (26%)
Global APHAB (EC, RV, BN) 1 (4%) 0 (-) 1 (4%)
Significant improvement* - - -
*  significant improvement if more than 22% benefit in 1 subscale or more than 10% benefit in EC, RV and BN 
subscales. (Cox et al. 1997)
Figure 2   Mean NCIQ scores per evaluation moment. A higher value indicates a  
better result. The error bars represent the 95% confidence interval.  
Note: results of unpaired t test versus baseline *p < 0.05, ** p < 0.01,  
*** p < 0.001, NS = not statistically significant.
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GBI
Of the 33 patients at the long-term evaluation moment, 27 (82%) had a positive total GBI 
scores (mean score +26.5, SD ± 17.5), 3 (9%) had no change in total GBI scores and 3 (9%) 
had a negative change in total GBI scores (mean score -5.9, SD ± 2.9) (Table 5). The overall 
mean score was +21.2 (SD ± 19.6). These results are lower compared to the 12-month 
results in which 23 patients (92%) had a positive GBI score (mean +22.6, SD ± 13.7), 
1 patient (4%) had no change and 1 patient (4%) had a negative change (-17.6). At this 
evaluation moment the overall mean score was +20.1 (SD ± 16.0). No significant difference 
in benefit between the evaluation moments was found in a paired t-test analysis (n=19 
patients; p > 0.05).
Discussion
This study evaluates the long-term subjective benefit in middle ear implantation for 
patients with therapy-resistant chronic external otitis. We compared data collected with 
the APHAB, NCIQ and GBI questionnaires and evaluated device use and device satisfaction 
as reported by AMEI users. Of the 56 patients who provided baseline data, at long-term 
follow-up 5 patients were deceased, 5 patients had become device non-users and 4 patients 
had known complications and were excluded from the study (see Table 1). At the long- 
term evaluation moment, 5 of the 39 patients reported being device non-users, meaning 
that the total percentage of non-user was 13%. Main reasons for non-use were insufficient 
Table 5   Overview of individual benefit values per evaluation moment,  
compared with baseline.
Evaluation moment 6-months 12-months Long term
NCIQ benefit (mean, ± SD) n=8 n=8 n=9
Physical, benefit 21.5 ± 12.2B   6.5 ± 10.7 18.6 ± 12.6B
Physiological, benefit 28.3 ± 20.7B 13.2 ± 18.7 12.7 ± 12.6A
Social, benefit 36.3 ± 20.6B 14.2 ± 16.6A 22.6 ± 20.8A
Total, benefit 28.7 ± 14.4B 11.3 ± 13.7 18.0 ± 12.4B
GBI, benefit in aided condition (mean, ± SD) n=25 n=33
Total 20.1 ± 16.0 21.2 ± 19.6
General 24.6 ± 18.2 25.0 ± 20.8
Social 14.0 ± 21.9 13.6 ± 22.6
Physical 9.3 ± 32.0 13.6 ± 34.0
A Paired t-test p < 0.05;  B p < 0.01
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benefit and device problems.  Mosnier et al. reported a comparable percentage of device 
non-users (15%) in their paper on long-term effects of active middle ear implantation (9). 
Schmuziger et al. (2006) also published long-term data on a group of 20 middle ear 
implant users. Although these authors reported no device non-use, their data was 
gathered only after 3.5 months of device use (11). In 2010, Rameh et al. published the long 
term postoperative results of their AMEI users. In general, patients were satisfied with their 
implants although great variation was found between the devices. The audiologic gain 
was adequate, but not spectacular. Especially, the daily life audiologic gain was poor in 
relation to patient satisfaction. Many patients considered their contralateral conventional 
hearing aids more satisfying (10).
In the long run, the majority of patients in our study are content with their AMEI: 71% of 
the patients report that the AMEI is worth the effort and 85% report wearing the device 
more than 4 hours a day (see Table 3). This result is comparable to the short-term results 
reported by Sterkers et al (3) and published long-term patient satisfaction results (9,10). 
The patients in our study consider the devices easy to use and the sound is judged 
positively by 87%. More than 80% would choose this device again or would recommend 
the device to others. These results are comparable with those published by Mosnier (77% 
satisfaction and 72% would repeat the surgery) (9). The respondents also reported being 
willing to pay an average price of up to 1750 Euros for their device, which is comparable to 
the average price of high-end conventional hearing aids in the Netherlands. 
The results from our study are better than the outcome presented by Rameh et al. (10). In 
their study, 42% of the VSB users were more satisfied with the implant than with the 
contralateral behind the ear (BTE) hearing aid, whereas only 29% of the MET users were 
more satisfied with it. Only 67% of the patients with a VSB and 55% of patients with a MET 
reported they would undergo the surgery again. We believe that these differences are 
best explained by differences in study inclusion criteria, such as cosmetic considerations 
because of visibility issues with regular hearing aids (10). Besides this, the results in our 
study are based on data of patients who are using the device and only 3 of the 5 non-users 
(total 13%).
The results of the APHAB questionnaire (Figure 1) suggest that patients experience a 
significant decrease in problems after AMEI implantation (compared to the pre-implant 
situation, viz. using conventional devices). Nevertheless, the results show a negative 
long-term trend. This leads to a decreasing level of statistical significance at each follow-up 
evaluation moment and even results in a non-significant difference at the long-term 
evaluation moment for the BN and RV subdomains. We found that the questionnaire 
scores dropped by approximately 10 points over the evaluation period of 7 years. Few 
results have been published on the long-term stability of perceived benefit and 
satisfaction of any type of hearing aid fitting. Similar to our study, Takahashi et al. found 
that the APHAB scores deteriorated over time at a similar rate in patients who used 
conventional hearing aids (21). This suggests deterioration in APHAB scores is not device 
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specific, but rather it is a general trend in long-term evaluation by means of questionnaires. 
In the paired-data analysis by Cox and Alexander (Table 4), this decline in benefit is visible 
as a decrease in number of patients with significant benefit (68% versus 43%) (20). 
The deterioration over time might be ascribed to advancing hearing loss (similar to 
presbyacusis) or the patient becoming accustomed to a new hearing situation without 
adverse effects of external otitis.  
Another method to evaluate hearing impairment disability is by using the NCIQ questionnaire. 
We previously applied this method to evaluate the short-term result of middle ear 
implantation (6). From the results displayed in Figure 2 and listed in Tables 2 and 5, we 
can conclude that middle ear implantation has a significant positive effect on NCIQ scores 
at all evaluation moments. The long-term total score of 61.3 proves to be comparable with 
the results after application of a BAHA or a cochlear implant (range 59-73) (13,15,16,18). 
Comparing the long-term and short-term evaluation moments, a decline in benefit over 
time is found for the APHAB results. In the unpaired data, this decline reaches 7.5 points.  
The results of the GBI QoL analysis show a significant difference of +21.2. Although we had 
expected improvements in the physical aspects domain as the patients all had complaints 
of external otitis, the benefit is almost completely accredited to the general domain. 
A large variation was found between individual patients. A disadvantage of the GBI is the 
retrospective character of the questionnaire, and as such, a recall bias might be present in 
the GBI scores. This is not apparent in the NCIQ and APHAB questionnaires, as a baseline 
measurement is available. The GBI scores in our study are slightly higher than those 
reported by Schmuziger et al (+14.7) and Mosnier et al. (+17.8) (9,11). 
Conclusions
Although a negative trend is found over time, the Vibrant Soundbridge and Otologics 
active middle ear implants provide significant long-term benefit in disability and quality 
of life. No difference in subjective results was found between the two devices. The 
percentage of device non-users was 13% and patient satisfaction scores and daily usage 
percentage were over 80%. Overall, active middle ear implants provide a good option for 
hearing rehabilitation in patients with sensorineural hearing loss and recurrent external 
otitis. 
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Abstract
Objective: To evaluate the long-term medical and technical results, implant survival and 
complications of the semi-implantable Vibrant Soundbridge (VSB), Otologics Middle ear 
Transducer (MET), and the Otologics fully Implantable Ossicular Stimulator (FIMOS)
Patients and methods: a retrospective cohort study was conducted in tertiary referral 
center for patients with chronic external otitis and either moderate to severe sensorineural 
or conductive/mixed hearing loss who were implanted with the VSB, MET or FIMOS. Main 
outcome measures: medical complications, number of re-implantations and explantations.
Results:  94 patients were implanted, 12 patients with a round window or stapes application. 
28 patients were lost to follow up. The average follow-up duration was 4.4 years (range 
1 month to 15 years). 128 devices were evaluated: (92 VSB, 32 MET, 4 FIMOS). 36 devices 
(28%) have been explanted or replaced (18 VSB, 14 MET, 4 FIMOS). Device failure was 7% for 
VSB, 28% for MET and 100% for FIMOS. In 16 patients (17%) revision surgery (n=20) was 
performed. Twenty patients (21%) suffered any medical complication.
Conclusion: medical and technical complications as well as device failures have mostly 
occurred in the initial period of AMEI implementation and during clinical trials or 
experimental procedures. All four FIMOS had technical difficulties. An important decrease 
in the occurrence of both medical and technical complications was observed. Application 
in more recent years did not show any complications and the recent device failure rates 
are acceptable. MRI incompatibility should be taken into account when indicating AMEI.
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Introduction
Active middle ear implants (AMEI) have been used in otologic surgery for more than two 
decades. The most frequently applied AMEI systems in the Netherlands are the Vibrant 
Soundbridge or VSB (Symphonix, San Jose, CA, USA and later Med-El, Innsbruck, Austria) 
and the Middle Ear Transducer or MET (Otologics LLC, Boulder, CO, USA and recently 
Cochlear Ltd, Sydney, NSW, Australia). The devices generally consist of an implanted 
actuator and an externally worn sound processor. The actuator is coupled to either the 
ossicular chain or to the round or oval window of the cochlea. The sound processor with 
battery is coupled by a magnet to an implanted receiver to enable communication with 
the internal part by radio frequency. The receiver is connected to the actuator. We also 
applied the Fully Implantable Middle ear Ossicular Stimulator (FIMOS) devices (Otologics; 
later called the Carina device). The internal battery has to be charged daily by the use of 
an external charging device. The microphone is also implanted, under the skin behind 
the ear. 
Indications
The indication for an AMEI varies from (pure) sensorineural hearing loss (1-4) to mixed 
hearing loss (5-10) and even pure conductive hearing loss (i.e. in case of a bony atresia of 
the external ear canal) (11,12). In the Netherlands, AMEIs are reimbursed for patients with 
sensorineural hearing loss, if they suffer from therapy resistant chronic external otitis that 
inhibits the use of a conventional hearing aid with any ear mould in the external ear canal. 
This limitation was proposed by our centre and became a requirement by the health 
authorities for the patient to be eligible for reimbursement of both the device and the 
treatment. 
As part of the European phase 1 trial, the initial patients in our centre were among the first 
to be implanted with a VSB in 1996 (3). In consequence, our center got also involved in the 
introduction of the MET and FIMOS.  Several experimental surgical techniques involving 
the implantation of the VSB have been studied, e.g. the transcanal approach and the use 
of additional cement to fixate the floating mass transducer (FMT) onto the long process of 
the incus. These applications will be discussed later on.
After the first introduction to apply the VSB to the oval or round window in mixed hearing 
loss by Colletti et al., we started to apply this method in our clinic (13). The FMT was either 
coupled to the remains of the stapes or the stapes footplate. In other patients, the FMT 
was placed in the round window niche, mostly in patients with subtotal petrosectomy 
after chronic middle ear disease. 
In the last years, a number of studies have been published about the applications of AMEI, 
focusing on both surgical as audiological outcome. These studies have mainly focused on 
the short and long term benefits in terms of amplification, stability and quality of life 
outcome. Some authors have published on the expanding indication range for the 
68
Chapter 2
application of AMEI, both for sensorineural hearing loss, mixed hearing loss and, specifically, 
in otosclerosis (14,15). Few publications discussed device explantation in the long run, 
either due to medical or technical problems, including the need for MRI diagnostics. In 
this study, we provide such long-term data on implant stability and complications to 
improve evidence based decision making for the indication of active middle ear implants.
Materials and methods
A retrospective cohort study was conducted at a tertiary academic medical centre. This 
centre was among the first to initiate and evaluate the application of AMEI in patients who 
experienced problems with conventional hearing aid revalidation. For this study we 
included the complete cohort of patients who received an AMEI. The implantations were 
carried out between October 1996 and February 2014. All patient charts were checked for 
complications during implantation and during the follow-up period. Furthermore, all 
re-implantations, explantations and other surgical procedures were evaluated. We 
adapted a previously described database for the analysis of complications in cochlear 
implantation, which was developed at our centre and is freely available online (16).
The first outcome parameter for the study was the number of explantations and re-im-
plantations per type of AMEI. Implant survival was calculated as the duration of follow-up 
until device explantation, either due to a technical implant failure or due to any medical 
indication. The second outcome parameter was the number of revision surgeries owing 
to medical or technical complications. The third outcome parameter was the total number 
of complications. 
Surgical procedure
For the surgical procedure, we refer to previous publications concerning the introduction 
of the implants. The standard surgical procedure was used for both the VSB and the MET as 
mentioned by Fisch et al and Jenkins et al (1,4). Although the devices have been developed 
for use in patients with pure sensorineural hearing loss, several patients have been implanted 
with mixed hearing loss, following the procedure described by Colleti et al (13). From 
September 2003 to October 2005, thirteen consecutive patients were implanted with a 
VSB using a transcanal approach. This surgical procedure has been described previously. 
In short, a bony canal or groove was drilled in the external ear canal to avoid a 
mastoi dectomy by providing an access for the electronic wire of the VSB device. The 
groove was covered with bone dust (17). 
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Statistical analysis
For the calculations and graphs we have used Microsoft Excel (Microsoft, Redmond, WA, 
USA), SPSS (SPSS Inc., Chicago, IL, USA) and Graphpad Prism (GraphPad Software Inc., La 
Jolla, CA, USA).
Results
Patient characteristics
In total, 94 patients have been implanted. The group consisted of 39 men and 55 women, 
with a mean age at implantation of 55 years (range 18 to 79 years). In the final situation at 
the time of analysis (2014), bilateral VSB implantation was indicated in 8 patients and 2 
patients were implanted with a VSB and MET (figure 1). The follow-up period was 4.4 years 
on average (range of 1 month to 15 years) with an average of 4.8 years for VSB (range 1-180 
months), 3.6 years for MET (range 1-153 months) and 5 months for the FIMOS (range 2-16 
months). During the follow-up period 28 patients were considered lost to follow up; 7 
patients had deceased, 12 patients were explanted and 6 patients were lost to follow up 
appointments. Three patients could not use their AMEI due to increased hearing loss. One 
patient switched to a conventional hearing aid, another one changed to a bone 
conduction device due to deterioration in mixed hearing loss and one patient received a 
cochlear implant. All non-users were included in the follow-up analysis.
Figure 1   Patient overview of the situation at the end of the study period and result  
of follow up. 
FU = follow up. CI = cochlear implant. BCD = bone conduction device. CHA = conventional hearing aid
70
Chapter 2
Mixed hearing loss
For 12 of the 94 patients, mixed hearing loss was the indication for primary or revision 
implantation. One of these patients was bilaterally implanted. All these patients were 
implanted with the VSB, either coupled to the stapes (n=10), or directly onto the round 
window niche (n=3). The coupling details are displayed in table 1. Some of the patients 
had mixed hearing loss as a result of a previous AMEI implantation that lead to incus 
necrosis (see complications). The audiometric results of the first five patients have been 
previously described by Verhaegen et al (8).
Surgical results
In total, 161 surgical procedures were evaluated, which were conducted between October 
1996 and February 2014. For the 94 patients, 104 primary implantations were registered, 
79 VSB (8 bilateral), 23 MET (2 bilateral) and 2 FIMOS. All patient characteristics per implant 
type can be found online in the table 2. The 4 recently implanted MET devices in 2014 
were obtained from Cochlear and will be addressed as cMET.
For 15 patients a revision implantation was performed (10 VSB, 3 MET and both FIMOS 
implants). Of these 15 patients, 6 patients needed a secondary revision implantation (3 
VSB and 3 MET). Unfortunately, one patient with a MET implant needed 3 more revision 
implantations (on a total number of 6 MET implants). He has recently been implanted with 
a cMET. For the FIMOS device, technical problems with charging of the internal battery 
and pain complaints lead to replacement of both devices with another. 
Some of the devices were explanted without reimplantation, both for medical as well as 
technical reasons. For the VSB, 12 devices were explanted because of medical indications, 
Table 1   Connection details of implantation in patients with mixed and conductive 
hearing loss.
Connection type n Remarks
Stapes coupling after incus necrosis 2 One patient implanted with a CI
Stapes head coupling in subtotal petro-
sectomy
4
RW coupling in subtotal petrosectomy 2
Stapes VORP to tympanic membrane 2 One explanted because of chronic pain
Stapes head coupling in aural atresia 1 Re-implantation; technical defect
RW coupling in mastoidectomy 1
Stapes remains coupling in mastoidectomy 1
Total 13 10 stapes and 3 round window
RW = round window. VORP = vibrating ossicular replacement prosthesis. CI = cochlear implant.
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which are presented in table 3. For the MET device, 5 patients were definitively explanted, 
4 because of medical complaints (pain complaints, a skin problem, decrease in audiological 
benefit and 1 unsatisfied patient) and 1 because of a technical defect, without the desire 
for revised implantation. So far, none of the recent cMET devices has had any technical 
problem. Concerning the 2 revised FIMOS implants, both devices were explanted again 
because of technical defects, leading to a total of 100% technical failure of these devices. 
No further FIMOS implantations were performed and both revision implants were 
replaced by a VSB.
Revision surgery
For 16 patients (17%) revision surgery, other than re-implantation or explantation of the 
device was performed. In total, 20 surgical procedures were conducted, varying in severity 
(table 4). Three revisions were indicated because of wire extrusions and skin defects in de 
external ear canal, as a result of the specific surgical method of implantation, the transcanal 
approach in patients with a therapy resistant external otitis. The evaluation of this method 
Table 2  Patient characteristics per implant type.
VSB MET FIMOS
Number 79 (8 bilateral) 23 2
Mean age (Y) 57 52 48 ; 58
Gender 44 F ; 27 M 12 F ; 11 M 2 M
F = female, M = male.
Table 3  Device explantations and indications.
Device VSB n MET n FIMOS n Total n
Medical 
indications
Incus arrosion 1 Skin defects 2
Pain complaints 3 Ossification 1
MRI indication 3 Dissatisfied patient 1
CI implantation 1 Incus fracture 1
Wire problems 4 17
Technical 
indications
Technical 
defects
6 Technical  
defects
9 Technical 
defects
4 19
Total 18 14 4 36
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has been described in detail previously (17). Middle ear inspection was indicated for 8 VSB 
implants because of a presumed decrease in fixation of the FMT onto the incus. Some 
revision or replacement of the magnet of the MET receiver was necessary in 4 patients, as 
well as revision of the position of the MET transducer onto the incus in 2 patients. One 
patient needed a myringoplasty because of a tympanic membrane perforation, which 
occurred after implantation. The other minor revisions were surgical corrections of the 
place of the implant or the magnet, a revision of the skin of the temporal bone and surgical 
correction of some bony overgrowth.
Implants
During the study period a total of 128 implants were implanted: 92 VSB devices, 32 MET (of 
which 4 cMET) and 4 FIMOS devices. In total, 36 devices were replaced or explanted, 18 
VSB (20%), 14 MET (44%) and 4 FIMOS (100%). Most implants (75%) were replaced or 
explanted within the first 5 years and about one third (36%) even within the first 18 months 
after implantation. Figure 2 shows that for the MET most implants were lost within the 
first 4 years of follow-up, whereas for VSB this was spread over the total 12 years of follow 
up. As can be seen in table 3, the reasons for the device replacement or explantation 
varied between medical issues (n=17; 47%), i.e. wire extrusions, incus erosion or strict MRI 
indication, and technical failures of the device itself (n=19; 53%). In total, the device failure 
rate due to technical defects was 7% for VSB, 28% for MET and 100% for FIMOS. 
Table 4  Description of revision surgery, excluding explantations.
Type of surgery n Implant
Middle ear inspection with crimping of FMT 8 VSB
Revision of implant or magnet 4 MET
EAC skin dehiscence revision (wire problems) 3 VSB
Correction of skin defect temporal skull 1 MET
Myringoplasty 1 VSB
Revision MET-incus coupling 2 MET
Revision of bone overgrowth 1 MET
Total 20
FMT = floating mass transducer. EAC = external auditory canal.
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Implant survival
Survival analysis was studied by summing all individual follow-up data. A subdivision was 
applied for the medical and technical failures. Non-users were not considered as lost to 
follow up in this analysis. Figure 3 shows the Kaplan Meier graph of the result per implant. 
For the VSB, it shows a steadily decreasing survival rate. The majority is explained by the 
explantations for the various medical indications. Some technical failures did occur for the 
VSB, mainly within the first years after implantation. On the other hand, for the MET device, 
the device explantation is mostly explained by technical failures. 
To calculate the average number of implant loss per follow up year for technical defects 
we added up the total duration of follow up per device. Non usage was not considered as 
device loss. The results can be found in table 5.  In short, the calculated implant loss for 
VSB is 1 per 74 years of follow up and for MET 1 per 13 years of follow-up. For cMET, no 
complications were registered. All 4 FIMOS implants were lost within a summed total of 27 
months of follow up.
Figure 2   Explantations during follow up period per half year.
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Medical complications
During the study period, 20 patients (21%) had a minor or more serious medical 
complication. Table 6 presents all the complications. Some of the complications are to be 
expected in AMEI implantation, especially the sacrifice of the chorda tympani nerve since 
the posterior tympanotomy needs to be large enough to pass the FMT of the VSB.
The wire extrusion complications all occurred in patients where the transcanal method 
was used. Some wire extrusions were revised and covered with temporal muscle fascia, 
Figure 3   Explantations during follow up period per half year.
Table 5  Device failure rate, revision rate and follow up duration
Implant type No. of  
implants
Technical 
defects (n)
Device failure 
rate (%)
No. of 
revisions and 
explantations
VSB 92 6 7 33
MET 32 9 28 22
FIMOS 4 4 100 4
Implant type Total sum  
of  follow up 
(year)
Follow up  
mean (y) and 
range (month)
Device failure 
rate (1/year)
Revision rate 
(1/year)
VSB 445 4.4 y (1-180) 1 / 74 y 1 / 13 y
MET 115 3.6 y (1-153) 1 / 13 y 1 / 5y
FIMOS 2.3 0.4 y (2-16) 1.7 / 1 y 1.7 / 1 y
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but in most cases the wire repeatedly extruded in the ear canal. These patients underwent 
revision surgery by the classical transmastoid approach. 
In four patients the long process of the incus was eroded at the location of the attachment 
of the clip of the FMT of the VSB device. In eleven cases Serenocem (Corinthian Medical 
Ltd, Nottingham, UK) was experimentally applied to strengthen the fixation of the clip 
of the FMT onto the long process of the incus. As a result of the erosion, 2 patients ended 
up with a mixed hearing loss. In these cases, the FMT was coupled to the stapes (see 
Verhaegen et al) (8). 
In general, the frequency of complications has decreased with the years as is presented 
in figure 4. The complication rate increased during 2003-2005, mostly because of the 
previously mentioned experimental transcanal approach technique. In the last 6 years 
of the evaluation period, hardly any complications have occurred during or after the 
implantation of the AMEI.
Mixed hearing loss
For the 12 patients with mixed hearing loss, the mean duration of follow is 28 months 
(range 8-61 months). In 3 patients the device has been explanted. One patient the level of 
sensorineural hearing loss progressed and he was implanted with a cochlear implant. In 
another patient pain complaints occurred over the area of the skull surrounding the 
implant and ultimately no other option than explantation was available. The third 
explantation was because of a technical failure. One of the 12 patients (8%) is a non-user, 
since the audiological gain was insufficient. In this patient the round window application 
technique was performed as part of a subtotal petrosectomy and the patient refused 
revision surgery.
Table 6  Complications.
More serious n Implant Minor n Implant
Incus erosion 4 VSB Insufficient  
coupling FMT
1 VSB
Wire extrusions  
in the ear canal
5 VSB Insufficient contact  
to incus
1 MET
Laceration of  
the chorda tympani
4 VSB Pain complaints due  
to ossification
1 MET
Skin dehiscence 1 MET
Infection 3 both
Totals 17 3 20
FMT = floating mass transducer.
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Discussion
This article provides a comprehensive description of a complete cohort of patients, 
implanted with an active middle ear implant. It presents the issues involved with the 
start-up and introduction of new devices: technical, as well as medical and surgical issues. 
We have focused this study on the outcome in implant survival and daily usage and the 
medical complications that occur during the surgery and thereafter. 
Previous publications have mainly focused on long term outcome of audiological results, 
patient satisfactions and daily usage by the patients. Sterkers et al. have published short 
term results of 125 VSB devices. During their follow-up of 17 months, 5 device failures had 
occurred. No serious events had occurred (18). Schmuziger et al. published results of 20 
VSB users with an average follow-up of 3.5 years. Complaints related to the chorda tympani 
had occurred in 3 of the 20 patients. In three patients revision surgery was necessary. They 
reported one device failure (5%) (19). In the article by Vincent et al, the authors report on 
the long term audiological results of 39 VSB users. No outcome results for device failure or 
complications were mentioned (20). Mosnier et al. have reported their results with an 
average follow up 6 years in 77 patients with a VSB. During this period, 7 patients (9%) 
were explanted, 3 because of device failure, 1 because of a switch to a cochlear implant, 2 
because of poor audiological benefit and 1 because of psychological problems. For 7 
other patients (9%) re-implantation was necessary because of device failure. They reported 
8 patients as non-users (10%). Five patients (6%) needed revision surgery, mainly due to 
problems with the coupling of the FMT onto the incus, magnet problems and fibrous 
Figure 4   Complication rate during follow up period.
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tissue in the middle ear. Chorda tympani complaints occurred in 8% of the patients and 
27% complained of aural fullness (21). In 2010, Rameh et al have reported their results on 
MET (n=19; 5.1 years), Carina (n=10; 1.9 years) and VSB (n=45; 3.3 years) implantations. 
Revision surgery due to implant dysfunction was needed in 16% of the MET implants and 
9% of the VSB implants. Non-use and complications are not mentioned (22). In another 
publication, Debeaupte et al. describe their experience with the successive generations of 
FIMOS devices. As in our series, all first generation devices in their series have been 
explanted. The most recent devices with at least a follow up of 22 months had survival 
rates of 100% (23). 
Since cochlear implants have been applied for over 30 years in greater numbers than 
AMEI, more knowledge of the reliability of these devices is available over the longer term. 
In 2010, a consensus statement was published on the international classification of CI 
reliability, which states guidelines on the report of device failures (24). In the current article 
we have tried to report according to this guideline. Considering the reports on technical 
device failure in literature, the revision rates are varying between 1.2% and 15.1% as 
presented by Wang et al. in 2014. The mean calculated device failure rate was 5.1%, ranging 
from 0.5% to 14.7% (25). In a recent, not included publication, Theunisse et al have 
published the results of over 1000 CIs in our clinic and reported a device failure rate of 
2.4% (16). 
In short, we can state that the failure rate of the VSB (7%) is acceptable within the range of 
the results of cochlear implants. Especially if we take into consideration that our series for 
VSB include the phase I primary clinical trial results as well. Moreover, we have observed a 
decrease in hardware failures (see figure 4). At present, the incidence of revision surgery 
or medical problems with the VSB is low. A similar decrease in implant failures and revision 
surgeries was observed for the MET. The overall rate of hardware failures was considered 
high (28%), which can be explained by technical failures of the early generation implants.
Considering the increasing availability of high-field MRI scanners, some technical and 
medical challenges may arise in patients with an AMEI, as well as other otologic implants. 
In a large US report in 2012 an increase in MRI usage between 1996 and 2010 is presented. 
The authors report an increase from 1.7% to 6.5% of the enrolled patients and 10 percent 
increase per year (26). 
In an extensive publication in 2011, Wagner et al have described a review on the results of 
all published in vivo en ex vivo experiments with the VSB and MRI scanning (27). They 
state that MRI up to 1.5 Tesla can be performed at calculated risk, although the possible 
side effects of loud hearing sensations and possible dislocation of the FMT should be 
weighed against the necessity of the imaging. Since 2014, the Med-El company has 
introduced the newest version of the VSB implant and states a MRI-compatibility up to 1.5 
Tesla (Med-El company information). The Cochlear MET has not been granted a MRI safety 
approval. However, experiments to assess the effects of MRI scanning on the present 
device are ongoing.
78
Chapter 2
Conclusion
The early introduction of the VSB, MET and FIMOS active middle ear implants at our centre 
has lead to this long term retrospective study of clinical follow-up outcome. During the 
years, both the technical and medical issues in implantation have drastically improved for 
the VSB and the MET, with few medical complications in the last few years. The technical 
challenges have been overcome by the industry, with a decreasing need for re-implantation 
and explantation rates. 
From a surgical point of view, we consider the VSB a reliable AMEI for the use in sensorineural 
and mixed hearing loss with an acceptable implant survival period and limited explantation 
rate. The MET has had a low reliability in the early days, which has strongly increased more 
recently. Compared to the VSB, the MET is applicable in relatively more extensive sensorineural 
hearing loss, since it provides a higher output as we have published previously (28,29). 
Therefore, we consider the MET an important alternative option. As the four experimental 
FIMOS devices that we applied all have been explanted within 2 years, we have not 
continued the application in our clinic, although Debeaupte et al. recently showed that 
the current Carina version has become more stable over time (23).  
We believe that candidacy for an active middle ear implant should be well considered, 
both audiological and medical. Possible complications concerning the surgical procedure 
and the follow-up period should be counseled. MRI compatibility will remain a challenge 
with an increasing frequency in MRI-diagnostics and possible increase in field strength.
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Direct acoustic cochlear stimulation
3.

Multicenter study with  
a direct acoustic cochlear implant
3.1.
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Multicenter Study With a Direct Acoustic Cochlear Implant.
Lenarz Th, Zwartenkot JW, Stieger C, Schwab B, Mylanus EAM, Caversaccio M, 
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Abstract
Objective:  To confirm the clinical efficacy and safety of a Direct Acoustic Cochlear Implant.
Patients and methods: A prospective multi-center study was performed at three University 
Hospitals in Europe (Germany, The Netherlands and Switzerland). Fifteen patients with 
severe to profound mixed hearing loss due to otosclerosis or prior failed stapes surgery 
implanted with a Codacs™ Direct Acoustic Cochlear Implant investigational device (ID) 
(Cochlear Ltd., Sydney) combined with a stapedotomy with a conventional stapes 
prosthesis. The pre- and post-operative (3 months after activation of the investigational 
Direct Acoustic Cochlear Implant) audiometric evaluation measured conventional pure 
tone and speech audiometry, tympanometry, aided thresholds in sound field and hearing 
difficulty by the APHAB-questionnaire.
Results: The pre- and post-operative air and bone conduction thresholds did not change 
significantly by the implantation with the investigational Direct Acoustic Cochlear Implant. 
The mean sound field thresholds (0.25 to 8 kHz) improved significantly by 48 dB. The word 
recognition scores (WRS) at 50, 65 and 80 dB SPL improved significantly by 30.4, 75 and 
78.2% respectively after implantation with the investigational Direct Acoustic Cochlear 
Implant compared to the pre-operative unaided condition. The difficulty in hearing, 
measured by the APHAB, decreased by 27% after implantation with the investigational 
Direct Acoustic Cochlear Implant. 
Conclusion: Patients suffering moderate to severe mixed hearing loss due to otosclerosis 
can benefit substantially using the Codacs investigational device.
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Introduction
Acoustic implants can be divided in 3 categories: middle ear implants (MEI), bone 
conduction implants (BCI) and direct acoustic cochlear implants (DACI). The transducers of 
MEI are coupled to the ossicular chain and make use of the ossicles to transmit the 
amplified vibration to the cochlea.  They were originally developed for pure sensorineural 
hearing losses, but have been indicated to be beneficial in mixed hearing loss when 
coupled to the round or oval window. BCI couple to the skull and make use of the cranial 
bone to transmit vibrational energy to the cochlea, thereby circumventing the outer and 
middle ear and directly stimulating the cochlea. Their main indication is pure conductive 
and mixed hearing loss. The strongest BCI transducers are able to partially compensate for 
the sensorineural component of the hearing loss as well (overclosure of the air-bone gap). 
DACI directly couple to the inner ear, i.e. via the oval or round window or via a surgically 
created window. They were developed to compensate for severe to profound mixed 
hearing losses. 
Mixed hearing loss combines sensorineural and conductive hearing loss and can possibly 
cause high hearing thresholds. Hearing devices that make use of the natural sound 
transmission structures of the ear (i.e. the external and middle ear), such as acoustic 
hearing aids or MEI, must provide a correspondingly high power output to compensate 
for the conductive hearing loss component and must still be able to provide a sufficiently 
amplified broad band signal to the cochlea to compensate for the sensorineural hearing 
loss. The coupling of MEI to the inner ear is also an important issue for effectiveness 
A more efficient approach might be to bypass the natural sound transmission structures 
of the ear and directly provide an amplified signal to the cochlea. In this approach, 
conductive losses no longer have to be compensated by increased output power, and the 
required amplification is determined by the sensorineural hearing loss only. This can be 
done with a BCI or a DACI. The BCI available today have limited power, and can therefore 
compensate for the sensorineural component of the hearing loss to a limited level. A DACI 
provides its power directly to the inner ear by vibrating the perilymph. However, a good 
coupling of the DACI to the perilymph is essential. In 2008, Häusler et al. (1) presented a 
new DACI, an implantable hearing system which included a newly developed transducer, 
the Direct Acoustic Cochlear Stimulator (DACS). This transducer coupled directly to the 
perilymph via a conventional stapes prosthesis. The device consisted of the transducer, a 
fixation system and a percutaneous plug, to which an externally worn sound processor 
was connected. It was implanted in four patients with severe to profound mixed hearing 
loss during a clinical trial. The trial proved the concept and showed that the hearing and 
speech intelligibility of those patients improved substantially after implantation with the 
DACS compared to the pre-operative unaided condition. 
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Since the initial clinical trial with the DACS system, Cochlear has further developed the 
device to improve upon important aspects of the design and functionality. These development 
steps have included the development of custom implantable electronics, an electronics 
packaging, and a transcutaneous communication and power link with the external sound 
processor. In addition, surgical tools to aid the surgeon to place the implant have been 
developed together with a modified fixation system, which allows more degrees of 
freedom. A Cochlear Nucleus Freedom sound processor (Cochlear Ltd., Sydney) was 
adapted to deliver acoustical information to the implantable electronics by using custom 
firmware. Finally, custom fitting rules have been developed together with investigational 
software to optimize treatment results.  All these efforts resulted in the new Codacs™ 
direct acoustic cochlear implant. Cochlear’s Codacs investigational device (ID) is depicted 
in Figure 1.
Between November 2009 and May 2011, the Codacs investigational device has been 
successfully implanted in 15 patients during a European multi-center trial. This publication 
presents the results of the clinical trial.
Methods
Device description
The concept of DACS was introduced by Häusler et al. (1). As the concept of the Codacs is 
the same, it will only be shortly illustrated again. The Codacs investigational device 
consists of an externally worn behind-the-ear sound processor with radio frequency (RF) 
coil. The implantable part consists of a receiver coil, the implant electronics and the elec-
tro-magnetic transducer (2). The sound processor is Cochlear’s Freedom sound processor 
with a modified firmware to allow for acoustic signal processing. Sound is picked up by 
Figure 1  Codacs investigational device. 
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the sound processor’s directional microphone and converted into a digital signal. The 
signal is then broken down into its constituent frequency components (20 bands), 
amplified and re-synthesized. The whole path from analysis to synthesis runs at a sampling 
rate of 19.6 kHz. The re-synthesized audio is then streamed over the RF-link into the 
implant. The RF link encoding and power transmission is copied from the Nucleus 
Freedom implant (Cochlear Ltd., Sydney) high-rate protocol. The implant decodes the 
incoming RF, and sends a stimulating current to the electro-magnetic transducer. The 
transducer (Figure 2) vibrates the off-the-shelf stapes prosthesis, thereby mechanically 
stimulating the perilymph in the inner ear and leading to sound perception. The actuator 
design was described in Häusler et al. (1) and Bernhard et al. (2) and has not been changed 
from its earlier design. 
The fixation system that keeps the transducer firmly in place within the mastoid cavity 
has been optimized to allow greater flexibility for the placement of the device (Figure 3). 
It consists of a bone plate, a ball joint and a clamping mechanism, which hold the actuator. 
During implantation, the bone plate is fixed to the temporal bone with bone screws. 
The ball joint allows a precise positioning of the clamping mechanism, and like this the 
actuator, in the mastoid. The ball joint and the clamping mechanism can be manipulated 
with the help of two torque limiting screwdrivers.
Surgical procedure
The surgical procedure to implant the DACI investigational device was based on the 
retromeatal approach taken during the clinical trial with the percutaneous DACS described 
by Häusler (1). 
In a first step, the location of the implant and the sound processor were marked on the 
skin using the surgical templates. After a postauricular incision, the underlying periosteum 
and lower portion of the temporalis muscle were incised and a flap was formed. A 
mastoidectomy in the shape of a kidney was performed and the bone of the posterior 
external ear canal was thinned. A bony bed for the implant body and a bony canal were 
Figure 2  Codacs ID actuator. 
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drilled. A tympanomeatal flap was created, after which the middle ear structures could be 
assessed and otosclerosis could be confirmed. In order to have a direct view on the whole 
footplate, a segment of the posterior canal wall was removed. A large posterior 
tympanotomy was performed to expose the middle ear. The ossicular chain was disrupted 
and the suprastructure of the stapes was removed using a laser. A small canal for the ball 
joint of the fixation system was drilled in the mastoid and the fixation system was placed 
and fixed with bone screws. A template of the actuator was used to find a good position 
of the fixation system. 
The ball joint was fastened with a screwdriver. A perforation of the stapes footplate was 
performed by laser or by drill. The implant body was placed in the bony bed and the 
actuator was positioned using the applicator. Once a good position for the actuator 
without contact to the surrounding structure was found, the actuator was fixed in its 
position. A conventional stapes prosthesis was inserted in the perforation of the stapes 
footplate and crimped to the artificial incus of the actuator via the ear canal. The actuator 
cable was protected by securing it in a bony canal and covered with bone paste and fibrin 
glue. Intra-operative testing was performed to check the functionality of the actuator and 
implant. The wound was closed subsequently.
The surgical approach is a transmastoid approach with an additional transcanal approach 
in some cases where the exposure of the stapes footplate is not adequate through the 
posterior tympanotomy. In 6 cases it was possible to perform the stapedotomy completely 
through the posterior tympanotomy after removal of the stapes suprastructure. In those 
cases, the elevation of a tympanomeatal flap and the partial removal of parts of the 
superior and posterior outer ear canal bone could be avoided and no reconstruction of 
the posterior ear canal wall with cartilage was necessary, that is, there was less manual 
work, less bone dust in the middle ear cavity, and less risk of infection. However, the 
advantages of the combined approach (transmastoid and transmeatal) are a better view 
on the stapes footplate and no need to expose the facial nerve. The transmastoid 
approach is described by Lenarz et al. (3). 
Figure 3  Codacs ID fixation system. 
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Study Protocol
The Codacs ID Clinical Trial was designed as a prospective, multicenter study in up to 15 
patients. Study centers were the Hannover Medical School (MHH) in Hannover/Germany, 
the Radboud University Nijmegen Medical Centre (RUNMC) in Nijmegen/The Netherlands 
and the Inselspital at the University of Bern/Switzerland. The study protocol was submitted 
to and approved by the responsible ethics commissions and competent authorities. The 
presented results concern all fifteen included patients. No patients were withdrawn or lost 
to follow up.
Adult subjects with otosclerosis and a severe to profound mixed hearing loss and subjects 
with a failed stapes surgery were considered for inclusion in the clinical trial. The bone 
conduction thresholds had to be at least 30 dB in the audiometric frequencies 0.5 kHz, 1 
kHz, 2 kHz, 3 kHz and 4 kHz and had to be measurable at those frequencies. The 
air-bone-gap had to be at least 30 dB in three of those five frequencies. 
All patients were informed about alternative treatments. For some patients, stapes surgery 
and wearing a hearing aid would have been the best alternative treatment; for others, a 
cochlear implantation would have been the only alternative solution. All patients who 
took part in the clinical trial chose to have a DACI investigational device implanted, as they 
would have needed surgery anyway and the DACI ID combines stapes surgery and 
acoustic amplification. 
All subjects needed to complete 5 study visits and were followed up to three months after 
initial activation of the DACI investigational device. Pre- and post-operatively medical and 
audiological evaluations were performed. These included a physical examination, a 
tympanometry, measurements of the air conduction (AC) and bone conduction (BC) 
thresholds at standard audiometric frequencies and a measurement of the unaided sound 
field thresholds using warble tones. Pre-operatively, the uncomfortable loudness levels 
were measured and a CT scan was performed to verify a sufficient mastoid size. Aided 
thresholds in sound field were measured pre-operatively using warble tones if the patient 
was wearing a hearing aid, and post-operatively with the DACI investigational device. The 
unaided and aided speech reception thresholds (SRTs) and word recognition scores (WRS) 
were obtained pre-operatively and post-operatively in the sound field using recorded 
speech. The SRT was measured at the lowest intensity level at which the subject could 
correctly repeat 50% of the speech. The WRS were measured at 50, 65, 80 and 95 dB SPL, 
if the uncomfortable loudness level was not reached at those levels. In Germany and 
Switzerland, the WRS were measured with the Freiburger word lists. In the Netherlands, 
the WRS were measured with the NVA word lists (word list from the Dutch Society for 
Audiology). 
The speech reception thresholds in noise were established pre-operatively and post-op-
eratively in sound field using the Oldenburg Sentence test (OLSA, developed by Wagener 
et al. (4) in Germany and Switzerland, and the Plomp test (developed by Plomp et al. (5) in 
The Netherlands. The signal to noise ratios at which 50% correct scores could be achieved 
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were assessed via an adaptive test procedure. The stimuli were presented at 0° azimuth 
and the noise level was fixed at 65dB. For all tests the contra-lateral ear was masked when 
necessary. A positive signal to noise ratio means that the speech had to be louder than 
the noise for the patients to be able to understand 50% of the speech. A negative signal 
to noise ratio means that the speech could be softer than the noise for the patient to be 
able to understand 50% of the speech. Normal hearing subjects can understand 50% of 
the speech at a signal to noise ratios of -7.1 dB or -5.5 dB SNR for the OLSA and Plomp 
respectively (4, 5).
The Abbreviated Profile of Hearing Aid Benefit (APHAB) (6) was completed by all study 
subjects pre-operatively and at the three months follow-up visit. The benefit was 
calculated by comparing the patient’s reported difficulty in the pre-op condition with 
their amount of difficulty when using amplification (with the DACI investigational device). 
The APHAB produces scores of 4 subscales: ease of communications (EC), reverberation 
(RV), background noise (BN) and aversiveness (AV). The global score can be calculated by 
averaging those four subscales. Intra-operatively the functionality of the implant was 
measured with a laser Doppler vibrometer and a free movement of the artificial incus was 
confirmed. A surgical questionnaire had to be completed by the surgeon after each 
implantation to give feedback on the surgical procedure. 
The DACI investigational device was fitted initially approximately 6 weeks after implantation. 
Part of the fitting process included an in-situ audiogram using implant stimuli. The fitting 
parameters were prescribed based on a fitting rule developed by Cochlear. At each study 
visit the subject was asked for adverse events that might have occurred.
Subjects
Fifteen subjects aged 47 to 79 (mean ± standard deviation (SD): 61 ± 9.4 years) were 
included in the clinical trial. Eight subjects were implanted at the Hannover Medical 
School, five patients at the Radboud University Nijmegen Medical Center and two patients 
at the Inselspital of the University of Bern. The surgeries were performed between 
November 2009 and May 2011. All study subjects, ten women and five men, had 
otosclerosis and a severe to profound mixed hearing loss. The duration of hearing 
impairment was between 10 and 55 years (mean ± SD: 24 ± 12.9 years). Eleven subjects 
had a hearing aid on the implanted ear pre-operatively, which they had used between 1.5 
and 32 years (mean ± SD:  9.7 ± 9.4 years). On the contra-lateral ear, eleven subjects had a 
hearing aid, three patients had a cochlear implant and one patient didn’t use any 
amplification. Six subjects had undergone a previous ear operation on the implanted ear 
(stapes surgery (3), tympanoplasty type III (1), ventilation tubes (1), middle ear inspection 
(1)). Each subject agreed to participate in the study by giving written informed consent. 
Table 1 presents an overview of the patients’ demographics. 
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Statistics
The statistical analysis was done with PASW 18.0 (SPSS Inc., Chicago, IL, USA) and included 
a normality test and a test on significant differences between pairs. Depending on the 
outcome of the normality test and the number of complete data sets, the paired Student’s 
t-test (Student’s t-test) or the Wilcoxon matched-pairs signed-rank test (Wilcoxon) was 
used to test statistical significance. The significance level was set to p= 0.05.
Results
Audiological outcome
All post-operative results shown and explained are the data from the 3 months follow-up 
visit i.e. three months after activation of the device.
Pre- and post-op audiometry
The mean pre- and post-operative air and bone conduction thresholds of all fifteen 
subjects are shown in Figure 4. 
Figure 4   Mean (n = 15) preoperative and postoperative air and bone conduction 
thresholds. Error bars represent SD.
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Pre-operatively, the patients, on average, had a severe to profound mixed hearing loss 
with a moderate sensorineural component and a mean air-bone gap of 46 dB. The pure 
tone average (PTA: average of air conduction thresholds at 0.5, 1 and 2 kHz) did not change 
significantly by the Codacs ID procedure (90 dB HL pre-op vs. 88 dB HL post-op; p > 0.05 
in all frequencies).  The bone conduction thresholds, however, improved significantly 
at 750 Hz (Wilcoxon, p = 0.041), 1 kHz (Student t-test, p = 0.01) and 1.5 kHz (Wilcoxon, 
p = 0.016) compared to the pre-operative bone conduction thresholds. The air-bone-gap 
increased significantly at one frequency only (500 Hz, Wilcoxon, p = 0.044). 
Sound field Audiometry
Pre-operatively the sound field thresholds were measured monaurally unaided and aided 
with the subject’s hearing aid (if the subject wore a hearing aid pre-operatively). Post-op-
eratively, the sound field thresholds were measured monaurally in aided condition with 
the DACI ID. An overview of the results is shown in Table 2.
Figure 5 shows the mean sound field thresholds and standard deviations of all patients 
measured pre-operatively unaided and post-operatively aided with the DACI investigational 
device at the subject’s three months’ follow-up visit. The mean (250 Hz to 8 kHz) pre- 
operative unaided sound field threshold was 86 dB HL, whereas the mean post-operative 
aided sound field threshold was 38 dB HL. Thus, the mean improvement of the sound field 
thresholds by the DACI investigational device was 48 dB. The improvement is significant 
in all frequencies (Student’s T-test or Wilcoxon, p ≤ 0.005 in the frequencies up to 4 kHz, 
p = 0.008 for 6 kHz and p = 0.043 for 8 kHz).
Figure 6 shows the mean sound field thresholds and standard deviations of the eleven 
subjects who used a hearing aid (HA) pre-operatively. The sound field thresholds were 
Table 2   Mean unaided and aided sound field thresholds and improvements  
by Codacs ID and HA.
Mean Sound Field Thresholds / Improvement n = 15 n = 11 
Pre-operative unaided [dB HL] 86 83 
Pre-operative aided by HA [dB HL] 52 
Post-operative aided by Codacs ID [dB HL] 38 37 
Improvement by HA [dB HL] 31(*) 
Improvement by Codacs ID [dB HL] 48* 46* 
Codacs improvement compared to HA 15(*) 
*indicate that there is a significant improvement in all (*) or most ((*)) frequencies
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Figure 6   Mean (n = 11) preoperative and postoperative unaided and aided 
sound-field thresholds. Error bars indicate SD.
Figure 5   Mean (n = 15) unaided and Codacs ID aided sound field thresholds.  
Error bars indicate SD.
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measured pre-operatively both unaided and aided with their hearing aid, and post-oper-
atively aided with the DACI investigational device at the subject’s three months follow-up 
visit. The mean (250 Hz to 8 kHz) pre-operative unaided sound field hearing threshold was 
83 dB HL, the mean pre-operative HA aided sound field hearing threshold was 52 dB HL 
and the mean post-operative DACI investigational device aided sound field threshold was 
37 dB HL. Thus, the mean improvement of the sound field thresholds by the hearing aid 
was 31 dB and by the DACI investigational device was 46 dB, i.e. an improvement of 15 dB 
compared to the hearing aid. The improvement with an acoustic hearing aid is significant 
in all frequencies (Wilcoxon, p ≤ 0.026) except for 8 kHz.  The improvement with the DACI 
investigational device is significant in all frequencies (Paired Student t-test or Wilcoxon, 
p ≤ 0.005 in the frequencies 250 Hz to 4 kHz, p = 0.008 for 6 kHz and p = 0.043 for 8 kHz). 
The improvement of the DACI investigational device aided sound field thresholds post- 
operatively compared to the HA aided sound field thresholds pre-operatively is significant 
in all frequencies (Student t-test, p ≤ 0.028) except at 2 and 8 kHz (Wilcoxon, p > 0.05). 
At 8 kHz, the number of pairs was only five, which might explain why the difference is not 
significant.
 
Figure 7 shows the effective gain that is delivered to the inner ear by the DACI investiga-
tional device. The effective gain is defined as the difference between the aided sound 
field thresholds and the bone conduction thresholds (here: pre-op bone conduction 
thresholds).  It reflects the gain which the DACI investigational device delivers to the inner 
ear and which is accepted by the patient. The average gain over all subjects and 
frequencies (0.5 – 4 kHz) is 17.2 dB. The greatest gain is achieved at 1500 Hz, the smallest at 
500 Hz. 
Figure 7   Mean (n = 15) gain delivered to the inner ear for the frequencies 0.5 to 4 kHz 
and the average of those frequencies. Error bars indicate SD.
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Speech Audiometry
To evaluate the speech recognition with the DACI investigational device, the speech 
reception thresholds (SRT) and the word recognition scores (WRS) were measured using 
recorded speech (Figure 8).
The SRT improved significantly (Wilcoxon, p = 0.008) by 40.7 dB from 91.9 dB SPL pre- 
operatively to 51.2 dB SPL post-operatively, aided with DACI investigational device. 
Comparing the aided results from the subjects who wore a hearing aid pre-operatively, 
the SRT improved significantly (Wilcoxon, p = 0.044) by 12.2 dB, from 61.3 dB SPL pre- 
operatively aided to 49.1 dB SPL post-operatively aided. 
The word recognition scores (WRS) were measured pre-operatively unaided and aided 
with the subject’s hearing aid (if the subject wore a hearing aid pre-operatively, n=11) and 
post-operatively aided with the DACI investigational device. The mean (n=15) pre-operative 
unaided word recognition scores at 50, 65 and 80 dB SPL were 0%, 0% and 5.3% (SD: ±15.2 
%) respectively. Post-operatively, the mean aided (with DACI investigational device) word 
recognition scores for all patients were 30.4% (SD: ±31.8%) at 50 dB SPL, 75 % (SD: ± 27.3 %) 
at 65 dB SPL and 85.5 % (SD: ± 25.3 %) at 80 dB SPL and improved significantly by 30.4%, 
75% and 78.2% respectively compared to the pre-op unaided condition (Student’s t-test, 
p = 0.002 for 50 dB, p < 0.001 for 65 and 80 dB).
Figure 8   Mean word recognition scores (WRS in % correct) for presentation levels of 
50, 65, and 80 dB SPL for the preoperative unaided condition (preop unaided), 
the preoperative aided condition with hearing aid (preop HA aided), and the 
postoperative aided condition with the Codacs ID at the 3 months follow-up 
visit (postop Codacs ID aided) for all patients (n = 15, left graph) and the 11 
patients that used a hearing aid preop (right graph). Error bars indicate SD.  
* p ≤ 0.05.
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For the patients that used a hearing aid pre-operatively, the mean (n=11) pre-operative 
unaided word recognition score at 50, 65 and 80 dB SPL were 0%, 0 % and 7.3 % (SD: ±17.5 
%) respectively. The mean (n=11) pre-operative HA aided word recognition scores at 50, 65 
and 80 dB SPL were 6.7% (SD: ± 11.2%), 41.8 % (SD: ± 32.8 %) and 61.8 % (SD: ± 35.9 %). The 
improvement was 6.7%, 41.8 % and 54.5 % respectively compared to the pre-op unaided 
condition. The mean (n=11) post-operative DACI investigational device aided word 
recognition scores were 36% (SD: ±34.6%) at 50 dB SPL, 77.3 % (SD: ± 30.4 %) at 65 dB SPL 
and 87.5 % (SD: ± 26.5 %) at 80 dB SPL, and improved by 36%, 77.3% and 80.2% respectively 
compared to the pre-op unaided condition, and 29.3%, 35.5% and 25.6% respectively 
compared to the pre-op aided condition. Post-operatively the mean (n=11) aided (with 
C-DACS ID) word recognition scores were 36% (SD: ± 34.6%) at 50 dB SPL, 77.3 % (SD: ± 30.4 
%) at 65 dB SPL and 87.5 % (SD: ± 26.5 %) at 80 dB SPL and improved by 36 %, 77.3% and 
80.2 % respectively compared to the pre-op unaided condition and 29.3 %, 35.5% and 
25.7% respectively to the pre-op aided condition. The aided sound field thresholds 
improved significantly at all levels (50 dB: Wilcoxon, p = 0.027; 65 and 80 dB: Student’s 
t-test: p ≤ 0.015) compared to the pre-operative aided condition. An overview of the word 
recognition scores is shown in Table 3.
The individual speech reception thresholds (SRT) in noise for the pre-operative condition 
(unaided or aided with HA) and the post-operative aided condition (with DACI investiga-
tional device) are shown in figure 9. If the OLSA or Plomp test was not measureable a 
value of +10 dB SNR was displayed with an arrow up, indicating that the real SRT was 
above +10 dB SNR.  In 10 of 15 patients the SRT in noise improved, in two patients it was 
worse (patients 2 and 13) and in three patients it was not measurable pre- and post-op 
(patients 11, 14 and 15). Individual results show impressive improvements of the SRT in 
noise of around 7 to 8 dB (patients 1, 3 and 10) or even greater for those patients where the 
SRT was not measurable pre-op, but post-op (patients 4 - 8) by the Codacs ID implantation. 
The mean SRT in noise results for the OLSA and Plomp test apart are shown in Table 4.
The SRT in noise for the Oldenburg sentence test improved on average by 4.2 dB, from 
+3.9 dB SNR (SD: ± 3.3 dB SNR) pre-operatively to – 0.3 dB (SD: ± 3.7 dB SNR) post- 
Table 3  Mean WRS scores.
50 dB SPL 65 dB SPL 80 dB SPL 
Unaided (n=15) 0% 0% 5.3 % 
HA aided (n=11) 6.7 % 41.8 % 61.8 % 
C-DACS ID aided (n=15) 30.4 % 75 % 85.5 % 
HA = hearing aid.
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operatively, which is statistically not significant (Wilcoxon, p>0.05). However, the critical 
test-retest difference for the OLSA is 1.4 dB SNR and, therefore, a significant benefit is 
confirmed when the signal to noise ratio of the speech reception threshold decreases by 
this value [7).
The SRT for the Plomp test improved on average by 2.4 dB, from +3.0 dB SNR (SD: 1.8 dB 
SNR) pre-operatively to 0.6 dB SNR (SD: ± 4.3 dB SNR) post-operatively, which is statistically 
not significant either (Wilcoxon, p > 0.05). The standard deviation of the Plomp test is 1 dB 
and therefore a change of 2.4 dB can be seen as significant benefit.
It should be noted that the post-operative measurements were done without any pre- 
processing or noise suppression.
Table 4  Speech in noise test results. 
Mean SRT  
pre-op  
(dB SNR) 
Mean SRT  
post-op  
(dB SNR)
Improvement 
SRT pre vs.  
post (dB SNR) 
p-value 
OLSA (n=3) +3.9 -0.3  4.2 p > 0.05 
Plomp (n=4) +3.0 +0.6 2.4 p > 0.05 
Figure 9   Individual preoperative and postoperative SRT in noise for all 15 patients. 
Preoperative SRT is measured with hearing aid except for patients indicated 
with a asterisk.
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Figure 10 shows the average APHAB subscale scores and the average APHAB total scores 
for all subjects (n=15) for their pre-operative and their post-operative condition. Please be 
aware that the APHAB questionnaire is a measurement of the daily condition i.e. with both 
ears. That means that the condition of the contra-lateral ear (e.g. aided with hearing aid or 
CI) has an influence on the measurement results. Three subscales (EC, BN, RV) and the 
global score show a significant benefit with the DACI investigational device compared to 
the pre-op condition (Student t-test, p ≤ 0.002). On average the ease of communication 
improved by 29%, the communication in background noise and reverberation were, 
respectively, 35 % and 39 % less difficult and the aversiveness decreased by 5.2 %. This 
results in a total benefit/less difficulty in hearing of 27 % after implantation. The biggest 
benefit could be achieved for reverberation, the smallest for aversiveness. The aided 
APHAB scores are close to the median norm as presented by Cox and Alexander. (6)
Adverse Events
During the clinical study ten adverse events occurred. Five adverse events were rated as 
serious and were reported to the responsible competent authority. The serious adverse 
events are listed in Table 5, the adverse events in Table 6. In one patient there was a 
strange sound sensation after activation of system and hearing was rated as inferior to the 
preoperative hearing aid condition. This patient underwent revision surgery during which 
a potential contact of the artificial incus with the surrounding bone was found. After 
revision the hearing was clearer but still not satisfying. The patient had better results in 
speech understanding in quiet but not in noise.
Figure 10   Mean (n = 15) difficulty in hearing shown for the 4 APHAB subscales and  
the global APAHB score. Error bars indicate SD.
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Discussion
Audiological results
As presented in the results, no significant increase in averaged post-operative bone 
conduction thresholds was found. However, some increase of the bone conduction 
thresholds was found in three patients (12.5, 11 and 16 dB). An explanation may be that the 
averaged results are balanced by the increase in post-operative bone conduction 
thresholds in the other subjects. An improvement of BC thresholds has been described by 
Arnold et al. (8) and Perez et al. (9) in regular stapes surgery. It is indicated that the inner ear 
Table 5  Serious adverse events. 
No. Patient Serious  
adverse event
Procedure 
related?
Device 
related?
Outcome
1 GE10-XRK-02 Deterioration of bone 
conduction thresholds 
and tinnitus
No No Resolved
2 GE10-XJH-03 Facial palsy Possibly No Resolved
3 GE10-XRK-02 Hearing of vibrating 
noise/feedback
Possibly Yes Resolved
4 GE10-XJH-03 Deterioration of bone 
conduction thresholds
No No Resolved
5 GE10-XJH-03 Heart attack No No Resolved
Table 6  Adverse events.
No. Patient Adverse event Procedure 
related?
Device 
related?
Outcome
1 NL06-JPV-02 Nausea and vomiting No No Resolved
2 NL06-XJH-03 Bronchitis No No Resolved
3 NL06-XJH-03 Deformed fixation 
system 
No Yes Resolved
4 NL06-XJH-03 Deterioration of bone 
conduction thresholds
Possibly Possibly Ongoing
5 CH02-XFL-02 Sensation at receiver 
site 
No No Resolved
6 CH02-XFL-02 Tinnitus in new 
frequency 
Possibly Possibly Ongoing
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function is, in fact, better than measured in the bone conduction testing caused by 
fixation of the stapes footplate in the oval window. After opening of the footplate and 
thereby relieving the fixation, better bone conduction thresholds were measured. (8)
No changes were found for the averaged air conduction thresholds, which indicates that 
the maximum conductive component – or air-bone gap – was reached already before the 
disruption of the ossicular chain. 
The aided sound field measurements reveal interesting results. For all fifteen subjects a 
significant benefit is achieved when the device is switched on. But most interesting is the 
achieved gain in the higher frequency range. Compared to the pre-operative hearing aid 
gain (Figure 6, note n=11), a substantially increase is achieved with the DACI investigation-
al device, which is even significant in most measured frequencies. The most plausible 
explanation is that the higher frequencies need to be tuned down in the acoustic hearing 
aid configuration to prevent feedback of amplified sounds. An acoustic hearing aid has to 
bridge the air-bone gap in case of mixed hearing loss. Due to the high gain the hearing 
aids have to deliver, they often work at their limit and, thus, the sound might be 
deteriorated. Also an impedance mismatch in the outer ear canal might be a reason for an 
irregular transfer of sound to the inner ear for the high frequencies. This is not the case 
with the DACI investigational device, since there is direct stimulation of the cochlea. 
Similar results were found in the study by Häusler et al., where the results of the DACS 
system were compared with acoustic hearing aid results after stapedotomy on the same 
ear. In that study, the hearing aid to which the DACS was compared featured the same 
signal processing capabilities and was fitted in the implanted ear (1). Not much has been 
published on MEI in otosclerosis. Venail et al. (10) presented data of 4 patients with 
otosclerosis using either the Vibrant Soundbridge (MED-EL, Innsbruck, Austria) or the 
Middle Ear Transducer (Otologics LLC, Boulder, Colorado, USA). From their figures it is clear 
that amplification in the high frequencies is poor, significantly poorer than in the mid 
frequencies (in contrast to the presented results with the DACI investigational device). 
Other authors reported on the implantation of middle ear implants in otosclerosis patients 
as well but mostly the aided sound field thresholds are not shown for 6 and 8 kHz or the 
average of a mixed group with various medical indications is shown (10-15). As the number 
of otosclerosis patients in those publications is low, there is insufficient data today to draw 
any firm conclusions yet.
As expected, the achieved WRS and SRT results in quiet with the DACI investigational 
device are significantly better than the unaided and aided pre-operative results. It is 
plausible that most of this increase in speech recognition is due to better hearing 
thresholds and, thus, due to increased audibility. In the literature, no data was found on 
speech recognition after stapedotomy in combination with regular hearing aid fitting in 
severe mixed hearing loss. With the percutaneous DACS clinical trial (1) a comparison was 
possible with an acoustic hearing aid since two stapes prostheses were implanted in the 
cochlea. (1) We believe that, in the current trial, a large component of the increase in 
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speech recognition can be ascribed to the direct coupling to the inner ear by the DACI 
investigational device device, surpassing the air-bone gap. 
In contrast to SRT in quiet, which is directly related with audibility, the SRT in noise test is a 
measure of sound quality. The effects of the direct coupling to the inner ear are most 
clearly visible in the speech in noise test results. Although no significant difference was 
achieved because of a large preoperative as well as postoperative difference between the 
subjects, blunt evaluation of the data shows an impressive improvement of the SRT in the 
OLSA and Plomp tests. A reason for the improvement might be the better perception of 
high frequency sounds and/or the reduced sound distortion due to the flat frequency 
transfer function of the DACI investigational device (2). In three patients the SRT in noise 
could not be measured post-op. This can be related to the poor results those patients 
already have in their speech test in quiet post-operatively. At an input level of 65 dB SPL, 
these three patients did not reach a 50% score. The poor results in the speech tests of 
these three patients cannot be explained really but it might be that the cochlear reserve 
and the otosclerotic involvement of the cochlea might play a role. It could be that for 
those three patients a cochlear implant would be a better solution. Further research needs 
to be done to find the limits of the DACI investigational device system and to refine the 
inclusion criteria e.g. set a minimum pre-operative aided WRS score. We recommend to 
measure the pre-operative word recognition score via headphones up to 100 dB SPL to 
get an impression of the possible hearing gain by acoustical amplification. As was 
expected, evaluation of the subjective results by means of the APHAB questionnaire 
showed a significant improvement in the EC, BN and RV subscales, whilst no significant 
difference was experienced in the averseness of sounds (AV) subscale. The DACI investigational 
device aided scores were close to the norm of Cox and Alexander (6).
Concerning the patient who underwent revision surgery two points have to be mentioned. 
Firstly, the device has to be properly placed with some degree of freedom to prevent a 
potential contact with surrounding bone structures. Secondly this patient had very good 
speech recognition scores pre-operatively with her hearing aid so that the incremental 
improvement which could be achieved by the DACI investigational device was small. 
Indeed, this patient was initially not satisfied with the DACI investigational device and it 
took long until she got adjusted to the different type of hearing she had with the DACI 
investigational device. After two years of use she has accepted the sound and rated it as 
superior to her hearing with the hearing aid preoperatively. It shows us that in terms of the 
indications one should not implant patients who are still doing well with their hearing aid 
and reach monosyllabic word score which bring them close to values of normal hearing 
people. 
Surgical results
The surgical procedure proved to be feasible. No adverse events occurred during the 
implantation procedure itself. As mentioned in the methods paragraph, two different 
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approaches were used by the surgeons. Some surgeons preferred the transmastoid 
approach with a posterior tympanotomy while others preferred the combined approach 
(transmastoid + transcanal) and set out to implant the DACI investigational device using 
the combined approach from the start of the operation. The transmastoid approach gave 
sufficient exposure of the stapes footplate in the six patients where it was used but it 
could happen that it is necessary to do the combined approach.  The disadvantage of the 
combined approach is that parts of the posterior wall of the outer ear canal have to be 
removed to have a good view on the stapes footplate. To avoid contact between the 
tympanic membrane and the artificial incus it is necessary to reconstruct the ear canal 
with cartilage. The ossicular chain was not reconstructed in any case using a second 
stapes prosthesis as has been done in the preliminary trial in 4 patients (1).
During the surgery the most described notification was the shortage in length of the rod 
to which the artificial incus is attached (see Figure 2). In some cases, it was difficult to 
approach the stapes footplate close enough. Therefore, it was not possible in all cases to 
mount the actuator in the fixation system in the requested area of the actuator housing. 
The size of the mastoid and the bulging of the sigmoid sinus limited the freedom of 
rotation for the fixation bracket by the ball joint. No postoperative wound complications 
occurred. It is crucial to place the transducer with the artificial incus right over the footplate 
in a distance similar to that of the natural incus in order to be able to place the piston of 
the stapes prosthesis perpendicular to the stapes footplate. It is also necessary to avoid 
any contact of the transducer housing, the rod and the artificial incus with surrounding 
bone or other tissue in order to avoid damping or interference with the sound transfer 
through the eardrum.
The present implantation procedure took a considerable amount of time, namely an 
average of 4 hours and 52 minutes (SD: ± 1h26). Nevertheless, the operation time 
decreased during executive surgeries and the eighth surgery in Hannover could be done 
in 2 hours and 23 minutes. Time could be gained by the training effect, especially on 
finding a good position for the fixation system. An important phase is positioning the 
transducer in the mastoid towards the oval window, fixed in its bracket, avoiding any 
contact to the posterior bony canal wall. In relatively small mastoids this may be time 
consuming. Contact with the posterior canal wall will lead to an inadequate transmission 
of energy to the inner ear, possibly necessitating revision surgery.
Adverse events
In three patients a deterioration of the bone conduction thresholds (drop in PTA of 12.5 
dB, 11 dB and 16 dB HL) was measured. In one patient this happened shortly after surgery, 
in the other two patients it happened after the DACI investigational device was switched 
on. In all these patients, surgery was uneventful, leaving no clear explanation for this 
phenomenon.  These patients were treated with corticosteroids and in two of the three 
patients the bone conduction thresholds recovered. The sound processor fitting of the 
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patient where the bone conduction thresholds did not recover was adapted, and the 
patient reached the same word recognition scores as before the drop in bone conduction 
thresholds. Monitoring the sensorineural hearing loss component of the patients’ mixed 
hearing loss is of importance to gather long term data, to evaluate the effect of direct 
mechanical stimulation of the inner ear. 
Limitations
The study protocol implied strict indication criteria for the application of the DACI investi-
gational device. Consequently, the patient group is very specific. Firstly, patients with 
otosclerosis and a mild sensorineural hearing loss will have no need for a DACI investiga-
tional device. They will have sufficient benefit of a stapedotomy, if necessary in combination 
with a hearing aid. In case of a small air bone gap and a moderate to severe sensorineural 
hearing loss it is questionable whether a high power hearing aid is indicated or whether a 
DACI investigational device will provide better results. This has to be investigated in future 
studies. The word recognition score under headphones measured up to 100 dB SPL might 
give a hint whether patients will benefit from a DACI investigational device or would 
rather get a cochlear implant using a hearing preservation procedure. For patients with 
severe to profound sensorineural hearing loss and limited speech discrimination, a CI 
might offer better revalidation options. Therefore, counseling is of great importance.
Secondly, the implantation of the present investigational DACI required a considerably 
otologic experience, as it was technically challenging. Although the fixation system offered 
three degrees of freedom for the positioning of the actuator, the margins were small. 
Changes in the system design will have to improve versatility and reduce surgery time.
Furthermore, a weakness of the present study is the lack of standardization in the 
procedure of the pre-operative acoustic hearing aids. Different types and models of 
hearing aids were used by the patients. Some of the patients used a cochlear implant 
contra lateral. This might have led to different fitting settings. However, we experienced 
that some of the users gave up using their hearing aid due to an unsatisfactory benefit. 
The other patients had a well selected hearing aid and could benefit from the acoustical 
amplification. 
Further research
Half of the study patients would fulfill the indication criteria to get a cochlear implant. 
Three of them have a cochlear implant on the contra-lateral ear and prefer the sound of 
the DACI investigational device to the sound of their cochlear implant. Further research 
should have a closer look at this patient group and investigate quality of life, and maybe 
additional subjective measures like music perception, with DACI investigational device 
compared to cochlear implants. New coupling sites should also be investigated to be able to 
implant the DACI investigational device in patients with other medical indications like e.g. 
radical cavities, severe sensorineural hearing loss or other etiologies of mixed hearing loss.
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Last, but not least, the long term effect of mechanical stimulation of the inner ear fluid is 
unknown at the moment and needs to be investigated further. Long-term data of the 
subjects implanted during this clinical trial need to be assessed and analyzed. 
Conclusion
Patients with severe-to-profound mixed hearing loss because of otosclerosis can benefit 
substantially using the Codacs investigational device. The most important criterion for 
success is that they still have measurable bone conduction thresholds and some speech 
recognition (via headphones or, e.g., BAHA) in the ear to be implanted. Ideal candidates 
are patients who had unsuccessful previous stapes surgery. For this nonrandomized 
patient group, the averaged audiometric results show better hearing thresholds in sound 
field, as well as a better speech understanding in quiet and noise with the Codacs 
 investigational device when com- pared with preoperative unaided and aided conditions 
using a state-of-the-art conventional hearing aid. All patients are satisfied with their device 
and use it daily. The results were gathered up to 3 months after the first device fitting. 
Although that is a short evaluation period, it should be noted that previous research with 
the first-generation DACS showed stable results over time (1). 
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Abstract
Objective: To study the stability of audiometric, functional and subjective results for 
patients implanted with the Codacs™ ID Direct Acoustic Cochlear Implant (Cochlear Ltd., 
Sydney) for mixed hearing loss due to otosclerosis.
Patients and methods: A retrospective study was performed in a tertiary academic center in 
a pre- and post-intervention design with multiple post intervention hearing aid measurements 
and patient questionnaires. Five patients with severe to profound mixed hearing loss 
due to otosclerosis were implanted with the Codacs ID in the European phase 1 trial. 
The changes in hearing disability and handicap were evaluated using the Abbreviated 
Profile of Hearing Aid Benefit (APHAB) and a questionnaire on daily usage. Aided and 
unaided pure tone and speech audiometry, aided thresholds and speech in noise 
recognition were measured on three evaluation moments and compared to pre-operative 
results.
Results: The mean follow up periods were 19 and 40 months. One patient suffered from 
decrease in sensorineural hearing. The overall aided and unaided thresholds showed 
stable values compared with the short term results. Pure tone averaged results did not 
differ significantly from the pre-operative hearing aid results. The aided speech reception 
and speech in noise recognition values showed a significant improvement compared to 
the baseline. APHAB scores were equally improved from the pre-operative situation. All five 
patients used their implant on a daily basis and were content with the device. No device 
failure or complications occurred.
Conclusions: The Codacs ID provides stable improvements up to 40 months after 
implantation. A significant improvement of speech understanding and speech in noise 
was found compared to pre-operative hearing aid results. One patient suffered from 
sensorineural hearing loss and was a poor performer. No other changes in residual hearing 
were found and other technical or medical complications did not occur.
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Introduction
For many years otosclerosis patients have been successfully treated for conductive and 
mixed hearing losses by regular stapes surgery. Fixation of the stapes footplate in otosclerosis, 
leading to a conductive hearing loss, was treated by improving the connection between the 
ossicular chain and the inner ear fluid with a prosthesis during stapedotomy or stapedectomy. 
In case of mixed hearing loss due to a combination of stapes fixation and cochlear otosclerosis, 
the hearing loss is only partially solved by stapes surgery alone. The sensorineural part of 
the hearing loss will remain and is in most cases treated with regular hearing aid fitting. 
For advanced sensorineural hearing loss due to otosclerosis, cochlear implants have been 
introduced (1,2). After systematic reviewing, the results comparing cochlear implants to 
stapedotomy combined with hearing aids, this option should be reserved as a second 
choice (3,4).
More recently, middle ear implants have been successfully applied in patients with mixed 
hearing loss due to otosclerosis (5-8). Both the round window application of the Vibrant 
Soundbridge (Med-El, Innsbruck, Austria) as the power stapes or vibroplasty technique 
have been introduced for mixed hearing loss (9-18). The mechanically enhanced vibrational 
energy is transduced onto the oval or round window by the floating mass transducer 
(FMT) of the vibrant soundbridge. Despite the good audiological results, the maximum 
output varies between 65 and 85 dB HL, depending on the coupling effectiveness (19,20). 
With the introduction of direct acoustic cochlear stimulation (DACS) by Häusler in 2008, 
a new treatment option became available (21). This technique combines the application 
of a regular stapedotomy piston with the surgical placement of an actuator with a so 
called artificial incus. The magnet in the actuator drives de incus and directly transduces 
the inner ear fluid through the coupled stapes piston. This device was further developed 
and tested in a phase 1 clinical study under the name of Codacs investigational device 
(Codacs ID) (Cochlear Ltd, Sydney, Australia). The application aims to aid patients with a 
mixed hearing loss as a results of otosclerosis with bone conduction thresholds worse 
than 30 dB HL (22). 
This study presents a follow-up report of the Dutch cohort of the phase 1 clinical study. All 
measurements were repeated after approximately 1.5 year and 3 years to determine the 
patient satisfaction and stability of the audiological results.
Materials and methods
Device description and intervention
The Codacs ID has been previously described in the phase 1 European trial report. It is 
based on the principle of direct acoustic cochlear stimulation and exists of an internal 
implantable part with a magnetic receiver under the skin of the retroauricular skull that 
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connects to the actuator which is placed in a bracket that is mounted in the mastoid 
cavity. Regular stapedotomy surgery is performed and the piston is coupled to the artificial 
incus. For all surgical details and device specifications we refer to the clinical trial report 
(22). 
Subjects
All five Dutch participants of the European trial (three women and 2 men) were included 
in the follow-up study. Table 1 presents the patient characteristics. Mean age at the 
moment of measurement 1 postoperative was 64 years and the mean duration of 
follow-up was 20 and 40 months after implantation. 
Study design
In this study we have repeated the three months’ measurements of the phase 1 clinical 
trial approximately one and a half and three years after implantation: unaided air 
conduction (AC) and bone conduction (BC) hearing thresholds, aided sound level 
thresholds, (un-)aided word recognition scores (WRS) and speech reception thresholds 
(SRT), as well as speech understanding in noise (Plomp testing, abbreviated to SIN). Patient 
satisfaction and subjective benefit in hearing disability was tested by the Abbreviated 
Profile of Hearing Aid Benefit (APHAB) (23). Daily use was tested with a specifically adapted 
questionnaire (table 2). The measurements at approximately 40 months was after fitting 
the new CP810 processor. 
Table 1  Patient characteristics.
Subject Gender Side Age (y) FU  
(months)
FU  
(months)
NL06-GWK-01 F R 59 22 43
NL06-JPV-02 F L 55 20 41
NL06-XJH-03 M L 71 20 39
NL06-JCJ-04 M R 56 16 39
NL06-GHP-05 F L 80 18 37
 Mean 64.2 19.2 39.8
  SD 10.9 2.3 2.5
Age at time of measurement and duration of follow up since implantation.  
F = female, M = male. FU = follow up
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Statistics
The statistical analysis was done with IBM SPSS Statistics 20.0 (IBM Armonk, NY, USA) and 
included a normality test and a test on significant differences between pairs (Student’s 
t-test or the Wilcoxon matched-pairs signed-rank test (Wilcoxon). The significance level 
was set to p = 0.05.
Table 2  Daily questionnaire outcome
Are you still using your Codacs? Yes 5 (100)
No 0     (0)
How many hours per day have you been using 
the Codacs on a regular basis?
Not worn 0     (0)
1-4 hours a day 1   (20)
4-8 hours a day 4   (80)
> 8 hours a day 0     (0)
In general, is your Codacs worth the effort? No 0     (0)
A little 0     (0)
Moderately 2   (40)
Much 3   (60)
Very Much 0     (0)
Do you have difficulties placing your Codacs? Yes 0     (0)
No 5 (100)
Can you handle the controls of your Codacs well? Yes 5 (100)
No 0     (0)
How do you judge the sound of the Codacs? Very Good 3   (60)
Good 0     (0)
Reasonable 2   (40)
Bad 0     (0)
Very bad 0     (0)
Would you recommend a Codacs to a friend  
with the same hearing loss as yours?
Yes 4   (80)
No 1   (20)
How much would you be willing to pay  
for you Codacs yourself?
Nothing 0     (0)
€   500 1   (20)
€ 1000 1   (20)
€ 2500 0     (0)
€ 5000 3   (60)
Would you, based on your experience with  
your Codacs, choose your Codacs again?
Yes 3   (60)
No 2   (40)
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Results
General results
All five of the originally included patients participated in the follow up study. The mean 
follow-up duration was 19 and 40 months after implantation (see table 1).  All patients 
were using their implant daily, although patient 3 was using it only for less than 4 hours 
(see table 2).  The other patients used their device 4 to 8 hours per day. The device was 
considered moderately to much worth the effort and 80% would recommend the device 
to other patients, although only 60% would reconsider the device based on their current 
experience. On average, the patients would have been willing to pay approximately 3300 
Euros for the device. No difficulties in placing or handling the device occurred and the 
quality of the sound was considered very good by 3 patients and reasonable by 2 patients, 
which was in accordance with the poorer outcome in audiological results for the latter 
two patients (specifically patient 3 and 5).
Residual hearing and benefit
Table 3 presents the results of all tone audiometry measurements. The mean bone 
conduction pure tone average for 0.5, 1, 2 and 4 kHz (PTA4) at baseline was 52 dB HL, 
although the patients varied strongly. During follow-up, the PTA4 mean results were 49 dB 
HL at 3 months, 51 dB HL at 19 months and 57 dB HL at 40 months (one missing value). 
The results of the mean PTA4 were analyzed using paired t-testing. For the follow-up 
results compared to the baseline, no significant differences (p>0.05) were found for the 
mean pre- and postoperative comparison of PTA4 thresholds for bone thresholds. 
Nevertheless, patient 3 suffered a decrease in residual hearing (10 decibels over all 
frequencies).
The mean air conduction PTA4 thresholds pre-operatively were 88 dB HL, resulting in a 
mean air-bone gap of 36 dB HL. After surgery, due to the disconnection of the stapedo- 
incudial joint, this air-bone gap remained and increased to 44 dB HL. The air conduction 
thresholds were 93 dB HL at 3 months, 95 dB HL at 19 months and 89 dB HL at 40 months 
(three missing values for the latter). For the 40-months results to few data was available for 
correct statistical analysis. For the 3 months and 19 months results, the comparison to the 
base line air conduction data shows no significant differences (p>0.05).
The free field audiometry PTA4 results were compared for the unaided pre-operative 
situation versus the postoperative aided situation. The mean unaided PTA4 was 83 dB HL 
and the long term aided results 35 dB HL for 3 months, 39 dB HL for 19 months and 41 dB 
HL for 40 months. Paired t-testing shows stable and significant results (all p<0.001). 
Compared to the aided pre-operative situation with a hearing aid (4 patients available, 
mean PTA 41 dB HL), no significant benefit could be determined (p>0.05). Because of this 
insignificance, we analyzed the results per frequency. As can be seen in the figure 1, the 
benefit between the aided conventional hearing aid and the Codacs ID is specifically 
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present in the frequencies from 4 kHz and higher. When separately comparing the paired 
t-test results for the 6 kHz (all FU moments) and 8 kHz frequencies (only available for 3 and 
19 months) to the aided pre-operative situation, a significant benefit (p<0.05) is found. 
Speech understanding and speech in noise
In table 4 the results of the speech tests are presented. The mean pre-operative unaided 
SRT was 81 dB HL, with poor results for patient 3 and 5. Four patients, except patient 3, 
used hearing aids and were tested in pre-operative aided conditions with an average SRT 
of 42 dB HL, which is a benefit of 35.5 dB HL (see figure 2). At the 3 month measurements, 
all 5 patients had an improved SRT with a mean of 36.4 dB HL. Patient 3 was not able to 
score better than 60% correct word scores at 80 dB HL, which was in accordance with his 
pre-operative score of maximum 60% correct at 120 dB HL. For the 19 months’ 
measurement his word score and SRT had worsened and for the 40 months’ measurement, 
he was not able to score better than 40% at 80 dB HL. The results for the other 4 patients 
remained stable and significant compared to the unaided conditions (p>0.01) and also 
significantly better compared to aided pre-operative conditions (p>0.05) at 19 and 40 
months, with an improved benefit compared to the preoperative hearing aids of 12.6 dB 
HL and 7.8 dB HL respectively (see figure 2).
Figure 1   Free field audiometry (FF) results per evaluation moment.
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Figure 2   Benefit in speech reception thresholds compared to pre-operative unaided 
conditions.
HA = hearing aid. N = 4 patients, excluding patient 3.
Table 4   Audiometry results of speech reception thresholds (SRT) and speech in  
noise ratios (S/N) thresholds in dB HL.
Subject Baseline 3 months 19 months 40 months
SRT  
unaided
SRT 
aided
S/N 
aided
SRT  
aided
S/N 
aided
SRT  
aided
S/N  
aided
SRT  
aided
S/N
NL06-GWK-01 73 40 2.0 20 -2.9 21 -1.9 26 x
NL06-JPV-02 54 34 5.6 20 -1.6 26 -2.6 30 x
NL06-XJH-03 95 x nm 40 nm 60 nm nm x
NL06-JCJ-04 72 35 2.0 45 0 23 0.9 30 x
NL06-GHP-05 110 58 8.4 57 6.8 33 5 50 x
mean 80.8 41.8 4.5 36.4 0.6 32.6 0.4 34.0 x
sdev 21.9 11.1 3.1 16.2 4.3 16.0 3.4 10.8 x
P vs unaided 0.013 0.002 0.005 0.010
P vs aided 0.421 0.059 0.024 0.068 0.041
Measurements with the implanted ear activated and the unimplanted ear closed off. P-value of paired 
t-test; n=5 for unaided and n=4 for aided conditions.
120
Chapter 3
For the analysis of the word recognition score (WRS) we have separated the results of 
patient 3 for the statistical analysis, see figures 3a and 3b. Due to poor WRS scores pre- 
and postoperatively and a decline in residual hearing, these results were considered as 
‘outliers’. The mean data for the other 4 patients is presented in figure 3a. Unfortunately, 
no test was taken from patient 2 during the 40 month evaluation. The mean pre-operative 
unaided scores were 0% for 50 and 65 dB HL and 16.5% for 80 dB HL. A significant benefit 
is achieved for the aided conditions postoperatively (not shown, p>0.05), except for the 50 
dB HL results with the hearing aid pre-operatively and at 40 months. When comparing the 
aided conditions with Codacs ID compared to the hearing aid pre-operatively, the only 
significant difference is found for all three presentation levels at 3 months  (p>0.05). 
For the speech in noise (SIN) test, data was available at 3 and 19 months. Because of the 
poor speech results, patient 3 was not considered in the analysis. Figure 4 and table 4 
present the results. The mean speech-to-noise ratio (S/N) improved from 4.5 dB pre-oper-
atively with hearing aids to 0.6 dB (3 months) and 0.4 dB (19 months). 
Subjective results
For the comparison of the subjective benefit we analyzed the APHAB questionnaires 
before implantation and at the different follow-up moments (figure 5). For the 40 months’ 
evaluation, the data for patient 4 was missing. Nevertheless, a significant improvement 
was found for the categories ease of communication, background noise and reverberation 
Figure 3a   Aided monosyllabic word score.
Patient 3 was excluded. For 40 months results, missing values for patient 2. HA = hearing aid. * = significant 
benefit compared to pre-operative hearing aid (p >0.05).
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Figure 4   Speech in noise results per patient and mean results.
Patient 3 has missing data. HA = hearing aid. SRT = speech reception threshold.
Figure 3b   Aided monosyllabic word score for patient 3.
Nm = not measurable. Pre-operative scores not measurable for all frequencies.
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(p<0.05). The Codacs ID did not bring any improvement in the aversiveness category in 
any of the evaluation moments. In total, a significant global score improvement was found 
for all moments, almost halving the percentage of difficulty in hearing from 58% to 30%. 
When analyzing the data according to Cox and Alexander, all 5 patients meet the criteria 
of significant improvement (viz. 10% improvement on EC, BN and RV subscales or 22% in 
a single scale) for both the short term as the long term follow up results (24).
Complications 
During the evaluation period no adverse events, complications or device failures have 
occurred.
Discussion
This article provides long term audiometric results on the Nijmegen cohort of the original 
phase 1 clinical trial patients for patients implanted with a Codacs ID direct acoustic 
cochlear implant. After three years a stable audiological outcome is found, with a 
significant improvement compared to the baseline measurements. Nevertheless, some 
findings are notable. 
Figure 5   Results for APHAB questionnaire.
EC = ease of communication, BN = background noise, RV = reverberation, AV = aversiveness, HA = hearing aid. 
* = significant benefit p > 0.05, compared to pre-operative with hearing aid. Missing data for patient 4 at 40 months.
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First of all, one patient (XJH-03) suffered a decrease in residual hearing of 10-15 dB HL and 
poor audiological outcome three months after surgery. He was treated with corticoste-
roids but only few of his residual hearing improved. His aided PTA4 was 35 dB HL before 
the event and did only improve to 40 dB HL after 6 weeks. At 1.5 years post-surgery the 
aided PTA4 was 47.5 dB HL and at 3 years 52.5 dB HL. His aided WRS was maximally 60% at 
80 dB HL, both before and after the intervention with corticosteroids. On the long term he 
did not further improve with the Codacs ID and speech in noise measurements could not 
be completed. At the 40 months measurements his maximum speech understanding was 
40% at 80 dB HL. His poor results are, beside the sudden loss in residual hearing, probably 
also explained by the 15 years duration of deafness and sound deprivation on the 
implanted ear.
For the other four patients, the long term results are more rewarding. The results in aided 
thresholds show a significant improvement over the pre-operative hearing aid in the 6 
kHz and 8 kHz frequencies (figure 1), that is stable during the follow-up period. 
Nevertheless, the difference in SRT of 7.8 dB HL on the long term compared to pre-operative 
hearing aids did not show any significant statistical result (p > 0.05), see figure 2. 
The aided monosyllabic WRS show a stable trend for the long term results (figure 3a). 
No difference was found compared to the pre-operative hearing aids for the louder 
sounds (80 dB HL). For the long term results at 65 dB HL a difference of 13% was found that 
did not prove to be significant. The softer sounds at 50 dB HL shows a decreasing trend 
compared to the baseline measurements. The long term improvement of 14% is still 
significant (p < 0.05). If we analyze the individual data (not presented), patients 1 and 4 
show better improvements than patients 2 and 5 on the softer speech results (50 dB HL). 
For the presentation level at 65 and 80 dB HL, patients 1, 2 and 4 show equally well 
improved results, whereas patient 5 did only improve slightly. She also suffered from 
speech discrimination loss (maximum WRS result of 80% correct at 80 dB HL). This is 
probably as a result of presbyacusis at her age of 80 years. 
Another notable result is the improvement in speech in noise. Table 3b and figure 4 
present the individual values for three evaluation moments. Especially patient 2 did 
improve impressively. Looking back, we believe that her pre-operative result with the 
hearing aid should probably be considered too poor. This might be explained due to 
conservative fitting of the hearing aid, since her aided pre-operative WRS at 65 dB HL was 
only 70 %. Analyzing the SRT results, we can calculate that the gain of the hearing aid was 
set at about 20 dB HL, as the unaided pre-operative free field SRT was 54 dB HL compared 
to 34 dB HL with the hearing aid switched on. Nevertheless, a stable result in the SIN tests 
with the Codacs ID is found for the other three patients, where the 19 months result of 
patient 5 even improved. No significance (p>0.05) was found for the mean benefit for the 
four patients of 4.1 dB HL signal to noise ratio. Considering the conservative fitting of 
patient 2, this benefit might be considered as too optimistic. 
124
Chapter 3
Benefit
We compared our results with the data by Busch et al. from another direct acoustic 
cochlear implant called DACS PI (Phonak Acoustic Implants SA, Lonay, Switzerland) which 
is no longer continued (25). This paper presents the results of 9 patients with otosclerosis, 
with the same hearing thresholds indication range. A comparable aided result is found 
with a mean PTA4 gain of 56 (±10 SD) dB HL with the DACS device, versus 53 (± 9.5 SD; n=4) 
dB HL in our study. The mean improvement in SRT at 6 months was about 10 dB, which is 
accordance with our study (16 dB at 19 months and 8 dB at 40 months). An improvement 
of the SNR was found of 3.5 dB versus hearing aids, which was 4.1 dB improvement in our 
study (19 months result). The aided WRS was comparable with our results (around 85% at 
65 dB HL and around 90-95% at 80 dB HL). The APHAB results were globally assessed 
equally. 
When comparing our data to the results of Lenarz & Verhaert et al. comparable results our 
found (26). In their study 19 patients were implanted with a Codacs ID, although 4 patients 
did not suffer from otosclerosis as a cause for their mixed hearing loss. A slightly smaller 
PTA4 gain improvement was found of 45.9 dB HL. An overclosure of the bone conduction 
thresholds was found in their study, which we could not establish in our data. The aided 
WRS outcome was comparable. The benefit in the APHAB score in their study was equal 
to our results (28% benefit), although the overall value was higher both before as after 
implantation.
Future options
Although the Codacs device has been developed to be applied in otosclerosis patients, 
some recent studies have presented alternative methods of applying DACI. As in the 
different coupling methods for the MET and Vibrant Soundbridge, the power of the 
implant does not necessarily have to be applied to the cochlear fluid by a stapes piston. 
Since the maximum output of the Codacs is almost unlimited, this would provide a very 
powerful alternative for the current middle ear implants, although these are much less 
expensive (20). As presented by Grossöhmichen et al., when connecting the DACI to an 
intact stapes supra-structure or mobile footplate, the energy could be transferred via a 
natural way to the cochlear fluid (27). Maier et al. have proven that round window 
stimulation seems to be an alternative option (28). Finally, Schwab et al. have proven that 
a DACI could be safely applied in subtotal petrosectomy surgery (29).
MRI incompatibility
When considering the use of acoustic implants, the MRI incompatibility of the devices 
should always be taken into account. Because of the magnet in the implant receiver, the 
device itself is not protected to any damage caused by the magnetic field of the 
MRI-scanner. Secondly, when imaging the head and specifically the brain, distortion will 
always remain a problem. Therefore, any revalidation option that would provide equal 
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results in the audiological and quality of life outcome needs to be balanced against the 
disadvantages or even the need to explant any acoustic implant (30). 
Limitations
The conclusions in this article are based on small study groups and referred publications 
are based on non randomized controlled trials. The level of evidence is therefore poor.
Conclusion
The Codacs ID DACI provides stable results up to 40 months after implantation. A significant 
improvement of speech understanding and speech in noise was found compared to 
pre-operative hearing aid results, which was comparable to previous studies. Especially 
the high frequencies can be stimulated superior to the pre-operative hearing aid. One 
patient suffered from sensorineural hearing loss and was a poor performer. No other 
changes in residual hearing were found and other technical or medical complications did 
not occur. The results in quality of life questionnaires were stable and significant over time.
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Abstract
Objective: To determine the dynamic range and the maximum output for 3 current 
middle ear implants and to discuss optimal candidacy in middle ear implantation.
Patients and methods: In a prospective multicenter clinical study we compared gain 
and output measurements for three types of middle ear implants: Otologics middle ear 
transducer (MET), Vibrant Soundbridge (VSB), and Direct Acoustic Cochlear Stimulator 
(DACS). The performance of these selected implants from users with severe, predominantly 
sensorineural, hearing loss (50-65 dB HL) was studied. Patients with chronic external otitis 
and sensorineural hearing loss used either a MET (n=9) or a VSB (n=9) implant. The patients 
with predominantly sensorineural hearing loss after surgically treated otosclerosis used a 
DACS (n=4). The patients were selected from two different implant teams but evaluated 
with the same protocol. The relative gain at threshold level was determined, viz. the bone- 
conduction threshold minus the aided sound-field threshold, divided by the bone- 
conduction threshold. Input-output measurements were performed with the devices in 
linear amplification mode and with unlimited output. In this latter data set, the maximum 
output and the input dynamic range of the devices were determined. 
Results: The relative gain for each of the three implants was comparable; however, these 
values were slightly lower than the generally accepted target values. The input dynamic 
range of the devices varied, with the widest range for the DACS and Otologics devices. 
Conclusion: The results from this study indicate that the first generation DACS device is a 
good option for patients with moderate/severe sensorineural hearing loss and surgically 
treated otosclerosis who require a hearing implant.
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Background
Several types of implantable hearing systems, or active middle ear implants (AMEI), have 
been introduced over the last two decades. In 1996, the Vibrant Soundbridge (VSB, Med-El, 
Innsbruck, Austria) became available for clinical evaluation (1), and this was followed by 
the Otologics Middle Ear Transducer (MET, Otologics LLC, Boulder, CO, USA). These 
semi-implantable devices have been successfully applied in patients with sensorineural 
hearing loss (2-4). These devices typically consist of an actuator that is directly coupled to 
the ossicular chain and driven by an external audio processor (5). More recently, middle ear 
implants have also been used in patients with otosclerosis (6-9).
The Direct Acoustic Cochlear Stimulator (DACS) device, introduced in 2006, is a version of 
a semi-implantable middle ear implant that bypasses the outer and middle ear structures 
and directly stimulates the cochlea (10,11). The DACS has been used in a feasibility study of 
patients with moderate/severe sensorineural hearing loss due to otosclerosis. 
The DACS system is a power-driven stapes prosthesis; an electromagnetic actuator is 
implanted in the mastoid cavity and connected to a conventional stapes prosthesis, 
which directly drives inner ear fluid movement. The external audio processor is connected 
to the actuator by a percutaneous plug. In the first DACS study, the ossicular chain was 
reconstructed during the implantation surgery by inserting an additional, passive stapes 
prosthesis (11). This surgery reduced the air-bone gap and a left a predominantly 
sensorineural hearing loss for the patients postoperatively.
Traditionally, to measure the gain and output of conventional hearing devices, artificial 
simulators are used. For middle ear implants, such simulators are not available; therefore, 
the basic amplification characteristics are typically measured in patients. For example, to 
measure gain, the functional gain (FG) can be determined by subtracting the aided sound 
field thresholds from the unaided sound field thresholds. However, measuring FG can be 
problematic when used for middle ear implant devices for three reasons. First, if an 
air-bone gap is present after the surgery, this proportionally raises the unaided threshold 
and will overestimate the FG. The measured FG will then be the sum of the pure device 
gain plus the post surgery air-bone gap. Second, noise-reduction algorithms, which are 
often present in current hearing devices including middle ear implants, can interpret test 
signals as noise and, consequently, reduce amplification. Finally, the middle ear implants 
studied here make use of adaptive, non-linear amplification. Therefore, sound field threshold 
measurements evaluate the (relatively high) gain for soft sounds and overestimate the 
gain for conversational speech levels (12). 
An additional basic amplification characteristic is the saturation (SAT) level of the device, 
which is the loudest input sound that can be properly processed by the device. The input 
level at the point of saturation can be measured by studying the output behavior of the 
device. Previous research has shown that it is possible to measure output limitation char-
acteristics objectively with a microphone placed in the ear canal. In the current study, we 
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have compared the basic capacities of three implantable hearing systems. The gain of 
the devices was compared in matched patient groups. In addition, the dynamic range and 
the maximum output of the three devices were determined, while the devices were 
programmed in linear amplification mode with unlimited output. The results of this study 
are used to discuss optimal candidacy for current middle ear implants.
Materials and methods
Patients 
All data are acquired from patients who used a (unilateral) middle ear implant: 4 DACS 
users, the only patients with the first generation DACS as described by Hausler et al. (11), 
9 VSB users and 9 MET users, who were selected from the Nijmegen database of 55 VSB 
users and 18 MET users. VSB and MET users were matched with the DACS users based 
on the degree of preoperative sensorineural hearing loss (criteria: bone-conduction 
thresholds between 30 and 60 dB HL at 500 Hz and between 50 and 75 dB HL at 4 kHz and 
a mean hearing loss between 50 and 65 dB HL at 0.5, 1, 2 and 4 kHz) and the length of 
device use (a minimum of one year). 
Figure 1 shows the mean preoperative bone-conduction thresholds of the implanted ear 
in patients from each group. The VSB and MET users had been provided with implants due 
to therapy-resistant chronic external otitis. These patients had a predominantly senso -
rineural hearing loss, although an air-bone gap in the order of 5-10 dB was common. Prior to 
Figure 1   Mean bone-conduction thresholds plotted as a function of frequency  
for three groups of middle ear implant users: patients using the Vibrant 
Soundbridge (VSB), the Otologics MET (MET) or the DACS.
Vertical lines represent the standard deviations.
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treatment, the DACS patients showed both sensorineural and conductive hearing loss 
caused by otosclerosis. At the DACS post-operative evaluation, the air-bone gap had been 
reduced because the fixed stapes had been replaced by a secondary, passive stapes 
prosthesis (11). A mean air-bone gap of 14 dB remained at 0.5, 1, 2 and 4 kHz (range 6 to 20 dB).
The VSB users were fitted with the audio processor 404 (Med-El, Innsbruck, Austria), the MET 
users were fitted with the Button processor (Otologics LLC, Boulder, CO, USA) and the DACS 
users were fitted with the Savia 211 processor (Phonak, Staefa, Switzerland). All fittings 
were performed by experienced audiologists. 
Parameters 
The two parameters used in this study are a FG-based gain ratio (GR) and the input level 
at output saturation (ILOS). (13).
Gain ratio (GR)
The bone conduction, based on the functional gain at the threshold level, was defined as 
the difference between the bone-conduction threshold and the aided threshold. This 
value, divided by the bone-conduction threshold, was called the gain ratio (GR) and was 
calculated per frequency. The GR per frequency can be compared with target values, as 
produced by prescription rules. According to the commonly used NAL-NL prescription 
rule, for conversational levels, the GR should be 0.46; this indicates that the desired FG 
should be approximately 0.46 times the hearing threshold (at 1-4 kHz) (14). For softer 
sounds, ratios higher than 0.46 are prescribed (15). These reference ratios can be used to 
assess the adequacy of amplification provided by the middle ear implant. This ratio is 
independent of the patient’s degree of hearing loss, unlike the FG. To determine the GR, 
noise-reduction algorithms were deactivated. All other settings were the patient’s daily 
settings.
Input level at output saturation (ILOS)
To determine the input level at saturation for the three implant devices, the procedure 
described by Snik et al. was followed (13). Briefly, sound pressure levels were measured 
with the Aurical REM system in the ear canal of the aided ear (Madsen, Taastrup, Denmark). 
Measurements were conducted while the ear canal was occluded with an EARlink foam 
tip (Aearo Company, Indianapolis, IN, USA). After a foam tip was inserted, a probe tube 
microphone was pushed through the standard opening in the plug. In this manner, the 
sound pressure level could be measured in the occluded ear canal. Sound pressure levels 
were recorded as a function of frequency during the presentation of a calibrated frequency 
sweep produced in the sound field (sweep from 250 Hz to 8 kHz at 60 dB SPL, as standard on 
the Aurical REM system). The first measurement was carried out with the audio processor 
off (reference curve), and the measurement was repeated with the audio processor on. 
The difference curve was used for further analysis. Similar curves were obtained at 50, 70, 
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80 and 90 dB SPL. From the difference curves, the input level at which the device saturated 
was determined at 1 kHz and 2 kHz. Figure 3 shows representative data. Output limiting 
options were deactivated, and the device was programmed in the linear amplification 
mode.
To measure sound field thresholds, warble tones were presented via a loudspeaker placed 
1 meter in front of the patient and calibrated according to Morgan et al. (16) Nine of the 
22 patients participated in a special session to measure the output limitation of the 
devices (three MET users, four VSB users and two DACS users). These patients were 
randomly selected. The measurements were carried out in sound-proof double-walled 
rooms. 
Results
The GR as a function of frequency is presented in Figure 2. The mean data are presented 
separately for the matched VSB, MET and DACS users. Vertical lines indicate the standard 
deviations. 
A representative example of an input-output measurement, as derived from sound- 
pressure measurements in the occluded ear canal, is presented in Figure 3. After turning 
the device on, there was an increase of 15-20 dB SPL at 1 to 3 kHz in the ear canal. The data 
in Figure 3 are from a patient using a DACS device.  These data have a linear increase until 
the output levels off at an input level of 75 dB SPL at 1 kHz and 80 dB SPL at 2 kHz. In a 
Figure 2   Functional gain at threshold level divided by bone-conduction threshold 
versus frequency for three groups of middle ear implant users: patients using 
the Vibrant Soundbridge (VSB), the Otologics MET (MET), or the DACS.
Mean values are displayed with standard deviations.
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second patient with a DACS, the input level at saturation was above 80 dB SPL; this patient 
could not tolerate stimulation louder than 80 dB SPL. For the other two implant systems, 
the output saturated at lower input levels. Figure 4 shows the maximum dynamic range 
Figure 3   Input-output curves at 1 kHz and 2 kHz obtained from probe-tube 
microphone measurements in the ear canal of a patient with a DACS device.
The arrows indicate the point of device saturation.
Figure 4   Hearing thresholds (striped), input level at saturation (ILS; grey) and the 
dynamic range (blocked) for the three groups of patients, as measured at  
1 kHz (left columns) and 2 kHz (right columns).
The mean data with the range are presented. The audio processors were programmed in linear amplification 
mode and the maximum output was not limited.
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of the three devices, which is defined as the difference between the input level at 
saturation and the aided thresholds, expressed in dB SPL, and obtained in the linear 
amplification mode. 
Discussion
In contrast to studies that assess individual benefit and satisfaction levels, the 
measurements in the current study are device specific, not primarily patient specific 
dynamic range and maximum output, and are therefore helpful when comparing systems. 
While previous studies addressed benefit measures, such as speech perception and 
patient opinions, this study investigated the basic performance of three active, semi-im-
plantable middle ear devices used in patients matched according to the extent of 
sensorineural hearing loss. Previously, it has been shown that the gain (amplification) and 
maximum output are important components in the evaluation of the basic function of 
implantable hearing systems (13,17). 
Figure 2 shows the gain ratio (GR), a measure that is, in principle, hearing-loss independent 
and can, therefore, be averaged over patients. Significant differences between the three 
devices were not found (t-test, p > 0.05). This result is not surprising because the actual 
gain is determined by the user, either by adjusting the volume (MET and DACS), or, if 
volume control is absent, by adjustments made during the device fitting. The desired gain 
ratio, according to the NAL rule, should be at least 0.46 (at 1, 2, and 4 kHz). This GR was 
found at 1 kHz and 2 kHz for the DACS users and at 2 kHz for the VSB users; for MET users, 
the values at 1 kHz and 2 kHz approached this target value. A target ratio of 0.46, as 
prescribed by the NAL rule, was matched but not surpassed by the three systems (14,15). 
As shown by Snik et al., the proper processing of loud sounds by the implant can be 
measured objectively with a probe microphone in the ear canal (13). The probe measures 
the vibrations produced by the actuator of the middle ear implant because these reach 
not only the cochlea but also the tympanic membrane. This probe thus measures the 
vibrations produced as a by-product. These vibrations are transmitted as acoustic signals 
into the ear canal and measured by a probe microphone. Although such measurements 
cannot be used to assess gain, they can be used to study the input-output behavior of 
middle ear implants (13). Measuring input-output behavior was possible with the VSB, the 
MET and the DACS (Figure 3). The input level at saturation was higher for the DACS than 
for the MET or VSB. As a consequence, the dynamic range was the widest for the DACS 
(see Figure 4). These data can be, in part, attributed to the percutaneous coupling 
between the actuator and audio processor, which may be more effective than the 
contact-free, radio-frequency coupling in the VSB and MET (18).
The individual (dynamic) hearing range of a patient can be determined from audiogram 
results as the difference between the hearing thresholds and the loudness discomfort 
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levels, or UCL (14).  For patients with a sensorineural hearing loss of 50-65 dB HL, the 
dynamic hearing range is in the order of 50-60 dB (19). The DACS device best approaches 
this value (Figure 4).  When the dynamic range of a hearing device is less than the patient’s 
hearing range, patients may choose to lower the gain to widen the dynamic range and 
prevent the distortion of loud sounds, such as their own voice, by the saturation of the 
device. This may explain why the amplification results for the VSB and MET are slightly, 
although not significantly, lower than those for the DACS (Figure 2).
Figure 4 shows that, for each device type, particularly for the VSB versus the DACS, the 
range of the input level at saturation minimally overlapped, suggesting that the differences 
between devices are important. 
A restriction of the present study is the limited number of patients in the maximum 
output measurements. However, by the present protocol, these measurements are not 
patient specific but rather device specific, thereby fully minimizing subjective patient 
factors. 
Compared to the implantation of the VSB and the MET, the DACS surgery is more invasive 
because the vestibulum is entered which can lead to damage. The risk of cochlear damage 
in the DACS surgical procedure is thought to be comparable to that of a classical 
stapedotomy, because a standard stapes prosthesis is used (11). Furthermore, the DACS 
system was developed and used only in patients with mixed hearing loss caused by 
otosclerosis. 
 
Conclusion
The results of the present study suggest that the percutaneous DACS middle ear implant 
has a amplification capacity that outreaches the VSB and has a comparable or better 
capacity than the Otologics MET middle ear implant to assist patients with moderate to 
severe sensorineural hearing loss, because of its larger dynamic range.  
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Abstract
Objective: To compare all amplification options for patients with mixed hearing loss by 
determining the maximum output of the available devices. 
Patients and methods: Patients with mixed hearing loss who were implanted with either 
the Vibrant Soundbridge (VSB) or Cochlear’s Direct Acoustic Cochlear Stimulator (Codacs) 
were compared to standard non-patient related measurements of one acoustic hearing 
aid, two percutaneous bone conduction devices (BCD) and one transcutaneous BCD. The 
dynamic range was determined by ear canal microphone measurements of the maximum 
output per frequency, which is the highest sound level that can be produced by a device 
without distortion, in combination with loudness scaling tests.
Results: The dynamic range is largest in the Codacs device, since 4 of 5 patients had 
unlimited output up to uncomfortable loudness. The VSB maximum output varies 
between 65 and 85 dBHL. BCD maximum output levels vary around 70dBHL and 80dBHL 
for the Baha Cordelle. The transcutaneous Sophono reached 56dBHL.
Conclusion: The best dynamic range is achieved by surgical closure of the air-bone gap 
and application of a regular hearing aid. By implantation of a Codacs device the utility of 
the complete dynamic range can also be achieved. Coupling of the VSB to the round or 
oval window results in a smaller dynamic range, but the surgery is less invasive. Stability of 
coupling of this device may vary and application in atretic or obliterated ears is possible. 
For moderate to severe mixed hearing loss a BCD is a straightforward solution which is 
independent of the middle ear status, although the transcutaneous device is only suitable 
for (sub-)normal sensorineural hearing.
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Introduction
Mixed hearing loss is a common otological condition. Mostly, it is caused by some 
abnormality of the middle ear or outer ear or by otosclerosis or middle ear disease in 
combination with sensorineural hearing loss of any cause. The first option to treat a patient 
with mixed hearing loss is reconstructive surgery. If reconstructive surgery is impossible 
because of medical reasons (e.g. aural atresia), technical reasons (remaining sensorineural 
hearing loss needs amplification) or personal reasons, then fitting the patient with a 
hearing device should be considered. Conventional acoustic devices, however, are not 
always an option because of medical reasons (chronic otorrhoea or aural atresia) or 
technical reasons (lack of power in case of a severe air-bone gap). In this case, the next 
option is to consider a transcutaneous or percutaneous bone-conduction device (BCD) or 
a middle ear implant directly coupled to the cochlea (1). This latter application is relatively 
new; in 2006, Colletti and co-workers published their results on the use of the Vibrant 
Soundbridge middle ear implant (VSB) with its actuator coupled directly to the round 
window instead of to the incus (the ‘classic’ application for patients with sensorineural 
hearing loss)(2). As shown later by Linder et al. (2009), this new VSB application is also 
effective after subtotal petrosectomy and obliteration of the middle ear cavity by filling it 
with abdominal fat, in patients with chronically infected ears (3). Furthermore, several 
papers have addressed the application of the VSB in atretic ears (4,5). Coupling the actuator 
to the oval window has also been described (6,7).
Recently, Häusler et al. (2008) introduced a new implant, the DACS device (Direct Acoustic 
Cochlear Stimulation), developed for patients with advanced otosclerosis (8). The actuator 
of the DACS device is anchored in the mastoid cavity and its vibrating piston, called the 
artificial incus, is connected to a stapes prosthesis. This device was recently further 
developed and renamed the Codacs device and has been tested in a phase 1 clinical 
study (9). 
Percutaneous BCDs have been available since 1987; viz. the Baha system (Bone Anchored 
Hearing Aid) (10). Research showed superior audiological results compared to conventional 
bone conductors (11). Despite its audiological superiority, there is still a search for 
transcutaneous solutions, as the skin-penetrating abutment of Baha requires lifelong daily 
care and infections around the abutment, although rare, can occur (11). Transcutaneous 
BCDs typically use a subcutaneously placed magnet, solidly connected to the skull bone. 
The externally worn driver, the audioprocessor, is coupled transcutaneously using a 
second coupling magnet, part of the audioprocessor. Recently, Siegert introduced such a 
transcutaneous BCD, called the Otomag device (12).
The aim of this paper is to compare all amplification options for patients with mixed 
hearing loss (conventional acoustic devices, transcutaneous and percutaneous BCDs, 
middle ear implants) by determining the maximum output of the available devices. The 
maximum output is the output level at which the device no longer behaves linearly and 
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saturates (13). In other words, the maximum output is the highest sound level that can be 
produced by a device without distortion. It was decided to express the maximum output 
level of all the devices in dB HL.  
Patients and methods
Study design
For the acoustic device, the maximum output level was measured on an ear simulator, 
part of TBS25 Test Chamber connected to the Affinity 2.0 Hearing Aid Analyzer (Interacoustics, 
Assems, Denmark) and the output was expressed in dB HL(14). We measured the maximum 
output of a standard, powerful acoustic device (Oticon Tego Pro Power; Oticon, Copenhagen, 
Demark) for matters of comparison. 
For the percutaneous BCD, the skull simulator was used, which measures the output of 
this BCD in ‘dB output force level’(15). The skull simulator was integrated in a second TBS 
25 Test Camber, connected to the Affinity Hearing Aid analyzer (Interacoustics). As 
described by Carlsson et al. (1997), the dB output force level can be transformed to dB HL 
by using the RETELdbc (Reference Equivalent Threshold Force Level for direct bone 
conduction) (16). The Baha Divino (standard Baha; Cochlear BAS, Göteborg, Sweden) and 
the most powerful Baha Cordelle (Cochlear BAS, Göteborg, Sweden) were measured on 
the skull simulator and the maximum output was determined and expressed in dB HL. 
Nowadays, as percutaneous BCD, not only Baha devices are available but also Ponto 
devices (Oticon Medical, Copenhagen, Denmark). The maximum output of the Ponto 
device was also determined on the skull simulator as the coupling of the Ponto and Baha 
soundprocessors are compatible. 
Håkansson et al. (1990) showed that the skull simulator can also be used to measure the 
output of transcutaneous bone-conduction implants (17). They connected the to-be-im-
planted magnet solidly to the skull simulator, used a layer of fresh skin over that magnet 
and then coupled the external sound processor. In this way, they studied the Audiant 
Xomed device, which is no longer on the market. The new transcutaneous bone-conduc-
tion implant, the Otomag Alpha 1 device (Sophono, Boulder, CO, USA) was studied in the 
same way (18).
As simulators for middle ear implants are lacking, in vivo experiments have been carried 
out to determine the maximum output (following Snik et al., 2004) (19). When stimulated, 
the implanted actuator radiates sound that can be picked up in the occluded ear canal by 
a probe microphone. This enabled the measurement of the actuator’s output as a function 
of the input level (19, 20). Next, they calculated the maximum output, being the input level 
at which the output levelled off, and the gain (or amplification) of the device. It should be 
realized that in mixed hearing loss the actuator directly stimulates the cochlea and 
surpasses the middle ear. Therefore, by definition, the gain at a given frequency is the 
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(post-implant) bone-conduction threshold minus the aided threshold.
Such microphone measurements in the ear canal might be compromised in ears with 
aural atresia or with obliteration of the middle ear cavity. In such cases, the input-output 
behaviour was studied with loudness scaling measurements.  following the procedures 
proposed by Moser (1987) (21). A 7-point categorical scale was used, with categories from 
inaudible to uncomfortably loud. The loudness categorization test was carried out with 
0.5, 1, 2 and 4 kHz narrow band noise.
Patients
The maximum output of the VSB and Codacs implantable devices was measured in 11 
patients with mixed hearing loss, who were recruited for this study. Six patients used a VSB 
device (Med-El, Innsbruck, Austria) with the actuator coupled either to the isolated stapes 
(n=5) or the round window membrane (n=1) and all used the VSB Amadé speech processor 
(Med-El, Innsbruck, Austria). The average (post-intervention) bone conduction threshold 
of this group at 0.5, 1 and 2 kHz (PTAbc) ranged from 45 to 68 dB HL. The history of the 
patients has been described in detail previously (7). The other patient group contained 
five patients with mixed hearing loss due to advanced otosclerosis who were fitted with a 
Codacs device (Cochlear, Mechelen, Belgium) as part of the European phase 1 clinical trial 
(9). The post-implant PTAbc ranged from 25 to 75 dB HL. Details of these patients are 
described elsewhere (9). Note that except for the unknown effectiveness of the coupling 
of the implant actuator to the cochlea, individual patient characteristics do not play any 
role in the present maximum output measurements.
During all measurements the hearing devices were set in an unlimited linear amplification 
mode with noise reduction and speech enhancement functions switched off. The 
microphone mode was set to omnidirectional. 
Results
Figure 1 presents the format for presenting the data. The x-axis presents the sensorineural 
hearing loss component of patients (mean value at 0.5, 1 and 2 kHz) and the vertical axis 
presents the maximum output of the tested hearing devices (averaged over the same 
frequencies). If the maximum output value is lower than the lower thick black diagonal 
line, the amplified sound is inaudible. The bold line at the top of the figure represents the 
highest output level that is tolerated by patients as reported by Dillon and Storey (1998) 
and expressed in dB HL (again mean value at 0.5, 1 and 2 kHz)(13). The desired dynamic 
hearing range is the area between the diagonal line and Dillon and Storey’s loudness 
discomfort line. 
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It is obvious that the maximum output should be loud enough for the whole dynamic 
hearing range of the patient to be utilized. Since this is not always achieved, we formulated 
a minimum criterion: a device is considered sufficiently effective if its maximum output 
reaches 30 dB louder than the inaudible diagonal line. This score is indicated by the dotted 
diagonal line in the figure running parallel to the inaudible value line). Thus, the hearing 
range should be at least 30 dB, which is the dynamic range of normal speech(22).
The horizontal lines in figure 1 present the average maximum output level of the 
conventional acoustic device, assuming absence of an air-bone gap (line labelled BTE-0) 
and assuming an air-bone gap of 50 dB (line labelled BTE-50). 
The three horizontal lines in figure 2 present the maximum output of the standard Baha 
(Baha Divino), the Baha Cordelle (most powerful Baha) and the Sophono device. Following 
the criterion of at least a 30 dB dynamic range, the maximum output levels indicate that 
the standard Baha Divino, the Baha Cordelle and the Sophono can be used up to 40 dB HL, 
up to 50 dB HL and up to 25 dB HL sensorineural hearing loss component, respectively. 
Figure 1   Maximum output as a function of hearing impairment.
The y-axis presents the maximum output averaged at 0.5, 1 and 2 kHz and expressed in dB HL. The x-axis presents 
the sensorineural hearing loss component averaged over the same frequencies. If a data point lies below the 
thick black diagonal line, it is inaudible. The middle dashed line presents the desired maximum output level of 30 
dB (taken from Dillon and Storey, 1998). The area between this line and the diagonal line presents the dynamic 
hearing range. The upper thick dashed line represents the loudness discomfort line. The horizontal lines display 
the maximum output of the behind-the-ear (acoustic) device assuming no air-bone gap (label BTE-0) and 
assuming a 50 dB air-bone gap (label BTE-50).
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The maximum output of the standard Ponto device was found to be 66 dB HL which is 
comparable to that of the Baha Divino. The Baha Cordelle is a unique device with respect 
to the maximum output which is unmatched by any other BCD.  
Irrespective of the applied measurement (microphone measurement in the ear canal or 
loudness scaling), the maximum output could not be determined for four of the five 
patients using a Codacs device. Non-linear behaviour did not occur up to the patients’ 
loudness discomfort levels. For the remaining patient, saturation was found at input levels 
of 80-85 dB HL. However, the gain could not be determined properly as bone conduction 
thresholds at 500 Hz and 2 kHz were beyond the limits of the audiometer (> 75 dB HL). 
From these data we concluded that the maximum output was louder than 102 dB HL. The 
arrows in figure 2 indicate that the maximum output of the other four patients was above 
their uncomfortable loudness level.
The VSB data points are also presented in figure 2. Measurements obtained with a 
microphone in the ear canal were only feasible for one patient. For the other patients, 
loudness scaling measurements were carried out. Figure 2 shows an obvious variation in 
the results. We expect variability owing to coupling effectiveness of the actuator to the 
cochlea and whether or not the middle ear cavity was air-filled or obliterated with fat (7). 
For two of the six patients, the maximum output was considered rather low (around 65 dB 
HL) whereas for the other four patients, a rather stable result was found around 85 dB HL.
Figure 2   The maximum output of the different hearing devices (for BCDs presented  
as horizontal lines) and for the VSB and Codacs directly coupled to the cochlea 
(presented as individual points).
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Figure 3 presents the mean maximum output data, however, this time separated per 
individual frequency: 0.5, 1, 2 and 4 kHz. The highest maximum output for all the devices 
is found at 2 kHz. The data of the VSB users were averaged, with the two lower outliers 
were excluded for the averaged calculations. This figure suggests a best bandwidth for 
the percutaneous BCD devices. No Codacs data could be included as the maximum 
output values remained unknown.
Discussion
Figure 1 shows the maximum output of the acoustic hearing aid. The output depends 
proportionally on the size of the patient’s air-bone gap; e.g. for patients without any 
air-bone gap, the entire dynamic hearing range is available. However, in case of a patient 
with an air-bone gap of 50 dB and accepting the minimum criterion of 30 dB dynamic 
range, this acoustic device should only be used in patients with (sub)normal cochlear 
functioning with up to 30 dB sensorineural hearing loss component. 
The maximum output of the Baha Divino, as presented in figure 2, is in accordance with 
published data on the device’s predecessors (16). Figure 2 shows that this device can be 
effectively applied for patients with a sensorineural hearing loss component of up to 40 
Figure 3   The mean maximum output level per device for the individual frequencies  
of 0.5, 1, 2 and 4 kHz. Note that to calculate the mean for the VSB, the two lower 
outliers were excluded.
151
4
Comparison of auditory implants
dB HL. This value is in agreement with the consensus in literature (11). For the Baha Cordelle, 
the upper application level of 50 dB HL is lower than the 60 dB HL that has been previously 
suggested by Bosman et al. (23). However, they used a less strict criterion, namely 50% 
word recognition. 
The Sophono Alpha 1 device has a maximum output approximately 15 dB less than the 
Baha Divino. This limits the application range of the Sophono Alpha. In principle, the 
Sophono device is a standard transcutaneous BCD with magnetic coupling instead of the 
classical coupling with a headband (12). Håkansson et al. showed that transcutaneous 
coupling is indeed 10 to 15 dB less effective than percutaneous BCD coupling, which 
explains the observed difference between the maximum output of the Baha Divino and 
the Sophono Alpha 1 devices (10). Recently Sylvester et al. published their first data on the 
application of the Sophono device in patients with conductive and mixed hearing loss. In 
agreement with our results they concluded that the Sophono device should only be used 
in patients with (sub-) normal cochlear function (24). 
The maximum output of the Codacs device is very loud, which means that, unlike the 
other devices, the patient’s full hearing range can be utilized. Also, in contrast with the 
other devices, this means that special attention has to be paid to output limitation when 
fitting this device. 
The results of the VSB with its actuator coupled to one of the cochlear windows shows a 
variable result; coupling effectiveness may play a role. Previous studies have addressed 
such questions as whether the VSB actuator could be coupled effectively to the (remains 
of the) stapes; how to assure proper contact between the actuator and the round window 
membrane; and what options would be best in atretic ears (2, 4-7). Recently, publications 
by Maier et al. (25) and Schwab et al.(26) indicate that the coupling of the transducers to 
the cochlea may vary as much as 20 dB, depending on various circumstances. The Med-El 
company suggests that the VSB coupled to the round or oval window can be used in 
patients with a sensorineural hearing loss component of up to 55 dB HL (27). Our presented 
results support this claim.
In a previous study, the maximum output of the VSB in its classic application was studied 
in 8 patients with pure sensorineural hearing loss and chronic external otitis (19). A mean 
maximum output level of 102 dB SPL was found, what equals 98 dB HL, in the 1 to 2 kHz 
region. The calculated mean at the same frequencies of the present data is 83 dB HL. 
Comparison of the two means suggest that the present VSB application on the round 
window and stapes suprastructure is 15 dB less effective than the classic VSB application.  
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Conclusion
In summary, four amplification options to treat patients with mixed hearing loss have 
been considered. The first option, if possible, is surgical closure of the air-bone gap and 
fitting of a conventional acoustic device. This option enables full use of the patient’s 
dynamic hearing range. The second option is the application of a Codacs implant 
(pending certification). This option will also enable full use of the patient’s dynamic 
hearing range. So far, the Codacs device has only been applied in patients with advanced 
otosclerosis, and long term stability data are still lacking. A stapedotomy is an essential 
part of the surgical procedure and carries its own risks.  
The third option involves application of the VSB device connected to the round or oval 
window. Although application of the VSB device is less invasive than that of the Codacs 
device, the coupling effectiveness is not yet well defined. In contrast to the Codacs device, 
it has been shown that the VSB device can be used in chronically diseased middle ears 
(after subtotal petrosectomy with obliteration of the middle ear cavity) and in atretic ears. 
Structural long-term data on the stability of the coupling between actuator and the 
cochlear windows have not yet been published. 
The fourth option is a percutaneous BCD, which offer effective amplification for patients 
with a moderate to severe sensorineural hearing loss. BCD surgery is relatively straight 
forward and the main advantage of a percutaneous BCD is that neither surgery nor 
performance is affected by the status of the middle ear. 
The search for transcutaneous BCDs remains, as the skin-penetrating abutment of 
percutaneous BCDs requires lifelong daily care and infections around the abutment may 
occur. However, the 10-15 dB improvement in effectiveness that was achieved by changing 
from transcutaneous to percutaneous transmission of sound vibrations would be lost (10). 
Nevertheless, the maximum output of the transcutaneous Sophono device is relatively 
low and makes this device only suitable for patients with normal or subnormal cochlear 
function.
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General discussion
Limitations of the studies
This thesis focuses on the clinical outcome of the implantation of active middle ear implants 
(AMEI) and direct acoustic cochlear implants (DACI). Although most of the data has been 
prospectively acquired (baseline and long term data in chapter 2.2 and the studies presented 
in part III), the long term clinical outcome of the AMEI cohort has been retrospectively 
studied (surgical results in chapter 2.1 and 2.3). The retrospective method of these latter 
studies may have invoked an under-reporting in the occurrence of minor complications. 
Potentially, the clinical observations might be influenced due to a heterogenic description, 
as data were not acquired in a pre-study well defined, structured and periodic order like in a 
prospective study. Nevertheless, the descriptive studies present a new and unprecedented 
follow up duration and detail of clinical results in implantable hearing implants in terms of 
safety and stability. The publication of these studies appeals to our strong belief that 
reporting these long term data is of great importance for the post market release experience 
of new implantable technologies for the rehabilitation of hearing loss.
No randomized studies have been conducted in this thesis. The lack of randomization 
introduces the possibility of bias, e.g. selection and/or confounding bias. None of the 
patients chose for an implantable hearing implant as a result of dissatisfaction with the 
hearing performance or quality with the conventional device. In all cases described, 
conventional hearing aids were contra-indicated as a result of the medical problems they 
caused. Implantable hearing aids were simply the last resort. Therefore, no comparison to 
another treatment was available for a controlled study and a pre and post intervention 
analysis was considered adequate. Previous studies have reported that recipients of active 
middle ear implants were critical about the quality of sound of the devices. This was 
caused by the restricted bandwidth and output capacity of their devices. Nevertheless, 
the quality of life of the patients improved significantly as a result of the fact that the 
patients were able to use their device all day. This certainly reflects the value of the 
availability of these devices for those who could otherwise not be rehabilitated.
In the structured prospective multicenter study on the Codacs device, independently 
monitored by an external monitor, no randomized comparison to conventional hearing 
aids was conducted. The purpose of this study was to determine the safety and efficacy 
of the experimental device. Therefore, a specific narrow selection was applied. Since the 
indication criteria was set for otosclerosis, which is a chronic stable disease, the patients 
were suitable for a pre- and post comparison of their own measurements.  It is however of 
importance to note that beneficial changes in terms of speech recognition-in-quiet, and 
in-noise may be explained by the improvement in pure tone thresholds with the Codacs. 
These results were consistent with the subjective results obtained in the recipients. The 
results of this study provide evidence that the device is safe to apply and that it provides 
a sufficient audiological benefit for the specific selection of patients. 
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The comparative articles on maximum output of the various devices (part IV) present 
original data which are patient independent and therefore individual patient characteris-
tics or selection criteria have not influenced these results. 
Benefit of the devices
The studies in this thesis present evidence that both the AMEI as DACI provide adequate 
benefit for the implanted patients. In chapter 2.2, the long term benefit in quality of life of 
AMEI has been reported for a mean follow up duration of 7.5 years. This study focused on 
a selection of the total patient cohort, because the first implanted patients were not 
prospectively evaluated with questionnaires. Although the level of benefit gradually 
decreased over time, a significant improvement is still found in the long term evaluation 
for 3 different quality of life questionnaires. No long term reports on quality of life outcome 
in AMEI surgery are present in the literature. These results are in accordance with the 
results on short term studies in the literature (1-4).
In chapter 2.3 the long term evaluation of the technical outcome of AMEIs is studied. Many 
of the first implantations were experimental or part of phase I trials. Therefore, growing 
pains occurred like, for example, the application of ionomeric glass cement to improve the 
coupling of the actuator to the middle ear ossicular chain. This application proved 
disappointing. Another example is the technically poor results of the Otologics Middle Ear 
Transducer (MET), which caused many revision surgeries (5). Fortunately, the quality of the 
implants and the implant surgery improved gradually over the years leading to less 
revisions and less explantations. Eventually, an overall explantation rate of 7% was found 
for the Vibrant Soundbridge (VSB) which is comparable to the rates of cochlear implants 
(6, 7). The overall explantation rate of the MET (28%) was high, but the rate has decreased 
in time, with no explantations with the newer Cochlear MET model (applied since 2010; 
chapter 2.3 and unpublished data).
For the DACI, two prospective studies have been conducted to evaluate the safety and 
efficacy of the investigational Codacs device. In chapter 3.1 the results of a multicenter 
study are presented. This study reported a significant decrease in difficulties with hearing 
compared to the pre-operative hearing aid or unaided situation, tested by the APHAB 
questionnaire (8). The audiometric benefit was evident. Most important was the finding of 
better hearing in the high frequencies compared to conventional hearing aids and, 
consequently, the improved results of speech-in-noise tests. Chapter 3.2 presented the 
long term stability of the Dutch cohort of Codacs implanted patients. The results were 
stable compared to a previous short term evaluation, both on the APHAB outcome as the 
audiometric evaluation. Most surprising was the ease of the fitting of the device. Apart 
from the evaluation visits initiated by the hospital, no further visits were necessary to 
adapt the fittings of these implants (unpublished data). 
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Complications in surgery
As in any surgical procedure, implantation of AMEI and DACI comes with surgical risks and 
complications. These risks are comparable to other otologic operations that include a 
mastoidectomy, atticotomy and posterior tympanotomy. It mostly concerns the risk of 
damage to the inner ear and vestibule, facial and chorda tympani nerves and postoperative 
problems of infection in the middle ear or surrounding the implant under the skin. In 
chapters 2.1, 2.3 and 3.2 we have described the complications that occurred in our series. 
Especially the so-called transcanal approach through the ear canal for the implantation of 
the VSB proved to be unsafe in our hands. When applying it in patients with external otitis, 
the wire of the device repeatedly extruded through the skin of the ear canal. For the 
regular approach, 20 complications have been described in chapter 2.3, classified as minor 
or more serious. For some of the complications revision surgery was required. Although 
device failure might not be classified as a medical complication but rather a technical 
failure, in most cases it still required a revision operation to explant or replace the device.
In part III we have described the study cohort for the DACI. In our own study group of 5 
patients, one patient suffered a decrease in sensorineural hearing. We could not identify 
any specific cause for this hearing loss, and treatment with corticosteroids did not improve 
his hearing thresholds. In the final evaluation, the thresholds were stable on the level of 
the postoperative deteriorated measurement. The patient had no postoperative 
improvement in speech understanding, which was explained by the advanced level of 
hearing loss and long period of hearing deprivation in the operated ear.
Selection of the best acoustic implant
Since several options are available in the treatment of sensorineural, mixed or conductive 
hearing loss, selecting the most adequate solution is challenging. Therefore, all patient 
characteristics should be taken into account: age, general health, fitness for surgery and 
anesthesia, hearing levels, life expectancy and the personal wishes and choices of the 
patient. When the level of hearing loss is evaluated, care should be taken to pay attention 
to the progressiveness of the hearing loss. If this is neglected, the implant might only be 
temporarily beneficial for the patient. This so called longevity issue is often neglected (9). 
The sensorineural hearing will deteriorate due to presbyacusis and in certain hereditary 
forms of hearing impairment even at a fast rate. For otosclerosis, both the sensorineural 
thresholds as the air-bone gap may deteriorate over time. Since the maximum output of 
the implantable devices vary strongly, as presented in part IV, some implants are not 
indicated when the sensorineural hearing (component) thresholds exceeds a certain level. 
Not only should the maximum output level of the device be powerful enough to reach 
the levels of the patient’s hearing, it should provide at least 35 dB dynamic range of 
hearing to provide acceptable speech audibility (see chapter 4.1). As a consequence, 
dealing with patients with mixed hearing loss, a maximum application range was set of 35 
dB HL mean sensorineural hearing loss component for standard percutaneous bone 
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implants, 50 dB HL for the Baha Cordelle, 45-50 dB HL for the VSB and 65 dB HL for Codacs, 
although the latter might even be larger due to the loudness discomfort at maximum 
output. These maximum ranges need to be considered, when the actuator of the implant 
would be directly coupled to the remaining ossicles or round window.
Magnetic resonance imaging (MRI) compatibility
Considering the increasing availability of high-field MRI scanners, some technical and 
medical challenges may arise in patients with acoustic implants. In a large US report in 
2012 an increase in MRI usage between 1996 and 2010 is presented (10). The authors 
report an increase from 1.7% to 6.5% of the enrolled patients and 10 percent increase per 
year. Azardamaki et al and Fritsch and Mosier have published about the interactions that 
need to be considered related to the magnetic field in the MRI-scanner and the metallic 
and magnetic parts of implantable hearing aids (11, 12). Most implants consist of an 
internal processor carrying a magnet which will couple to the externally worn sound 
processor. One risk might be displacement of the implant in the patient because of 
translational and rotational forces. Another risk is the production of heat due to the effect 
of radiofrequency absorption. Another problem might be demagnetization of the 
implanted magnets. Finally, the diagnostic use of the MRI itself is obscured due to the 
artifacts that will be created due to the metallic and magnetic implant parts. Especially in 
the VSB the torque effects need to be considered since the FMT is an active magnet which 
is coupled directly to the middle ear ossicles. 
Another problem is demagnetization of the magnet, part of the FMT, which might 
influence the output of the device. In an extensive publication in 2011, Wagner et al have 
described a review on the results of all published in vivo en ex vivo experiments with the 
VSB and MRI scanning (13). Although no severe torque on the FMT was measurable, some 
displacement of the position of the FMT onto the incus had occurred. Demagnetization of 
the implant and receiver magnet was only limited. The voltage induction in experimental 
setting showed no limits that would damage the implant. Nevertheless, it might lead to 
hearable activation of the FMT, which did occur in some patients. No significant heating 
of the device was measurable in an experimental setting. In the in vivo reports dislocation 
of the FMT and VORP as well as bending and rotation of the attachment to the incus have 
been reported. This has also been confirmed in temporal bone studies (14). Wagner et al 
state that, for the VSB, an MRI up to 1.5 Tesla can be performed at calculated risk, although 
the possible side effects of loud hearing sensations and possible dislocation of the FMT 
should be weighed against the necessity of the imaging. Since 2014, the Med-El company 
has introduced the newest version of the VSB implant and states a MRI-compatibility up 
to 1.5 Tesla (company information). In contrast, the percutaneous bone-conduction 
implants with its titanium coupling is not affected by MRI and its effect on the MRI image 
is less then 1 cm. 
165
5
Closure
Future developments
Miniaturization and battery improvement
A problem in acoustic devices might be cosmetics, or the size of the device. The actuator 
is one of the bigger elements which has decreased in size over the years. Most of the size 
of the AMEI audioprocessor is the actuator and the magnet to couple the audio processor 
to the implanted receiver, part of the internal part of the implant. Because of the ongoing 
development, each generation of implants has led to some decrease in size. This so called 
miniaturization will hopefully lead to even smaller sizes for the external processors and for 
AMEIs to smaller internal components, to facilitate easier and less traumatic implantation 
procedures.
Improvement of implantable microphones and fully implantable devices
For the totally implantable device used in our studies, the FIMOS, a drawback has been the 
feedback of sounds in and to the skull itself. As the microphone is implanted just 
underneath the retroauricular skin of the cranium, many of the sounds to the skull (e.g. 
combing of the hair, scratching) are picked up and amplified. Another problem is the 
distortion of the own voice because of amplification and suppression issues. These 
problems cannot be easily solved. Reducing the volume is not appropriate but effective. 
Better acoustic isolation of the microphone is the better option. In addition, improvement 
of the implanted rechargeable battery might lead to longer battery lifetime, requiring 
fewer revision surgery.
Reimbursement issues
In the local situation in the Netherlands, direct reimbursement of AMEIs is not provided by 
the health insurance companies. However, about ten years ago, the implantation of the 
VSB and MET were approved as regular health care by the national healthcare authority 
council (CvZ). Therefore, they can be applied under the formulated indication criteria, 
namely for hearing impaired patients who could not benefit from conventional 
behind-the-ear devices, caused by chronic external otitis or patients with a severe hearing 
loss. Reimbursement has to be supplied by the hospitals. In other European countries like 
the United Kingdom, Switzerland and Germany these devices are directly reimbursement 
by the health insurance. More recently, in Belgium, the VSB has also been accepted for 
reimbursement, with the limitation that the application of a bone conduction implant is 
contra-indicated (personal communications).
Nowadays, the indications for AMEIs have broadened to mild and severe mixed hearing 
loss. As the knowledge of the expanding indications for AMEIs has not yet spread 
adequately amongst otolaryngologists in the Netherlands, the number of eligible patients 
for middle ear implantation will probably increase in the future. Until this moment, the 
reimbursement of the devices is indirectly funded through hospital budgets, since the 
number of implantations is too few to develop a specific funding category. Not only the 
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costs of the implant should be considered, but also the replacement costs of the external 
audioprocessor (after e.g. 5 years as is the case for percutaneous bone conduction 
implants). The cost effectiveness of middle ear implants was determined in two previous 
studies (15, 16). Therefore, a dedicated diagnosis related group (DRG) also called ‘diagnose 
behandel code’ (DBC) should be introduced, specifically for AMEI and DACI. It should 
cover the costs for a newly created procedure code that includes the implantation of the 
device, the actual costs of the device itself and the audioprocessor and the fitting 
appointments in an audiological center. These DRG’s have been available for the 
implantation of bone implants and cochlear implants for many years. 
General conclusion
The studies that have been conducted for this thesis provide evidence that the application 
of AMEIs nowadays in patients with SNHL and comorbid external otitis, as well as severe 
mixed hearing loss, is associated with a low incidence of complications, which decreased 
over time. The initial medical-technical challenges with the implants seem to have been 
solved by the manufacturing companies and recent explantations are few. The so-called 
transcanal approach in the implantation of the VSB should be avoided in patients suffering 
from external otitis, due to complications with wire extrusions in the ear canal. So far, the 
complication rate for DACI seems to be low. Long term evaluation with quality of life 
questionnaires (after a mean of 7.5 years) resulted in a report of significant decrease in 
disability due to implantation. Overall more than 80% of the patients that still use the 
device is content with the device and 90% of them use it daily.
A new alternative in the surgical treatment of advanced otosclerosis was studied and 
described in two chapters. A direct acoustic cochlear implant (Codacs) was tested in a trial 
study. The study showed that the device was both safe and effective. Compared to the 
pre-operative situation with a conventional hearing aid, better audiological results were 
obtained. In a long term study the audiological results proved to be stable in all 5 patients, 
evaluated at 20 and 40 months, post device fitting. Only one complication occurred, for 
which no explicit relation with the device was found.
Two chapters present evidence that the maximum output of acoustic implants vary 
greatly. The comparison between the VSB, MET and Codacs devices showed that the VSB 
has a smaller aided dynamic range of hearing than the MET for patients with sensorineural 
hearing loss. The dynamic range of hearing with the Codacs was even larger than for the 
MET. A criterion was set to provide a dynamic range of hearing of at least 35dB. With that 
criterion applied to patients with conductive or mixed hearing loss, maximum allowable 
levels for the sensorineural hearing loss component were defined. Non-audiological 
factors that play a role have been discussed; an international consensus on the application 
of acoustic implants has not yet been determined. 
In conclusion, this thesis provides additional scientific evidence to the literature that 
acoustic implants have a key position in surgical restoration of selected hearing impaired 
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patients for whom conventional solutions are contra-indicated or provide insufficient 
benefit. Active middle ear implants can be considered as alternative to conventional 
treatments like reconstructive surgery and bone-conduction implants in specific patient 
groups
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Summary
Active middle ear implants or AMEI have been applied for over two decades in the surgical 
rehabilitation of hearing loss. It comprises the implantation of an actuator that is coupled 
to the middle ear ossicles and a receiver. The (external) soundprocessor communicates 
with the receiver by radiofrequency or electromagnetical signals. These signals are 
decoded and transformed into a vibration of the actuator, thereby vibrating the ossicles 
and subsequently stimulating the cochlea. More recently, direct acoustic cochlear implants 
or DACI have been developed which provide a method to directly drive the fluids in the 
inner ear. The DACI is a type of middle ear implant that provides a powerful vibration to a 
stapes prosthesis (coupled to its actuator) that is inserted through an opening in the 
stapes footplate. 
This thesis has focused on the long term results of AMEI on several outcome factors, such 
as quality of life, complications and implant failures. The results of the first clinical 
application of a DACI have been evaluated in a short term multicenter trial and a long term 
follow-up study. Furthermore, two studies have been conducted to evaluate the device 
characteristics for maximum output and saturation of the amplified sounds. The first 
chapter offers an introduction to the theory of hearing and hearing loss and to the various 
acoustic implants. 
Active middle ear implants
In chapter 2.1, a selected study group of 13 subsequent patients suffering from sensori -
neural hearing loss and therapy resistant external otitis was evaluated after an experimental 
procedure to implant the Vibrant Soundbridge or VSB. Shortening of the time of surgery 
and decrease in perioperative complications was hypothesised, using an approach 
through the outer ear canal, rather than using the regular approach through the mastoid 
cavity. In this study, the connecting wire of the implant between the receiver and the 
actuator was guided through the ear canal and buried in an artificial groove in the bony 
part of the canal. During a mean follow-up period of 51 months, apart from 2 perioperative 
sacrificed chorda tympani nerves, 7 postoperative complications were observed in 6 of 
the 13 patients (46%). The complications were a collapse of the ear canal (n = 1), repeated 
extrusions of the conducting wire (n = 5) in the ear canal and a perforation of the tympanic 
membrane (n = 1). No further postoperative complications occurred during the follow-up 
period and no postoperative complications were observed for the other 7 patients. After 
careful consideration, it was concluded that this so called transcanal approach for VSB 
implantation is unfavourable in patients with therapy-resistant external otitis.
In the chapter 2.2, the effects on quality of life and the level of handicap for the patients 
implanted with a VSB implant or a semi- implantable Middle Ear Transducer (MET) were 
studied using validated questionnaires. The Abbreviated Profile of Hearing Aid Benefit 
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(APHAB and the Glasgow Benefit Inventory (GBI) were administered pre-operatively and at 
short and at long term intervals, postoperatively. Data of 33 patients (80%) were available, 
with a mean post-operative duration of 7.5 years. No difference in subjective results was 
found between the VSB and MET patient groups. The total percentage of non-use was 
13%. The long-term APHAB results showed a significant decrease in overall disability for 
43% of the patients compared to 54% at 1-year postoperative. The GBI results show a 
significant long-term increase in quality of life with positive scores for 82% of the 33 
assessed patients. These results are lower compared to the 12-month results in which 23 
patients (92%) had a positive GBI score. The results of all questionnaires showed a negative 
trend over time, but the evaluated AMEI provide a significant long-term benefit in disability 
and quality of life with a benefit that was slightly better than the results reported in the 
literature.
In chapter 2.3, the result of a long term evaluation of the complete cohort of AMEI patients 
is presented. This study evaluated the number of explanted devices due to a medical or 
technical reason, the number of revision procedures and the total complication rate. The 
VSB and MET devices were implanted as well as a fully implantable middle ear ossicular 
stimulator (FIMOS).
In total 94 patients were implanted, of whom 12 patients eventually with a round window 
or stapes coupling rather than the regular application to the incus. A number of 28 
patients (30%) were lost to follow up: 7 patients had deceased, 12 patients were definitively 
explanted, and 6 patients were lost to follow-up appointments. The average follow-up 
duration was 4.4 years (range 1 month to 15 years). Altogether, 128 devices were evaluated: 
(92 VSB, 32 MET, 4 FIMOS). 36 devices (28%) were explanted or replaced (18 VSB, 14 MET, 4 
FIMOS). The device failure rate was 7% for VSB, 28% for MET and 100% for FIMOS.
In 16 patients (17%) revision surgery (n=20) was performed, which mostly concerned 
revision of the skin and the implanted magnet and middle ear inspections to evaluate the 
coupling of the device to the incus.  Finally, 20 patients (21%) suffered a medical 
complication of which the erosion of the long process of the incus and extrusions of the 
wire in the ear canal were the most notable. The complication rate decreased steadily over 
time and no complications were found in the last 3 years of the evaluation, whereas the 
number of implantations increased over time. This trend is best explained by the learning 
curve and experimental procedures in the explorative first years of middle ear implantation. 
Because of incompatibility with an MRI scanner, 12 of the 92 VSB implants were explanted. 
This issue has more recently been addressed by the industry. The VSB is now compatible 
for low-strength magnetic fields. For the other implants, this issue is still ongoing.
Although the number of complications, device failures and revision procedures in the past 
can be considered high, the decreasing trend over time shows that experimental phase in 
the development and implantation procedure of AMEIs has passed. Therefore, AMEI may 
be considered as a valuable and safe contribution in the surgical rehabilitation of hearing 
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loss, since the benefits in audiological and quality of life outcome have been previously 
established. 
Direct acoustic cochlear implants
Chapter 3.1 presents a phase 1 prospective multicenter trial conducted in Germany, 
Switzerland and the Netherlands. Fifteen patients who suffered from severe mixed 
hearing loss as a result of advanced otosclerosis were included to be implanted with an 
experimental direct acoustic cochlear implant (DACI). Rather than performing a regular 
stapes replacing surgery, this procedure comprised the implantation of a device that was 
made up of a vibrating rod, the actual actuator, and a sound processor. The vibrating rod 
was coupled to the stapes replacing prosthesis, which connects directly to the perilymph 
fluid in the inner ear. A previous study provided evidence of an additional benefit in the 
higher frequencies compared to a regular stapedotomy combined with conventional 
hearing aids. The study goal of this trial was to confirm the audiological efficacy and safety 
of the device.
The pre- and post-operative air and bone conduction thresholds did not change 
significantly by the implantation with the DACI. The mean sound field thresholds (0.25 to 
8 kHz) improved significantly by 48 dB compared to the pre-operative unaided situation 
and by 15dB compared to aided with a hearing aid (n=11). The improvement of the DACI 
aided sound-field thresholds postoperatively compared with the HA aided sound-field 
thresholds preoperatively was significant in all frequencies except at 2 and 8 kHz (n=5). 
The word recognition scores at 50, 65 and 80 dB SPL improved significantly by 30, 75 and 
78% respectively compared to the pre-operative unaided condition and 29%, 36%, and 
26% respectively to the preoperative aided condition (n=11). The speech in noise test 
improved significantly by 4.2 dB and 2.4 dB signal to noise ratio (SNR), measured with two 
different tests (n=7). In eight patients, no pre-operative speech in noise was measureable. 
Three of these patients did not improve in speech in noise results, whereas the five other 
patients improved from not measureable to 0.5 dB SNR on average. Difficulty in hearing, 
measured by the APHAB questionnaire, decreased by 27% after implantation with the in-
vestigational DACI. Three patients suffered deterioration in bone conduction thresholds, 
which could not be related to the procedure or the experimental device. Two patients 
fully recovered. One revision procedure was necessary to change the position of a 
transducer that contacted the bony wall of the external ear canal.
The study concluded that the DACI investigational device is safe to implant and beneficial 
for severe to profound hearing loss in patient with otosclerosis, compared to the 
preoperative situation with hearing aids. An important criterion for success is the need for 
patients to still have measurable bone conduction speech recognition in the ear to be 
implanted. 
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In chapter 3.2, a long term follow up study of the Dutch cohort of five patients implanted 
with the experimental DACI is presented. The stability of the audiometric, functional en 
quality of life results was evaluated after approximately 1.5 and 3.5 years.
One patient suffered from decrease in sensorineural hearing of 10 dB. This hearing loss has 
remained stable during the follow up. He did not improve in speech understanding after 
implantation, despite adequate aided thresholds with the DACI. For the other patients, the 
overall aided and unaided thresholds showed stable values compared with the short term 
results. The mean unaided pure tone average was 83 dB HL and the long term aided 
results 35 dB HL for 3 months, 39 dB HL for 19 months and 41 dB HL for 40 months. The 
pure tone averaged results did not differ significantly from the pre-operative hearing aid 
results. The aided speech reception and speech in noise recognition values showed a 
significant improvement compared to the baseline. Four patients used hearing aids and 
were tested in pre-operative aided conditions with an average speech reception threshold 
of 42 dB HL, which is a benefit of 35.5 dB HL. With the DACI, these results were 36.4 dB HL 
at 3 months and an improved benefit compared to the preoperative hearing aids of 12.6 
dB HL and 7.8 dB HL at 19 an 40 months. The mean speech-to-noise ratio (S/N) improved 
from 4.5 dB pre-operatively with hearing aids to 0.6 dB (3 months) and 0.4 dB (19 months) 
postoperatively. The APHAB questionnaire scores were equally improved from the 
pre-operative situation. In total, a significant improvement was found for all follow up 
moments, almost halving the percentage of difficulty in hearing from 58% to 30%. All five 
patients used their implant on a daily basis and were content with the device. No device 
failure or complications occurred.
This study concluded that the DACI experimental device provided stable results up to at 
least 40 months after implantation. A significant improvement of speech understanding, 
speech in noise and disability was found compared to pre-operative hearing aid results.
Comparison of auditory implants
Chapter 4.1 evaluates a study on 22 selected patients suffering from severe sensorineural 
hearing loss with a VSB or MET middle ear implant or with a first-generation DACI. The 
implants were tested to determine a gain per frequency related to the cochlear hearing 
level, best estimated by bone conduction thresholds (thus a gain-threshold ratio). This 
value is independent of the patient’s degree of hearing loss and it can be compared to the 
commonly used NAL-NL hearing aid prescription rule. The second parameter was a 
measure of the input level at which the tested device saturated, which means that the 
amplification was no longer advancing at a linear mode and the sounds were no longer 
properly processed by the device. At that certain input level the maximum output of the 
device could be determined by simply adding the gain. Next, this maximum output was 
related to the level of sensorineural hearing loss of the patient to determine the dynamic 
range of hearing that the device offers for the amplification of sounds. Data were gathered 
in 9 patients (three MET, four VSB and two DACI users).
177
5
Closure
The gain-threshold ratio varied from approximately 0.2 at 0.5 kHz to 0.45 at 2 kHz and no 
significant difference was found between the three devices. The desired gain ratio, 
according to the NAL rule, should be at least 0.46 (at 1, 2, and 4 kHz). This ratio was found 
at 1 kHz and 2 kHz for the DACI users and at 2 kHz for the VSB users; for MET users, the 
values at 1 kHz and 2 kHz approached this target value. The input level at saturation was 
higher for the DACI than for the MET or VSB. As a consequence, the dynamic range of 
hearing was the largest for the DACI. This means that the DACI is better able to prevent the 
distortion of loud sounds due to device saturation.
The results of this study suggested that the DACI has an amplification capacity that 
exceeds the VSB and has a comparable or better capacity than the MET because of this 
larger dynamic range of hearing.  It could therefore be outperforming the other implants 
in the rehabilitation of patients with severe sensorineural hearing loss that would need an 
acoustic implant. However, in contrast to the other two systems, implantation of a DACI is 
cochlear invasive.
In chapter 4.2, the methods of the study in chapter 4.1 were applied to evaluate the 
amplification options for patients suffering from mixed hearing loss with varying levels of 
sensorineural hearing loss. In this study the VSB (coupled to the stapes or round window) 
and DACI were measured in patients and compared to three bone conducting devices 
(BCD), viz. the Sophono transcutaneous BCD, the regular BAHA Divino (percutaneous 
BCD) and the more powerful BAHA Cordelle percutaneous BCD. The BCDs were tested on 
a skull simulator for the maximum output level. This maximum output was determined 
per frequency. These mean values were considered in relation to patients’ level of the 
sensorineural hearing loss component. 
The mean maximum output (at 0.5, 1 and 2 kHz) was 55dB HL for the Sophono, 70dB HL 
for the Divino and 85dB HL for the Cordelle. For the VSB, varying results were found. For 
two patients a poor result was found, which was explained by a poor coupling of the 
transducer to the oval or round window of the cochlea. Without these outliers excluded, 
the VSB provided a mean maximum output of 85 dB HL. For the DACI, all five patients 
could be stimulated louder than their loudness discomfort levels. This means that the 
DACI saturates at levels above a level around 110 dB HL. Assuming a minimal dynamic 
range of hearing of 35 dB HL, this study suggested that the maximum level of the 
sensorineural hearing loss component in mixed hearing loss should not be more than 20, 
35, 50, and 50 dB HL for the Sophono, the BAHA Divino, the BAHA Cordelle, and the VSB 
device respectively. No maximum level of sensorineural hearing loss is set for the DACI, 
since it provides the ability to amplify the sounds to the loudness discomfort levels and 
therefore offers the full dynamic range of hearing amplification to the patient. 
In the chapter 5.1, the previous chapters are discussed and the pros and cons for the 
various types of AMEI are discussed. The selection criteria for the most adequate acoustic 
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implant and the considerations on MRI compatibility are outlined. Furthermore, the future 
developments and reimbursement issues are discussed.
In conclusion, this thesis provides new scientific evidence that AMEI and DACI have a key 
position in the surgical restoration of selected hearing impaired patients. AMEIs should 
be considered in conductive and mixed hearing loss and DACIs can be beneficial for 
patients with severe to profound mixed hearing loss owing to advanced otosclerosis. 
When the treatment of chronic external otitis fails in patients suffering from sensorineural 
hearing loss, an AMEI provides a safe and well accepted solution, with adequate and 
stable benefits in quality of life. The transcanal approach is contra-indicated in this 
category of patients. AMEI and DACI can also be applied after surgery for chronic otitis 
media or cholesteatoma after subtotal petrosectomy.
When an acoustic implant is considered for a patient, the sensorineural levels of hearing 
loss need to be thoroughly evaluated. Progressiveness of hearing loss should be 
considered as well as MRI compatibility. 
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Samenvatting
Actieve middenoorimplantaten (AMOI) worden al sinds 2 decennia toegepast in de 
chirurgische revalidatie van gehoorverlies. Het implantaat is opgebouwd uit een actuator 
die gekoppeld is aan de gehoorbeentjes en een implanteerbare signaalprocessor. Deze 
processor verwerkt en versterkt de geluiden die door een in- of uitwendige microfoon 
worden aangeboden. In het geval van een semi-implanteerbaar middenoorimplantaat 
communiceert een uitwendige geluidsprocessor met het implantaat via radio- of 
magnetische golven. Deze signalen worden gedecodeerd en omgezet in een vibratie van 
de actuator, waardoor de gehoorbeenketen in trilling wordt gebracht om in het binnenoor 
te worden waargenomen.
Recentelijk zijn directe akoestische cochleaire implantaten (DACI) ontwikkeld waarmee 
een toepassing beschikbaar komt om de vloeistof in het binnenoor direct in trilling te 
brengen. Een DACI is een middenoorimplantaat dat een sterke vibratie kan overbrengen 
op een gekoppelde stijgbeugel prothese die door een opening in de voetplaat van de 
stijgbeugel contact maakt met de binnenoorvloeistoffen in het geval van ernstig 
gehoorverlies bij geavanceerde otosclerose. 
Dit proefschrift is toegespitst op de lange termijn resultaten van AMOI op verscheidene 
uitkomsten, waaronder de kwaliteit van leven, complicaties en implantaat falen. De 
resultaten van de eerste klinische toepassing van DACI zijn geëvalueerd in een korte 
termijn multicenter onderzoek en een lange termijn vervolgstudie. Daarnaast zijn er twee 
studies verricht naar de implantaat karakteristieken qua maximale versterking en saturatie 
van deze versterkte geluiden. Ter introductie worden de theorie van gehoor, gehoorverlies 
en de verscheidene implantaten beschreven. 
Actieve middenoorimplantaten
Hoofdstuk 2.1 beschrijft een studie onder een geselecteerde studiegroep van 13 
opeenvolgende patiënten met perceptief gehoorverlies en therapieresistente otitis 
externa. Deze patiënten ontvingen een zogenaamde Vibrant Soundbridge (VSB) 
implantaat dat middels een nieuwe experimentele procedure geplaatst werd. De 
hypothese was een verkorting van de procedure en een afname van perioperatieve 
complicaties door een benadering van het middenoor via de gehoorgang in plaats van 
de reguliere procedure door de mastoidholte. De verbindende draad tussen het 
implantaat en de actuator werd door de gehoorgang geleid en in een groeve in het bot 
van de gehoorgang begraven. Gedurende een follow up periode van 51 maanden 
werden 7 postoperatieve complicaties waargenomen bij 6 patiënten (46%). Deze 
complicaties bestonden uit een samenvallende gehoorgang (1), terugkerende extrusie 
van de verbindende draad (5) en een perforatie van het trommelvlies (1). Perioperatief 
werd bij 2 patiënten de chorda tympani zenuw opgeofferd. Er werd geconcludeerd dat 
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deze zogenaamde ‘transcanal’ methode om de VSB te implanteren ongunstig is voor 
patiënten met therapieresistente otitis externa. 
In hoofdstuk 2.2 wordt een studie beschreven waarin de kwaliteit van leven en de mate 
van beperkingen werden bestudeerd middels gevalideerde vragenlijsten bij patiënten 
met een VSB of een semi-implanteerbare ‘Middle ear transducer’ (MET). De toegepaste 
vragenlijsten waren de Abbreviated Profile of Hearing Aid Benefit (APHAB) en de Glasgow 
Benefit Inventory (GBI), welke preoperatief en op korte en lange termijn postoperatief 
werden afgenomen. De gegevens van 33 patiënten (80%) waren beschikbaar, waarbij de 
gemiddelde postoperatieve duur 7,5 jaar was.  Er werd geen verschil gevonden tussen de 
beide implantaat types. Het totale percentage van niet-gebruikers was 13%. De lange 
termijn APHAB-resultaten lieten een significante afname van klachten zien voor 43% van 
de patiënten vergeleken met 54% 1 jaar postoperatief. De GBI-resultaten laten een 
significante verbetering in de kwaliteit van leven zien voor de lange termijn met een 
positieve score voor 82% van de patiënten, vergeleken met 92% na 1 jaar (23 patiënten). 
De uitkomsten van de vragenlijsten lieten een negatieve trend zien, maar de uitkomsten 
bleven significant ten opzichte van preoperatief. De verbetering was enigszins hoger dan 
de resultaten in de literatuur. 
In hoofdstuk 2.3 zijn de resultaten uiteengezet van een lange termijn evaluatie van het 
complete cohort van AMOI-patiënten. In de studie zijn de aantallen geëxplanteerde 
apparaten geëvalueerd, evenals het aantal revisie ingrepen en de complicatie frequentie. 
De explantaties werden onderverdeeld in een medische of een technische reden. De VSB, 
de MET en de zogenaamde experimentele ‘fully implantable middle ear ossicular 
stimulator’ (FIMOS) implantaten werden toegepast. 
In totaal werden 94 patiënten geimplanteerd, van wie 12 patiënten middels een ronde 
venster of stapes koppeling in plaats van de reguliere koppeling van het implantaat aan 
de incus. Een totaal van 28 patiënten (30%) werden verloren in de follow-up: 7 patiënten 
stierven, 12 patiënten werden definitief geëxplanteerd en 6 patiënten verschenen niet 
meer voor de vervolgconsulten. De gemiddelde vervolg-duur was 4,4 jaar met een 
spreiding van 1 maand tot 15 jaar. In totaal werden 128 implantaten geëvalueerd: 92 VSB, 
32 MET en 4 FIMOS. Hiervan werden 36 implantaten (28%) geëxplanteerd of vervangen (18 
VSB, 14 MET, 4 FIMOS). Dit bracht de totale technische faal frequentie per implantaat type 
op 7% voor de VSB, 28% voor de MET en 100% voor de FIMOS.
Bij 16 patiënten (17%) werd een revisie operatie verricht (in totaal 20 operaties). De meeste 
operaties betrof een revisie van de huid of de geïmplanteerde magneet. Verder werd de 
koppeling van het implantaat aan de incus geverifieerd door middel van een middenoor-
inspectie in 8 patiënten. Twintig patiënten (21%) leden aan een medische complicatie. De 
meest opvallende waren erosie van het lange been van de incus (4 patiënten) en extrusie 
van de draad in de gehoorgang (5 patiënten). De complicatie frequentie naam af met de 
185
5
Closure
tijd en in de laatste drie jaar van de evaluatie kwamen er geen complicaties meer voor, 
terwijl de implantatie frequentie juist toenam. Deze trend is het best te verklaren door de 
leercurve en de verschillende experimentele toepassingen in de eerste jaren van de 
toepassingen van AMOI.
Vanwege de incompatibiliteit van de vroege generatie VSB-implantaten met MRI-scanners, 
werden 12 van 92 implantaten geëxplanteerd omdat er voor de patiënt een noodzaak 
voor een scan was. Dit probleem is recentelijk door de fabrikant opgelost. De VSB is nu 
compatibel met MRI-scans tot 1,5 Tesla. Voor de overige implantaten is dit probleem nog 
steeds aan de orde.
Hoewel het aantal complicaties, falende apparaten en revisie procedures als hoog kan 
worden bestempeld, laat de afnemende trend in de tijd zien dat de experimentele fase 
van de toepassing van AMOI voorbij is gegaan. De implantaten mogen beschouwd 
worden als een waardevolle en veilige bijdrage in de chirurgische revalidatie van 
gehoorverlies. De voordelen op zowel audiologisch gebied als de kwaliteit van leven zijn 
al in eerdere studies vastgesteld. 
Directe akoestische cochleaire implantaten
Hoofdstuk 3.1 presenteert de resultaten van een eerste fase prospectieve multicenter 
studie die in Duitsland, Zwitserland en Nederland is uitgevoerd. Vijftien personen met 
ernstig gemengd gehoorverlies door gevorderde otosclerose werden geïncludeerd voor 
een implantatie met een experimenteel direct akoestisch cochleair implantaat (DACI). Dit 
implantaat bestaat uit een geluidsprocessor en een zogenaamde actuator, wat een 
titanium behuizing met een trillend uiteinde omvat. In plaats van een reguliere stijgbeugel 
vervanging, waarbij een prothese gekoppeld worden aan het aambeeld, wordt de 
stijgbeugel vervangende prothese tijdens de operatie aan de actuator gekoppeld, zodat 
deze direct met de perilymfe vloeistof in het binnenoor contact maakt. In een eerdere 
studie was reeds aangetoond dat het implantaat een toegevoegde versterking biedt in 
de hoge frequenties, vergeleken met een reguliere stijgbeugelvervanging in combinatie 
met een hoortoestel. Het doel van deze studie was de audiologische werkzaamheid en 
de veiligheid van het implantaat aan te tonen. 
De pre- en postoperatieve beengeleidingsdrempels werden niet beïnvloed door de 
implantatie met het DACI. De gemiddelde vrije veld geluidsdrempel (0,25 tot 8 kHz) 
verbeterde significant met 48 dB vergeleken met de ongeholpen preoperatieve situatie 
en met 15 dB vergeleken met de preoperatieve geholpen situatie met een hoortoestel (11 
patiënten). Voor alle frequenties behalve de 2 en 8 kHz drempels werd een significant 
verschil gevonden vergeleken met het hoortoestel preoperatief (5 patiënten). De scores 
van het woordverstaan bij 50, 65 en 80 dB verbeterde significant met 30, 75 en 78% res-
pectievelijk vergeleken met de ongeholpen preoperatieve situatie en met 29, 36 en 26% 
respectievelijk vergeleken met de preoperatieve hoortoestel situatie (11 patiënten). De 
spraakverstaan-in-ruis scores verbeterden significant met 4,2 decibel voor de ongeholpen 
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en met 2,4 decibel voor de geholpen situatie (7 patiënten). In de overige 8 patiënten was 
preoperatief geen score meetbaar. Postoperatief was er voor 3 patiënten nog geen spraak 
in ruis test meetbaar, voor de overige 5 patiënten was er een verbetering tot een score van 
0,5 decibel signaal/ruis verhouding. De beperkingen van het gehoorverlies op het 
dagelijks leven werden met een gevalideerde APHAB-vragenlijst geëvalueerd, waarbij 
sprake was een een afname met 27% na de operatie.  Drie patiënten leden toch aan een 
milde vermindering van hun spraak verstaan, waarbij geen relatie met het implantaat kon 
worden gerelateerd en bij twee patiënten was het probleem reversibel. Voor 1 patiënt 
was een revisieoperatie nodig omdat het implantaat contact maakte met het het bot in 
de gehoorgang, wat succesvol werd verholpen.
De conclusie van de studie was dat het DACI veilig was om te implanteren voor patiënten 
met ernstig tot zeer ernstig gehoorverlies bij otosclerose en een goede verbetering van 
het gehoor werd bereikt vergeleken met de preoperatieve situatie met hoortoestellen. 
Een belangrijk criterium voor het succes met het implantaat is de meetbaarheid van de 
begeleidingsdrempels en beengeleide spraak in het te implanteren oor. 
In hoofdstuk 3.2 wordt een lange termijn vervolgstudie gepresenteerd voor het Nederlands 
cohort van geïmplanteerde patiënten met een DACI. De stabiliteit van de audiometrische, 
functionele en kwaliteit van leven resultaten werd gerevalueerd na ongeveer 1,5 en 3 jaar.
Bij één patiënt werd een perceptief gehoorverlies van 10 decibel vastgesteld. Dit gehoor - 
verlies bleef stabiel aanwezig gedurende de evaluatieperiode. Zijn spraak verstaan 
verbeterde niet na de implantatie, ondanks adequate geholpen drempels met het 
implantaat. Voor de overige patiënten waren de lange termijn evaluaties van de geholpen 
en ongeholpen drempels stabiel. De gemiddelde ongeholpen preoperatieve score was 
83 decibel en de postoperatieve geholpen drempel 35, 39 en 41 decibel voor respectievelijk 
3, 19 en 40 maanden postoperatief. Voor de vier patiënten die preoperatief een hoortoestel 
droegen, kon een vergelijking worden gemaakt met het implantaat. Het hoortoestel 
leverde gemiddeld een verbetering van de gehoordrempel van 35,5 decibel. Met het 
DACI kon een additionele verbetering boven dit niveau worden bereikt van 12,6 en 
7,8 decibel bij 19 en 40 maanden respectievelijk. De gemiddelde spraak-ruis verhouding 
verbeterde van 4,5 decibel preoperatief met een hoortoestel naar 0,4 decibel bij 
19 maanden. De APHAB-vragenlijsten werden opnieuw afgenomen, waarbij een stabiele 
verbetering van 58% naar 30% beperking in het dagelijks leven werd gevonden. 
Alle patiënten droegen het implantaat dagelijks en waren tevreden met het resultaat. 
Er traden geen complicaties op en er waren geen technische mankementen.
Concluderend toont deze studie aan de resultaten met het DACI een stabiel resultaat 
tonen tot 40 maanden na implantatie. Er werd een stabiele en significante verbetering 
gevonden voor het spraakverstaan in rust en in rumoer en voor de beperkingen in het 
dagelijks leven vergeleken met de preoperatieve situatie met een hoortoestel. 
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Vergelijking van akoestische implantaten
In hoofdstuk 4.1 wordt een evaluatie beschreven van 22 geselecteerde patiënten met een 
ernstig gehoorverlies, waarvoor zij geimplanteerd waren met een VSB, MET of DACI. De 
toestellen werden getest om een versterking per frequentie te bepalen, in relatie tot de 
perceptieve hoordrempel, de zogenaamde gain-threshold ratio (GTR). Deze ratio is 
onafhankelijk van de ernst van het gehoorverlies van de patiënt en kan worden vergeleken 
met de gebruikelijke NAL-NL-regel voor het afstellen van reguliere hoortoestellen. De 
tweede parameter was het bepalen van de saturatie van het implantaat, oftewel de 
maximale versterking die het implantaat nog zuiver kon versterken zonder bijgeluiden of 
volumeverlies bij een bepaald volume van het binnenkomende geluid. Het verschil tussen 
de maximale versterking van het implantaat en het perceptieve drempelniveau van de 
patiënt werd als het dynamisch bereik vastgesteld. De gegevens van 9 patiënten konden 
hiervoor worden geanalyseerd (3 MET, 4 VSB en 2 DACI gebruikers).
De GTR varieerde van ongeveer 0,2 bij 0,5 kHz tot 0,45 bij 2 kHz en er werd geen significant 
verschil gevonden tussen de implantaten. De gewenste GTR volgens de NAL-NL-regel zou 
tenminste 0,46 moeten zijn (gemiddeld van 1, 2 en 4 kHz). Deze ratio kon alleen worden 
gevonden voor 1 en 2 kHz bij de DACI-gebruikers en voor 2 kHz bij de VSB-gebruikers. 
Voor de MET-gebruikers benaderde de GTR deze waarde. Het grootste dynamische bereik 
werd gevonden voor het DACI en het kleinste bereik voor de VSB.
De resultaten van deze studie suggereren dat het DACI een grotere versterking kan bieden 
dan de VSB en een vergelijkbare of betere capaciteit heeft dan het MET implantaat. 
Daarom kan het DACI mogelijk beter presteren bij patiënten met een ernstig tot zeer 
ernstig gehoorverlies. Het is echter wel meer invasief dan de overige implantaten omdat 
er een open verbinding met de cochlea nodig is.
In hoofdstuk 4.2 werd een vergelijkbare studie verricht als in het voorgaande hoofdstuk, 
maar dan bij patiënten met een gemengd gehoorverlies, met een gevarieerd niveau van 
de perceptieve drempel. De implantaten VSB, gekoppeld middels de irreguliere toepassing 
aan de stapes of het ronde venster, het DACI en 3 typen beengeleidingsapparaten werden 
vergeleken. De typen beengeleider waren de Sophono trancutane toepassing, de 
reguliere Baha Divino percutane toepassing en de Baha Cordelle, welke een sterkere 
percutane toepassing benut. Deze drie apparaten werden op een zogenaamde schedel 
simulator getest voor hun maximale versterking per frequentie. De gemiddelde waarden 
werden gerelateerd aan het perceptief gehoorverlies van de patiënt om opnieuw het 
dynamische bereik te bepalen. 
De gemiddelde maximale versterking (bij 0,5 , 1 en 2 kHz) was 55 decibel voor Sophono, 
70 decibel voor Divino en 85 decibel voor de Cordelle. Voor de VSB werden variërende 
resultaten gevonden. Bij twee patiënten was sprake van een slechte koppeling, wat een 
slecht resultaat gaf. Met de exclusie van deze afwijkende resultaten, was de gemiddelde 
uitkomst voor de VSB 85 decibel. Voor het DACI werd bij alle 5 patiënten een versterking 
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gevonden die luider was dan hun oncomfortabele luidheidsgrens. Dit betekent dat een 
DACI pas saturatie vertoont boven een luidheid van 110 decibel. Uitgaande van een 
minimaal dynamisch bereik van 35 decibel, levert deze studie de suggestie dat er een 
maximale grens aan het perceptieve gehoorverlies kan worden toegepast voor de 
implantaten. Dit is namelijk 20 decibel voor Sophono, 35 decibel voor Divino en 50 decibel 
voor Cordelle en VSB. Voor DACI geldt geen maximale grens aangezien dit implantaat het 
geluid kan versterken tot de luidheidsgrens en dus een volledig dynamisch bereik kan 
benutten.
In hoofdstuk 5.1 wordt een discussie over de voorgaande hoofdstukken gevoerd en 
worden de voor en nadelen van de diverse middenoorimplantaten afgewogen. De selec-
tiecriteria voor het meest adequate akoestische implantaat worden uiteengezet en de 
overwegingen ten aanzien van MRI-compatibiliteit worden benadrukt. Tot slot worden de 
toekomstige ontwikkelingen en de problemen met de vergoedingen bediscussieerd. 
Concluderend levert dit proefschrift nieuwe wetenschappelijke inzichten dit aantonen 
dat actieve middenoorimplantaten en directe akoestische cochleaire implantaten een 
essentiële positie hebben ingenomen in de chirurgische mogelijkheden van gehoorver-
betering voor slechthorende patiënten. AMOI moeten overwogen worden in conductief 
en gemengd gehoorverlies en DACI zijn van toegevoegde waarde in de behandeling van 
ernstig tot zeer ernstig gehoorverlies bij patiënten met gevorderde otosclerose. Indien de 
behandeling van chronische otitis externa faalt bij patiënten met een hoortoestel, kan 
een AMOI een veilige en goed getolereerde oplossing bieden met stabiele resultaten op 
de kwaliteit van leven. Wel is de zogenaamde transkanaal methode gecontra-indiceerd 
voor deze categorie van patiënten. AMOI en DACI kunnen eveneens worden toegepast na 
eerdere chirurgie voor chronische otitis media, cholesteatoom of in combinatie met een 
subtotale petrosectomie. 
Wanneer een akoestisch implantaat wordt overwogen voor een patiënt is het relevant dat 
zowel het niveau van het perceptieve gehoor als de eventuele progressiviteit goed 
worden geëvalueerd. Daarnaast dient de MRI-compatibiliteit altijd een onderdeel van de 
afweging te zijn.
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List of abbreviations
AC  Air conduction (threshold)
APHAB Abbreviated Profile of Hearing Aid Benefit 
AMEI  Active middle ear implant(s)
BAHA or BAHI Bone anchored hearing aid(s) or implant(s)
BC  Bone conduction (threshold)
BCI  Bone conduction implant(s)
BCD  Bone conduction device(s)
BI  Bone implant
BTE  Behind the ear device
CHA  Conventional hearing aid(s)
CHL   Conductive hearing loss
CI  Cochlear implant
cMET  Cochlear Middle ear transducer
Codacs ID Cochlear’s direct acoustic cochlear stimulator investigational device
DACS  Direct acoustic cochlear stimulator
DACI  Direct acoustic cochlear implant(s)
dB  Decibel(s)
dBHL  Decibel(s) of hearing loss
dBSPL Decibel(s) sound pressure level
EAC  External auditory canal
FF  Free field audiometry
FG  Functional gain
FIMOS  Fully implantable middle (ear) ossicle stimulator
FMT  Floating mass transducer
FU  Follow up
GBI  Glasgow Benefit Inventory 
GR  Gain ratio
HA  Hearing aid(s)
Hz / kHz (kilo-)Hertz
HL  Hearing loss
IL(O)S input level at output saturation 
MEI  Middle ear implant(s)
MET  Otologics Middle ear transducer(s)
MRI  Magnetic resonance imaging
NCIQ  Nijmegen Cochlear Implant Questionnaire
NIHL  Noise induced hearing loss
oMET Otologics middle ear transducer(s)
PTA   Pure tone average of 0.5, 1 and 2 kHz thresholds
PTA4   Pure tone average of 0.5, 1, 2 and 4 kHz thresholds
RF  Radiofrequency
SIN  Speech in noise test
SMA  Suprameatal approach
SNHL  Sensorineural hearing loss
SNR  Signal to noise ratio
SRT  Speech reception threshold
TM  Tympanic membrane
TMA  Transmeatal approach
UCL  Uncomfortable loudness level
VORP  Vibrating ossicular replacement prosthesis
VSB  Vibrant Soundbridge
WRS  Word recognition scores
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Dankwoord
Geen enkel proefschrift kan zonder dankwoord. Het is tenslotte een veel, zo niet meest, 
gelezen onderdeel en het doet eer aan de mensen die hebben bij gedragen aan het tot 
stand komen van het manuscript. 
Prof.dr.ir. A.F.M. Snik, beste Ad. Natuurlijk op de eerste plaats. Wat heb ik je geduld veel 
op de proef mogen stellen. Niet alleen voor de vele taken die we met elkaar hebben 
vastgesteld voor mijn promotietraject, maar ook tijdens de gesprekken die we op je kamer 
hebben gehad over de artikelen en analyse van de data. Altijd stond je deur wagenwijd 
open en vond je een gaatje in je agenda. In jouw werkkamer heerst een soort aura van 
academische kennis, waarvan ik me buiten je deur weleens afvroeg waarom ik deze niet 
zou kunnen meenemen om continue op het scherpst te kunnen blijven! Bedankt voor 
alle ondersteuning bij het schrijven van de artikelen en de vele opstapjes die je me hebt 
geboden. De ruimte die je me gegeven hebt om te promoveren op mijn eigen tempo en 
zelf de inhoud en vorm mede te bepalen is erg waardevol geweest. Ook heb ik je aandacht 
voor mijn privéleven altijd bijzonder gewaardeerd. 
Prof. dr. E.A.M. Mylanus, beste Emmanuel. Ik ken niemand met zo’n volle agenda als jij. 
Ik bewonder je vermogen om zoveel verschillende ”petten” te kunnen dragen en deze 
taken ook met de volste inzet te vervullen. Samen hebben wij de klinische trial van 
Cochlear uitgevoerd en ik ben je dankbaar voor de verantwoordelijkheid die je mij daarin 
hebt gegeven. Ik voelde me daardoor erg gesteund in je vertrouwen, wat me sterk 
gemotiveerd heeft. De vele besprekingen in de Codacs projectgroep hebben we samen 
bezocht en hier heb ik veel van kunnen leren! Bedankt dat we de trials tot een succes 
hebben kunnen maken en voornamelijk ook voor de erkenning van de auteurspositie in 
het artikel van de multicenter trial. Daarnaast heb je me chirurgisch enorm geïnspireerd, 
omdat je de meest complexe oorchirurgie zo eenvoudig kunt laten lijken en je al je tips & 
tricks met me hebt gedeeld. 
Dr.dr.hc J.J.M. Mulder, beste Jef. Als operateur van een groot deel van de Otologics en 
VSB-patiënten komt dit promotieonderzoek voor een belangrijk deel tot stand door jouw 
werkzaamheden. Om deze reden zijn met name jouw bijdragen aan de chirurgische kant 
van de artikelen van belang geweest. Je rustige en bedachtzame karakter zijn zowel 
persoonlijk, klinisch en chirurgisch een inspiratie. Bedankt voor de prettige samenwerking 
en ik heb veel van je kunnen leren, vooral ook op de OK.
Leden van de manuscriptcommissie, Prof. dr. A.J. van Opstal (voorzitter) en Prof. dr. M. M. 
Rovers: hartelijk dank voor uw kritische blik en waardevolle aanvullingen. U hebt met uw 
opmerkingen met name de discussie naar een hoger plan getild. Prof. dr. phil. nat. H. Maier, 
I am honored that you are part of my thesis committee. 
Prof.dr. C.W.R.J. Cremers. Hoewel ik een van de promovendi binnen de otologie ben die 
niet meer onder uw supervisie promoveert, ben ik u natuurlijk enorm erkentelijk voor al 
het baanbrekende werk dat u binnen de otologie en met name de implantologie van het 
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middenoor hebt betekent. Veel van de gerefereerde artikelen komen (mede) van uw 
hand en u bent de grondlegger van de middenoorimplantatie in Nijmegen en Nederland. 
Het artikel over de chirurgische complicaties van de transcanal methode hebben wij nog 
samen kunnen schrijven, wat mij een plezierige kijk heeft gegeven in uw manier van 
publiceren. Zonder al uw voorgaande inzet en werkzaamheden had dit manuscript 
vandaag niet bestaan, veel dank daarvoor. 
Prof.dr. H.A.M. Marres, beste Henri. Hoewel ik streng aan de tand werd gevoeld tijdens de 
sollicitatie, werd ook direct tijdens het tweede gesprek de knoop doorgehakt dat ik in 
2009 mocht beginnen aan de “KNO-afdeling met de beste opleiding van Nederland”. 
Ik ben nog altijd trots om hier als AIOS te hebben mogen werken. Ik heb respect voor de 
manier waarop je de sterke KNO-afdeling van het Radboud naar een nog hoger niveau 
weet te tillen. Hoewel ik had gehoopt als AIOS in de kliniek van je briljante kennis en 
vaardigheden te kunnen leren, heeft mijn eigen differentiatie in de otologie dit enigszins 
verhinderd. Desalniettemin, bedankt voor het goede opleidingsklimaat!
Dr. F.H.M. van den Hoogen, opleider van het jaar 2013, beste Frank. Wat was het een 
genoegen om van jou te mogen leren. Inspirerend, motiverend en altijd goedlachs. Voor 
mij ben je het voorbeeld van een rolmodel binnen de geneeskunde en ik hoop veel van 
jouw medische en persoonlijke kwaliteiten te kunnen overnemen. Bedankt voor de 
prettige sfeer tijdens onze voortgangsgesprekken en de prioriteit die jij aan de opleiding 
van AIOS geeft binnen de afdeling.
Beste stafleden van de KNO-afdeling van het Radboud UMC. Promoveren is natuurlijk een 
belangrijke toegevoegde waarde als KNO-arts, maar het vak leer je toch echt tot in de 
puntjes te beheersen en toe te passen door de opleiding als AIOS. Dit leer je niet uit een 
boek, maar door goede voorbeelden van leermeesters zoals jullie zelf. Ondanks de vele 
prioriteiten die er op een academische afdeling bestaan, blijft de opleiding hoog in het 
vaandel staan. Bedankt voor de prettige werksfeer en de laagdrempelige supervisie. Jullie 
brengen de opleiding zijn hoge niveau en leveren daarmee een grote bijdrage aan de 
kwaliteit van de KNO-heelkunde in heel Nederland!
Ook aan de andere otologen van het Radboudumc ben ik veel dank verschuldigd. Jullie 
hebben mij in mijn laatste anderhalf jaar als differiant otologie veel ruimte gegeven om 
mijn chirurgische vaardigheden te verbeteren. Dit is natuurlijk niet van directe invloed op 
dit proefschrift geweest, maar het heeft mij wel beïnvloed in de keuzes in mijn carrière. 
Hopelijk blijven jullie zulke goede supervisie geven.
Dr. N. van Heerbeek, beste Niels. Jou wil ik als mijn mentor persoonlijk bedanken. Hoewel 
er gelukkig niet veel zaken zijn die we te bespreken hebben gehad, vind ik je persoonlijke 
benadering erg prettig. Met name de ontvangst bij je thuis heb ik gewaardeerd. Jouw 
relativeringsvermogen heeft me veel geleerd en de hulp die je hebt geboden bij het 
maken van keuzes was erg waardevol.
Dr. H. Bouman en de staf van het Rijnstate ziekenhuis Arnhem. Bij jullie heb ik de KNO- 
heelkunde in zijn brede spectrum zelf leren toepassen. Jullie hebben een goede balans 
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tussen de routinewerkzaamheden en een leeromgeving voor de AIOS en hebben mij veel 
zelfstandig laten werken, wat ik enorm heb gewaardeerd. Beste Henk, jouw strenge 
supervisie heeft mijn soms eigenwijze karakter de goede kant opgestuurd. Bedankt.
Dr. E.J.J.M. Theunisse en de overige staf van het Viecuri medisch centrum Venlo. Hoewel ik 
in jullie B-stage echt hoopte te promoveren is ook dat niet gelukt. In jullie praktijk heb 
ik weer specifieke kneepjes van het vak geleerd, waardoor ik nog efficiënter kan werken. 
Beste Eric, jouw chirurgische supervisie is ongekend in het vertrouwen dat je mij als AIOS 
hebt gegeven om zelf de oorchirurgie te beheersen. Bedankt.
Medewerkers stafsecretariaat, in het bijzonder Carine Hendriks. Enorm bedankt voor de 
ondersteuning en de prettige samenwerking. 
Medewerkers van het volwassenen audiologisch centrum Radboud UMC. Zonder al jullie 
inspanningen waren de patiënten in onze studies niet zo zorgvuldig geselecteerd en 
betrouwbaar gemeten. Met name voor de Codacs studie heb ik zo’n duizend audio - 
grammen mogen screenen, die tenslotte allemaal van jullie hand zijn gekomen. Bedankt 
voor jullie werk. 
Ing. J. Noten, beste John. Alle middenoorimplantaat-patiënten hebben meermaals jouw 
audiologen kamer van binnen gezien. Daarnaast heb je voor alle Codacs patiënten in de studie 
het implantaat uitgebreid ingesteld en de audiometrie verricht. Je hebt me een interessante 
kijk in de audiologie gegeven en de patiënten lopen zelf stuk voor stuk met je weg. 
Dr. L.J. Hoeve en dr. J.A. Borgstein, beste Hans en Hans, onder jullie begeleiding begon 
mijn carrière in de KNO-heelkunde in het Sophia kinderziekenhuis. Jullie hebben mij 
beiden (op je eigen manier) geïnspireerd en ik heb genoten van de 6 maanden in “het 
sophie”. Ik denk met plezier terug aan ons wadloopweekend, bedankt dat jullie me 
daarvoor hebben mee gevraagd! Weet dat jullie belangrijk zijn geweest in mijn afweging 
om KNO-arts te worden!
Collega (oud-) AIOS en onderzoekers in het Radboud UMC: Olivier, Go, Pauw, Timmer, 
Beijen, Thomeer, Taus, Anne-Martine de Lord, Straatmans, Loupie, Honings, Scheffer, 
Dirven, Faber, Theunisse, Vesseur, Henrieke, Jas, Ingrid, Ruud, E-line, Anne, Saskia, Josephine, 
Thijs, Chrisje, Machteld, Corinne, Bas, Luuk, Charlotte, Maayke, Mieke, Ivo en David. Bedankt 
voor een super tijd in “de Radbout”. Wat een geweldige sfeer hebben wij onderling gehad: 
een beetje competitief (bij vlagen richting anderen zeer competitief), maar vooral 
luisterend naar elkaar en echte samenwerking. Als geen ander begrepen jullie hoe zwaar 
het leven van AIOS en onderzoeker soms kon zijn. Maar ook welke vreugde je voelt als je 
naam voor het eerst als eerste auteur op een artikel staat. Jullie zijn en worden stuk voor 
stuk geweldige kno-artsen! Henrieke en Ingrid, bedankt voor de gezellige uurtjes die we 
in de auto hebben doorgebracht, al was het soms slapend! We hebben prettig samen 
gewerkt in de perifere stages.
Mijne heeren Comprixaenen: een kort woord van dank is ook aan jullie gericht! Het 
Ardennen weekend is een fantastische traditie die we er zeker in moeten houden! Ik ben 
blij dat ik in 2016 weer eens mee kon gaan. 
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Mijn paranimfen Rik Nelissen en Caroline Verhagen: ik vind het een eer dat jullie mij bij de 
verdediging willen bijstaan. Lieve Caro, we hebben samen ongeveer hetzelfde traject door- 
lopen. Eerst was jij de onderzoeker op afstand in Amsterdam, hoewel je eerder was 
begonnen dan ik. Toch mocht ik eerder met de opleiding starten. Omdat we dicht op 
elkaar konden beginnen, hebben we veel lief en leed gedeeld en daar altijd uitgebreid 
over kunnen praten, voornamelijk op de racefiets. Ik denk dat ik jou op moeilijke momenten 
heb bij kunnen staan, maar jij mij zeker ook. Daarom is het voor mij zo toepasselijk dat jij 
als paranimf wilt optreden. Ik vind het echt knap dat je het fellowship in Cambridge hebt 
kunnen bemachtigen! Jouw promotie komt vast ook op korte termijn af. Rik, met jou heb 
ik vanaf het begin een klik gehad. We hebben mooie ritjes in de auto gemaakt, steevast 
met jouw ipod luid aan de speakers! De diners met zijn vieren zijn altijd erg gezellig en ik 
was erg verrast toen je me als jouw paranimf vroeg. Echt super dat je er voor mij ook wilt 
staan.
Lieve vrienden, waaronder Ivo & Celine, Ronald & Kiek, Marloes & Jaro, Frederik en Kirsten, 
Thea & Paul, Pim & Liesbeth, Kim & Bart, maar ook alle anderen: bedankt voor de 
gezelligheid die jullie in ons leven brengen, Ingeborg en ik genieten er keer op keer van!
Peter, Sander, Johan en Erik: hoewel jullie niets, maar dan ook niets, met mijn studie, 
opleiding en beroep te maken hebben, krijg ik van jullie zoveel respect voor wat ik bereikt 
heb. Work hard, play hard is een uitspraak waarbij jullie met name aan het laatste hebben 
bijgedragen. Na deze promotie begrijp je dat ik mij niet meer mag misdragen! Zorg 
daarvoor! Bedankt voor de vele jaren dat wij al zulke goede vrienden zijn.
Ivo en Frederik, ook jullie wil ik graag apart noemen. Ondertussen zijn we alle drie al hard 
aan de bak in onze eigen richtingen in de geneeskunde. Ik waardeer onze vriendschap die 
al sinds het begin van de opleiding bestaat in het bijzonder omdat we door onze eigen 
belevenissen zoveel in het werk kunnen relativeren. Hoewel de frequentie van onze 
borrels nog wel weer wat omhoog mag, ben ik ervan overtuigd dat we dit tot lang in de 
toekomst kunnen volhouden!
Rob en Margareth, Kerstin en Robin, lieve schoonfamilie. Tja, waar moet ik beginnen. 
Al vanaf het moment dat ik jullie ontmoet heb, ben ik altijd warmtevol ontvangen. Ik krijg 
van jullie zoveel respect, dat ik me ongelooflijk gestimuleerd heb gevoeld om het beste 
uit mezelf naar boven te halen. Alle momenten dat ik het nodig heb gehad kon ik op jullie 
steun vertrouwen en als klankbord hebben jullie mij zoveel de juiste richting in geholpen. 
‘Kuuroord Tholen’ heeft op veel manieren bijgedragen aan het afronden van dit proefschrift 
en de vele weekenden en vakanties die we al samen hebben doorgebracht zijn de 
belangrijkste rustmomenten in mijn drukke leven geweest. Rob en Mar, jullie zijn zulke 
geweldige zorgzame schoon- en grootouders, daar zijn geen woorden voor. 
Mijn broertje Paul en lieve Kristel. Wij zijn soms verschillend, maar tegelijk ook weer zo 
hetzelfde. Hoewel jij altijd erg naar mij opkijkt, heb ik juist verschrikkelijk veel bewondering 
voor jou. Jouw leven is al minstens twee keer zo zwaar geweest als het mijne en toch heb 
jij met alle kracht het voor mekaar gebokst om zo’n prachtig gezinsleven te kunnen 
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starten. Als jij je ondernemingszin zo doorzet weet ik zeker dat je toekomst nog meer 
moois in het verschiet heeft. Zeker in het afgelopen jaar hebben wij veel gezamenlijke 
veranderingen in ons leven doorgemaakt, waardoor we weer wat dichter bij elkaar 
gekomen zijn. Ik hoop dat we nog lang zo doorgaan!
Lieve papa en mama, zonder jullie zou ik niet staan waar ik nu ben gekomen. Aan mijn 
jeugd koester ik niets dan warme herinneringen. Jullie hebben mijn nieuwsgierigheid 
altijd gevoed en mij altijd gestimuleerd om mijn eigen wereld te ontdekken. Hoewel ik al 
vroeg het nest verliet, hebben jullie mij vrijgelaten en altijd ruim gesteund. Dit heeft het 
mogelijk gemaakt dat ik zoveel van mijn interesses heb kunnen uitvoeren, van zeilen en 
vakanties, tot bestuurservaring en straks nog werken in het buitenland. Pap, hoewel jij als 
medisch specialist eigenlijk nooit de connectie hebt gelegd naar mijn werk, heb je ook 
nooit geprobeerd mijn carrière keuzes te beïnvloeden. Ik heb je bewondering altijd 
(zonder al te veel woorden) gevoeld en hoop nog vele jaren in goede gezondheid van je 
aanwezigheid te mogen genieten. Lieve mama, altijd maar dan ook altijd heb je mij 
verzorgd, opgevoed, gesteund en gestimuleerd. Jij staat in de kern van mijn leven, hoewel 
ik dat niet altijd voldoende laat merken. Zonder jou zou ik niet zijn wie ik nu ben en ik zou 
niet weten wat ik zonder jou als moeder, schoonmoeder en beppe voor mijn kinderen 
zou moeten.
Lieve Ingeborg, aller- allerliefste Borg, alles maar dan ook alles in mijn leven beleef ik het 
liefst samen met jou. We zijn al meer dan 12 jaar in elkaars leven en ik had geen andere 
vrouw aan mijn zijde gewild. We hebben samen al op veel plekken gewoond en geleefd, 
al veel van de wereld gezien. Jij hebt mijn ogen geopend en mijn angsten weggenomen. 
Je hebt me gestimuleerd waar dat nodig was en geremd als ik te hard van stapel liep. Je 
hebt mijn frustraties doorstaan en maakte ruimte voor me wanneer ik daarom vroeg. Ik 
weet hoeveel dit proefschrift van jouw en onze tijd heeft gevraagd. Keer op keer maakte 
je weer tijd vrij zodat ik achter de computer kon kruipen. En elke keer schoof de deadline 
weer verder op: voor ons huwelijk, voor ons eerste en daarna voor ons tweede kindje. Nu 
is het dan echt zover. Ik kan niet beloven dat ik nooit meer om je tijd hoef te vragen, maar 
ik kan je wel zeggen dat ik je eeuwig dankbaar ben voor al het geluk dat je in mijn leven 
brengt en voor de twee mooiste meisjes die ik ooit heb gezien. Jij bent mijn alles en ik zal 
er altijd voor je zijn. 
Lieve Féline en Julie, pappa houdt van jullie! Jullie zijn het mooiste cadeau dat ik ooit heb 
gekregen.
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Curriculum vitae
Joost Willem Zwartenkot werd op 12 oktober 1982 geboren in Franeker en groeide op in 
Leeuwarden. Als zoon van een psychiater en een psychotherapeute was zijn interesse in 
de mens en het menselijk lichaam al vroeg gewekt. In 2000 behaalde hij zijn vwo-diploma 
aan het Stedelijk Gymnasium Leeuwarden. Na uitloting voor geneeskunde in datzelfde 
jaar volgde een studiejaar in Groningen, waar hij zijn propedeuse Biologie behaalde aan 
de Rijksuniversiteit Groningen in 2011. Vervolgens startte hij met de studie geneeskunde 
aan de Erasmus Universiteit Rotterdam. Deze studie werd een jaar onderbroken voor een 
bestuursfunctie bij de Rotterdamse studentenroeivereniging ‘Skadi’. 
Na de coschappen verrichtte hij een afstudeeronderzoek binnen de KNO-heelkunde 
onder leiding van dr. Hans Hoeve en dr. Hans Borgstein in het Sophia kinderziekenhuis te 
Rotterdam, waarna hij onder de hoede van dr. René Poublon een half jaar oudste coschap 
volgde op de afdeling KNO-heelkunde in het Erasmus MC te Rotterdam. In het NKI-AVL te 
Amsterdam was hij nog enkele maanden te gast op de afdeling hoofd-hals oncologie bij 
prof.dr. A.J.M. Balm.
In 2009 werd de basis voor dit proefschrift gelegd op de afdeling KNO-heelkunde van het 
Radboudumc onder leiding van prof.dr.ir. Ad Snik, dr. Emmanuel Mylanus en dr. Jef Mulder. 
In april 2011 startte hij op dezelfde afdeling met de opleiding tot KNO-arts onder supervisie 
van prof.dr. Henri Marres en dr. Frank van den Hoogen. Zijn perifere stages volgde hij in 
het Rijnstate ziekenhuis te Arnhem onder supervisie van dr. Henk Bouman en in Viecuri 
MC te Venlo onder supervisie van dr. Eric Theunissen. Tijdens zijn opleiding tot KNO-arts 
heeft Joost zich met name in de otologie ontwikkeld. Daarnaast heeft hij 2 jaar lang deel 
mogen uitmaken van de visitatiecommissie-opleidingen van de landelijke beroepsvereni-
ging voor KNO-artsen en volgde hij in zijn laatste jaar een management leergang voor 
specialisten in opleiding in het Radboudumc. Zijn KNO-opleiding heeft hij voltooid per 1 
juni 2016, waarna hij in het St. Antonius ziekenhuis te Nieuwegein/Utrecht is gaan werken 
als chef de clinique. Vanaf 1 juli 2017 zal hij een fellowship neurotologie volgen in het St 
Vincents hospital in Sydney, Australië.
In 2013 is hij getrouwd met Ingeborg Ligteringen, met wie hij al een relatie heeft sinds 
2004. Zij zijn de trotse ouders van hun dochters Féline en Julie.
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